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Abstract 
Background 
More people are being diagnosed and treated for diabetes who are aged 
over 75 years. Compared to younger diabetic populations there is less 
published evidence available in the older person. At the extremes of old 
age the evidence base is even smaller. 
Aim 
To examine several aspects of diabetic epidemiology in the older person 
in order to expand the evidence base for practice and policy. 
Methods 
People with diabetes were identified from a representative community 
based sample of 15095 people aged at least 75 years old. Associations 
between diabetes and its end points were identified. Admission to hospital 
and death were assessed in an older diabetic population. 
Results 
There were 1177 people identified with type 2 diabetes giving a 
prevalence of 7.80% (95% Cl, 7.11-8.47). The prevalence of diabetic 
complications of poor vision, proteinuria, raised creatinine, angina, 
myocardial infarction, cerebrovdscular accident and foot ulceration were 
all increased in the diabetic population. Older diabetic people 
demonstrated a good uptake of diabetic services including regular eye 
examination, annual chiropody and dietician attendance. However, the 
understanding of daily diabetic management was poor with a high 
prevalence of cognitive impairment (22.5%) in the diabetic population. The 
rate of admission to hospital and length of hospital stay were increased in 
the older diabetic person compared to the non diabetic person; rate ratio 
for admission, 1.31 (95% Cl, 1.23-1.39) and the length of stay 13.9 days 
Abstract 
versus 12.4 days, p<0.001. Finally, the risk of death among people with 
diabetes was higher than for people without diabetes, hazard ratio 1.50 
(95% Cl, 1.38-1.65), p<0.001. The hazard ratio was similarly raised in both 
men and women with diabetes across the age ranges studied. 
Conclusion 
This thesis presents the largest community based study in the older 
diabetic person. Diabetes was shown to contribute to morbidity and 
mortality until the extremes of old age. 
Abstract 
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Chapter 1 Introduction 
Chapter 1. Introduction 
1.1 Diabetes mellitus, a disease overview 
1.1.1 History of Diabetes and terminology 
The first description of diabetes mellitus occurred in 150 BC by the 
Greek writer Aretaeus, in his work 'On the Causes and Symptoms of 
Chronic Diseases'(1). He described thirst, polyuria and dehydration. 
Around 500 AD Brahmin writers in India noticed the sweetness of 
urine as insects were attracted to it. They described two forms of the 
disease. A serious fatal condition occurring in childhood and an adult 
form associated with obesity(1). The condition continued to be 
described throughout the following centuries with the 17th century 
English physician Thomas Willis describing diabetes mellitus as the 
"pissing evil"(1). Increased knowledge of glucose metabolism and 
pancreatic function improved understanding of the disease over the 
next 250 years. In 1921 Banting and Best discovered and isolated 
insulin in Toronto, Canada. The first use of insulin on a human 
patient occurred in 1922 by Professor J. J. R. MacLeod, who was in 
charge of the Canadian team. It became obvious that repeated 
injections were required and modern diabetology was born. Work by 
Frederick Sanger in the 1950s revealed the protein structure of 
insulin which allowed different preparations of the drug to be 
produced improving its efficacy. In 1982 human insulin became the 
first genetically engineered drug to be licensed in the world. Oral 
preparations of drugs which stimulate insulin production have been 
used in diabetes since the 1950s. In combination with other newer 
oral drugs and insulin the treatment options for diabetes mellitus 
have and continue to increase and improve. 
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A separate, much rarer disease exists called diabetes insipidus. This 
is not related to diabetes mellitus, although like diabetes mellitus, the 
condition results in large urine volumes if left untreated. Hence 
diabetes insipidus derives its name from the same Greek origin as 
diabetes mellitus. This thesis did not consider diabetes insipidus 
further. For ease of reading, diabetes mellitus has been referred to 
simply as diabetes for the rest of this thesis. 
1.1.2 Aetiology of diabetes mellitus 
Diabetes is a broad diagnosis resulting from a deficiency of insulin, 
either absolute or relative, which in turn causes high levels of blood 
glucose. Shared symptoms arise as a result of abnormal glucose 
levels. 
Diabetes can be partitioned into type 1 and type 2 (although there 
are related conditions such as Gestational diabetes, which were not 
considered further in this thesis). Type I diabetes results from an 
absolute lack of insulin. It occurs in early life or early adulthood. It is 
believed to be caused by auto-immune destruction of the ß islet cells 
of the pancreas, which produce insulin. 
Type 2 diabetes tends to occur in middle age and beyond and 
worsen over time. The initial defect is thought to be an increased 
resistance to insulin in the peripheral tissues and an increased 
secretion of insulin. Insulin resistance continues to worsen over time. 
When the maximal insulin secretary capacity has been exceeded, 
any further increase in blood glucose causes a decline in insulin 
generation. Possible mechanisms for the decline in insulin secretion 
include chronic ß cell failure and high levels of glucose itself causing 
toxic damage to the ß cells. Eventually this may result in an absolute 
17 
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failure to secrete insulin. The combined affect of increasing insulin 
resistance and gradual failure of insulin secretion causes raised 
glucose levels and type 2 diabetes mellitus. 
For more detail on the exact definition of diabetes mellitus including 
the World Health Organisation (WHO)(2) and American Diabetic 
Association (ADA)(3) definitions please see chapter 3.3.1 below. 
1.1.3 The epidemiology of diabetes mellitus 
As a proportion of all diabetes, type 1 and type 2 diabetes are 5-10% 
and 90-95% respectively(4). Both are increasing in prevalence in 
both the western and the developing world(5). The reasons for the 
increasing prevalence of type 1 diabetes are unclear. Factors 
contributing to the increase in type 2 diabetes include: increasing 
levels of obesity, the aging population and to a lesser extent the 
improved survival of those currently diagnosed with diabetes(5; 6). In 
the UK the prevalence of type 2 diabetes is estimated to be around 
1% of the total adult population(7), however, up to a further 3% of all 
adults who have diabetes remain undiagnosed in the community(8). 
Diagnosis is often made by chance in asymptomatic individuals(4). 
This may be as part of routine testing by health professionals or 
health screening, for example for life insurance. There are no 
national screening programs for diabetes mellitus in the UK. In 
America, the ADA have suggested three yearly screening for adults 
over 45 years old(9), despite evidence to suggest that opportunistic 
screening can have a poor yield(10). Screening for diabetes is more 
cost-effective if targeted at people with hypertension(11), although 
overall benefit, frequency and method of screening are yet to be 
firmly established(12). 
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Two clinical epidemiological trials regarding diabetes are of 
particular significance and warrant discussion. The first is the 
Diabetes Chronic Complications Trial (DCCT) from America(13) and 
the second is the United Kingdom Prospective Diabetes Study 
(UKPDS) co-ordinated in Oxford, England(14). The DCCT trial 
recruited 1441 younger individuals, aged 13 to 39 years with type 1 
diabetes and was the first trial to conclusively prove that reducing 
blood sugar levels prevented microvascular complications but with a 
higher incidence of hypoglycaemia(15). The UKPDS recruited 3642 
people with type 2 diabetes, aged between 25 and 64 years. It 
involved a complex design evaluating many different aspects of 
diabetic care. It resulted in the publication of numerous landmark 
papers including the reduction of microvascular complications with 
improved gylcaemic control, evaluation of different treatment 
regimes and highlighted the importance of hypertension in diabetic 
individuals. Many of the different papers published from the UKPDS 
have been quoted throughout this thesis. 
1.1.4 Treatments used in diabetes mellitus 
Type I diabetes requires the administration of exogenous insulin via 
subcutaneous injection. Type 2 diabetes can sometimes be 
controlled with diet and weight loss; restricting the glucose intake 
and allowing the available insulin to go further by having less tissue 
mass to work on. Adipose tissue is implicated in increased insulin 
resistance and decreased insulin sensitivity. If this approach does 
not control the disease, oral medication may be prescribed. Oral 
hypoglycaemic drugs work by either stimulating the pancreas to 
produce more insulin or restricting glucose uptake from the 
alimentary tract and liver. Within the last decade newer medications 
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have become available which increase the sensitivity of peripheral 
tissues to respond to insulin. If these measures are not successful 
people with type 2 diabetes may require the use of insulin to 
maintain adequate blood sugar control. 
1.1.5 Complications of diabetes mellitus 
Like most major diseases diabetes is a condition which contributes 
to co-morbidity as well as causing specific complications. For 
example, people with diabetes are more likely to fall, be socially 
deprived, have disabilities or suffer poor health. However, much of 
this co-morbidity is caused by specific problems relating to diabetes. 
These are now discussed in detail. 
The specific complications of diabetes are numerous and there are a 
number of methods of classifying them. One method is to divide 
them into acute and chronic complications, according to the 
timescale over which the complication occurs. 
1.1.5.1 Acute complications 
Acute complications result from either a lack of insulin or an excess 
of insulin. An acute lack of insulin causes an acute metabolic 
derangement. In type 1 diabetes, the absolute lack of insulin causes 
blood glucose to rise. The resulting metabolic derangement occurs 
over a short time, usually 2-3 days and is often how the disease first 
presents to medical attention. Type 1 diabetic individuals who control 
their disease poorly, either due to concurrent illness or inadequate 
insulin administration are also prone to this acute metabolic state. A 
rarer scenario is the acute metabolic derangement seen in type 2 
diabetes, where a relative lack of insulin causes patients to develop 
a similar but not identical, metabolic state, over a longer time period, 
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which can be up to several weeks. Both of these conditions are 
serious with high mortality but do not affect the majority of those 
diagnosed with diabetes who are able to control their disease 
correctly. 
An acute excess of insulin causes a low blood sugar or 
hypoglycaemia. Within the context of diabetes, an excess of insulin 
is caused solely by the medication used to treat the condition. As 
diabetes results from a lack of insulin and subsequent high blood 
sugar, the main treatment options are based on replacing insulin or 
stimulating the pancreas to produce more insulin. Maintaining the 
blood sugar as near physiologically normal as possible is the best 
way of preventing chronic complications and so every attempt is 
made to keep the blood sugar as near normal as possible. In so 
doing, it is common to cause the blood sugar to drop below 
physiological levels. It happens within minutes and is potentially 
extremely dangerous. Once the symptoms are recognised by an 
individual it can usually be easily and quickly reversed by either 
eating, consuming drinks containing glucose or the administration of 
intravenous glucose. 
1.1.5.2 Chronic complications 
Chronic complications affect both type 1 and type 2 diabetic 
individuals(4; 16). They are the result of a chronically high and 
physiologically abnormal glucose regulation. They occur over a 
longer time period, often many years. They can broadly be divided 
into two groups; microvascular complications, which affect the 
smaller blood vessels in the body, and macrovascular complications, 
which affect medium and larger sized blood vessels in the body. 
21 
Chapter 1 Introduction 
Superoxide formation, secondary to high glucose within the 
mitochondrial electron-transport chain, is believed to form an 
underlying common pathway for the formation of diabetic vascular 
complications(17). 
Microvascular complications are caused by a chronically high blood 
glucose. In a study of PIMA Indians conducted in the US, baseline 
glucose levels at the start of 10 years of follow up predicted the 
development of nephropathy and retinopathy. This population was 
aged over 35 years(18). Blood glucose levels also predicted diabetic 
individuals who progressed to nephropathy in a seven year cohort 
study in the U. S of 232 type I and type 2 diabetic people(19). The 
UKPDS 35 showed that individuals who maintained the lowest blood 
glucose sustained the least microvascular complications(14; 20), 
although they are at the highest risk of hypoglycaemia(21). 
Microvascular diseases affect the eye, especially the retina, known 
as diabetic retinopathy and the kidney, known as diabetic 
nephropathy. 
Macrovascular complications are more complicated and there has 
been no conclusive evidence that lowering blood sugar prevents 
macrovascular complications(22; 23). It is believed that simply 
lowering the glucose level does not mimic the physiology of a non 
diabetic individual(24; 25). Even after treatment has begun diabetic 
individuals remain insulin resistant. Continuing insulin resistance 
contributes to a reduction in endothelial dependent vasodilatation 
and vascular smooth muscle vasodilatation in diabetic subjects. 
Abnormalities observed in nitric oxide controlled pathways have 
been proposed as mechanisms for these processes (25). Ultimately, 
diabetic arteries stiffen earlier than non-diabetic arteries(26). 
22 
Chapter 1 Introduction 
Diabetes is also associated with dyslipidemia(27; 28); high 
triglycerides, high low density lipoprotein (LDL) and low high density 
lipoprotein (HDL). This poor lipid profile is established as an 
independent risk factor for medium and large vessel atherosclerotic 
disease. Finally platelet function is adversely altered in diabetes and 
individuals are prone to arterial thrombosis(25). It is a combination of 
these factors which have been proposed for the high prevalence of 
macrovascular complications even in diabetic people who maintain 
very good overall control of their blood glucose. 
Macrovascular diseases include coronary heart disease, 
cerebrovascular disease and peripheral vascular disease. While 
diabetes is not the sole cause of any of these large vessel 
conditions, it is well established that individuals with diabetes have a 
greatly increased chance of developing these conditions compared 
to individuals without diabetes(16). 
Central, peripheral and autonomic nerves are also prone to damage 
in diabetic individuals. This group of conditions are known as 
diabetic neuropathies. Their aetiology has not been fully 
established(16) and can not simply be attributed to micro or 
macrovascular disease. Abnormal glucose metabolism, oxidative 
injury and vascular Insufficiency are all thought to contribute(29). A 
comprehensive review of epidemiological and trial evidence by 
Gaster et a/ in 1998 suggested a trend towards greater neuropathy 
with poor glycaemic control but did not conclusively prove this(30). 
1.1.6 Hypertension and diabetes mellitus 
Hypertension is common in people with type 2 diabetes(31). 
Hypertension is now also being recognised as an important factor in 
23 
Chapter 1 Introduction 
the development of both microvascular and macrovascular 
complications(4; 32; 33), particularly diabetic renal disease(34) and 
diabetic eye disease(35). 
1.2 Guidelines and recommendations for diabetes care 
Due to the importance of diabetes and its impact on health, many 
national and international recommendations and guidelines have 
been developed. In the UK some of the most important guidelines 
exist as part of the National Service Framework (NSF). The NSF is a 
Department of Health initiative designed to improve health standards 
in specific areas of care. There are currently nine different NSFs. 
Three are of particular relevance to this thesis(4; 36; 37). 
" The NSF for diabetes, 
" The NSF for older people 
" The NSF for renal services 
In 1997, the St Vincents Joint Task Force for Diabetes, an 
international collaboration, identified diabetes in the elderly as an 
important and growing problem throughout the world; where 
treatment and care was often inadequate(38). The European Union 
Geriatric Medical Society (EUGMS) recently published their 
guidelines for the management of diabetes in the older person(39). 
This document was written in collaboration with the International 
Diabetes Federation, the European Associations for the Study of 
Diabetes and the St Vincents Declaration Primary Care Diabetes 
Group. It represented a major step forward in the clinical care of the 
older person with diabetes. 
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1.3 Diabetes mellitus in the older person 
The vast majority of older diabetic individuals have type 2 diabetes 
rather than type 1 diabetes. This is because of the poor life 
expectancy of any individual with type 1 diabetes during the earlier 
part of the 20th century. Insulin did not become available until 1922 
before which life expectancy after diagnosis was only 2.6 years for 
people with type 1 diabetes. Even after insulin's introduction, the life 
expectancy of a 10 year old with type 1 diabetes in 1938 was still 
only 39.8 years because diabetic care was still poor compared to 
todays standards(40). 
Medical management of diabetes in the older person often 
varies(41). This is due to two reasons. Firstly, older people with 
diabetes are a group who have been under represented in clinical 
trials and there is a lack of published scientific evidence to guide 
treatment recommendations. Many major studies of diabetes did not 
recruit patients over the age of 65 years, including the UKPDS(14). 
The lack of information increases with age, with little evidence 
available regarding diabetic people aged 80 years or above. This 
lack of available information is true for virtually every aspect of 
diabetes. Common perceptions that treatment is not worthwhile 
because of the age of the patient, potential difficulties with day to 
day management and reduced life expectancy, along with the 
expected time lag to develop complications, may be reasons for the 
under treatment of the elderly patient with diabetes. If the patient is 
not symptomatic, either hypoglycaemic or hyperglycaemic, then the 
existing treatment regime is often considered to be adequate. 
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If the older diabetic person is to be treated as aggressively as their 
younger counterparts then it is vital to ensure that definite benefit is 
conferred by treatment. Hypoglycaemia, adverse drug reactions, the 
burden of multiple drug treatment and increased anxiety are all 
potential factors which have been used to argue against more 
aggressive treatment of diabetes, particularly in those at the oldest 
ages, though without a good evidence base. Equally if there are 
indeed benefits of aggressive control of glucose and/or hypertension 
in older people with diabetes, then they need to be firmly 
established. The data presented in this thesis would constitute one 
of the largest self reported studies of diabetes in this age group. 
As discussed in this section, the vast majority of elderly people with 
diabetes have type 2 diabetes. In this thesis all the subjects with 
diabetes had type 2 diabetes. Therefore for the ease of reading all 
references to "diabetes" relate to type 2 diabetes, unless specifically 
stated. 
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1.4. Thesis Objectives 
1.4.1. Objective 1: To establish the prevalence of diabetes and 
its complications in people aged 75 years and over. 
Firstly, the prevalence of diabetes, including previously undiagnosed 
diabetes and glycosuria was estimated. Following this, the diabetic 
population was described. The description of the diabetic population 
included demographic characteristics and social status. Other 
descriptive factors of interest were socio-economic status, smoking 
history, alcohol intake and anthropometric data. Finally, 
microvascular and macrovascular endpoints, were estimated within 
the study population. The population attributable risk fraction was 
calculated for each diabetic endpoint. 
1.4.1.1 Background 
The prevalence of type 2 diabetes has increased in all age groups 
and populations over recent decades(6). In the older person exact 
prevalence estimates vary between authors. Variations exist 
because the age of populations varies between studies, ethnic 
differences exist, case ascertainment varies and the method of 
diagnoses of diabetes can vary(42). No U. K. contempory large scale 
community based population estimates of the prevalence of diabetes 
in the older person are currently available. 
Large well conducted studies, such as the WHO multinational study 
of vascular disease in diabetes (WHO MSVDD), have established 
the increased prevalence of diabetic end points in diabetic younger 
populations(43; 44). The prevalence of diabetic end points has 
previously been assessed in older populations. However, these 
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studies have tended to be small and contained limited information 
regarding the very oldest diabetic populations. 
1.4.2 Objective 2: To describe the management and patient 
understanding of their diabetes in this age group 
For the diabetic participants, the treatments taken for diabetes and 
who, if anyone, was medically responsible for managing their 
diabetes were recorded. Next, an estimation of the degree and type 
of home glucose testing was made. The degree to which additional 
diabetic services were utilised was then described. The occurrence 
and management of hypoglycaemia was assessed. Correct 
management of hypoglycaemia and its avoidance requires a high 
degree of patient understanding about their condition. Three specific 
questions regarding the level of understanding were then described 
for the diabetic population. The final part of this objective was to 
assess associations of these exposures and the presence of 
diabetic endpoints. 
1.4.2.1 Background 
The day to day management of diabetes is largely patient based. 
Education is recommended for everyone with a new diagnosis of 
diabetes. Education enables patients to take responsibility for their 
own care. There are several components of successful, long term, 
patient based management. These include diet, correct self- 
medication, monitoring blood glucose and the use of specialties 
allied to diabetic health care. 
Numerous health professionals can be either solely or jointly 
responsible for a diabetic persons care. This could be the GP, 
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diabetic specialist nurse or hospital specialist. The degree to which 
the older person sees any of these medical specialists is largely 
unknown. Diabetes is treated on a multi-disciplinary basis, using 
hospital and community based specialists to aid individual 
knowledge and treatment. It is believed that the use of a range of 
diabetic specialists aids in the overall care of the patient. For 
example, dieticians provide advice regarding weight loss and 
suitable diet. Chiropodists aid in foot management in the diabetic 
person and regular eye screening can detect and treat diabetic eye 
disease. The degree of utilisation of these different services has not 
been assessed in a large older age group. 
Home glucose testing is designed to maximised a persons ability to 
mange their own disease; tightly regulating blood sugar while at the 
same time preventing hypoglycaemia. This thesis provided a 
description of the level and type of home glucose testing in an 
elderly group of this age in the United Kingdom. It also provided an 
estimate of the prevalence of hypoglycaemia in the older diabetic 
person. 
It is likely that some older diabetic individuals have poor 
understanding of every day management of their condition, 
exacerbated in those with cognitive impairment. The level of 
diabetes understanding amongst an elderly population has never 
been assessed on this scale before. This thesis provides an 
interesting insight into the degree of understanding of the disease in 
an older diabetic population and the factors that were associated 
with it. 
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1.4.3 Objective 3: Evaluation of the relationship between 
hypertension and diabetes in this age group. 
The next objective investigated the relationship between diabetes 
and hypertension, both diastolic and systolic, in older diabetic 
patients. The diabetic hypertensive population was described. 
Hypertension was then assessed in relation to diabetic end points. 
1.4.3.1 Background 
The control of hypertension, both systolic and diastolic, is 
increasingly recognised as being equally and possibly more 
important than blood sugar control(32; 33; 45). Increasing amounts of 
evidence support the role blood pressure plays in the pathogenesis 
of most diabetic end points, particularly diabetic retinopathy(46) and 
diabetic renal disease(34; 47). The affect of blood pressure in 
causing diabetic end points was shown convincingly from UKPDS 36 
and 38 and from the micro-HOPE sub study of the Heart Outcomes 
Protection Study(32; 33; 45). While the affect of blood pressure has 
been established the exact levels which require treatment are not 
yet established. (27; 33; 45). The American Diabetic Association 
(ADA) currently recommends 130 mmHg systolic and 80 mmHg 
diastolic as the maximum levels of blood pressure for people with 
diabetes. The ADA recommends that diabetic individuals, of all ages, 
with blood pressure readings higher than these levels should have 
their blood pressure treated. European guidelines recommend less 
aggressive blood pressure treatment in the older diabetic person 
and the guidelines make allowances for comorbidity(39). Whether 
blood pressure has the same associations with diabetic end points in 
older people has yet to be established, let alone whether specific 
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thresholds for treatment of blood pressure are appropriate. There is 
some evidence that hypertension at the extremes of old age 
behaves in a different manner to younger populations(48) and there 
is currently no consensus regarding the best type of anti- 
hypertensive medication to use(49). 
1.4.4 Objective 4: Evaluation of the relationship between renal 
function and diabetes in this age group. 
This objective involved the investigation of the relationship between 
renal function and diabetes in an elderly diabetic group. Firstly, the 
older diabetic population with renal impairment was described. 
Comparisons of renal function (proteinuria, creatinine measurements 
and Glomerular Filtration Rate) in people with and without diabetes 
were then conducted. 
1.4.4.1 Background 
End stage renal failure is increasing in prevalence(50). Type 2 
diabetes has recently become the commonest reason for end stage 
renal failure and subsequent dialysis in Western Europe(31). The 
majority of diabetic renal disease shows a similar morphological 
pattern and disease progression. Typically, larger and larger 
amounts of protein are lost from the kidney into the urine, eventually 
leading to impaired renal function and failure(51). Advanced age and 
male sex have both been identified as non-modifiable risk factors for 
the progression to end stage renal failure among diabetic 
people(47). Established modifiable risk factors include elevated 
blood pressure, albuminuria, proteinuria, poor glycaemic control and 
smoking(47; 52). Once end stage renal failure has developed in 
patients with type 2 diabetes the life expectancy is very poor(50), 
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with cardiovascular death having a disproportionably high incidence 
in people with diabetic renal disease(50). There is, however, 
growing evidence that the progressive renal impairment seen in 
diabetes is preventable(47). In addition there is evidence to suggest 
that some medications may prevent onset, and delay progression, of 
diabetic renal disease(53). This thesis provided an assessment of 
several of these areas in an older diabetic population. 
1.4.5 Objective 5: Comparison of the rate of admission to 
hospital in an older diabetic population, compared to an older 
non diabetic population. 
This objective undertook to assess and describe the data available 
regarding admission to hospital; admission rates, number of 
admissions and the length of stay in an elderly diabetic population. 
1.4.5.1 Background 
Diabetes has been established as an independent predictor of 
health care utilisation in adults aged 71 years or older(54). A six year 
cohort study in America showed that diabetes predisposed to 
repeated admission to hospital in the same individual. This study 
used the Medicare program and assessed people aged over 70 
years(55). If diabetes contributes to health care use and repeated 
admission then elderly diabetic patients will have a higher rate of 
admission to hospital. This thesis provides the opportunity to assess 
admission rates, the length of stay of participants with diabetes and 
some of the risk factors for admission to hospital in an older diabetic 
population. 
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1.4.6 Objective 6: Evaluation of the affect of diabetes on 
mortality rates in an older population. 
The final objective of the thesis investigated the risk of death; all 
cause mortality and cause specific mortality (circulatory and renal) in 
the older diabetic person. The risk of death in diabetic people with 
renal impairment was also assessed. 
1.4.6.1 Background 
Although it is likely that diabetes affects morbidity and mortality in 
the older person, the evidence is sparse. In 1997, Sinclair and 
colleagues performed a comprehensive literature review of 20 
studies(56). They concluded that there was likely to be an 
association between diabetes and death rates. More recent studies 
have confirmed the association with mortality and diabetes in the 
older person(57-60). In general these studies suggest that diabetes 
remains an important contributor to mortality in the older person, but 
the extent of its effect declines with increasing age. The limitations of 
these studies are that they provided little detailed information in the 
very oldest people and none for diabetic people aged over 90 years 
and that there is no consensus among them regarding the affect of 
gender and diabetic mortality. 
The predominant cause of excess mortality in people with diabetes 
is cardiovascular disease(60; 61). Cardiovascular death has been 
estimated to be the cause of death in up to 86% of diabetic 
people(62). As well as cardiovascular disease being the major cause 
of death in people with diabetes, diabetes has become a greater 
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contributor to the burden of cardiovascular mortality and morbidity 
for all adults(63; 64). This is due to several reasons. Firstly the 
increasing prevalence of diabetes. Secondly the rate of improvement 
in cardiovascular outcome is lower in diabetic individuals than non 
diabetic individuals(64). Finally diabetes is often associated with 
multiple cardiovascular risk factors(61) which increase the diabetic 
individuals risk of cardiovascular disease still further. 
In addition to their contribution to end stage renal disease, poor 
renal function and proteinuria are both independent risk factors for 
both all cause(60) and cardiovascular mortality(65). It also follows 
that if diabetes affects renal function, the rate of renal mortality 
would be raised in the older diabetic person. 
It has not been established conclusively whether cardiovascular or 
renal mortality are increased in the older diabetic person and there is 
comparatively little evidence of the affect of diabetes at the extremes 
of age. Neither has the affect of proteinuria or poor renal function in 
old diabetic people been assessed on a large scale. The 
associations with death (all cause, circulatory specific and renal 
specific) and the affect of renal impairment on mortality in elderly 
diabetic people, many of them very old, were studied in this thesis. 
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Chapter 2. Methods 
2.1 Background 
2.1.1 The MRC Trial of the Assessment and Management of 
Older People in the Community (the MRC study) 
Investigators: Professor Astrid Fletcher (London School of 
Hygiene and Tropical Medicine), Dr Dee Jones (University of 
Wales College of Medicine), Professor Chris Bulpitt (Imperial 
College London), Dr Alistair Tulloch (University of Oxford). 
Trial steering committee: Professor Sir John Grimley Evans 
(Chairman from 2001), Professor Sir Andy Haines (Chairman 
1994-2000), Professor Carol Brayne, Professor Karen Luker. 
Funding for the trial was provided by the Medical Research 
Council, the Department of Health and the Scottish Office. Local 
ethics committee approval was obtained for each of the 
participating general practices. 
The data presented in the following chapters was collected as 
part of the MRC study. It was therefore important to describe the 
trial in some detail. The trial was a two stage large multi-centre 
trial involving 106 general practices. The principal objectives of 
the trial were to evaluate different packages of multidimensional 
assessment and management of elderly people(66). 
Background to the MRC trial 
Three studies published in the 1960s and early 1970s identified a 
high level of undetected disease and unmet social needs in 
elderly people(67-69). Subsequently six randomised controlled 
trials were conducted in the late 1970s and 1980s(70-75). Five of 
these trails were conducted in the UK and one in Denmark. All of 
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them had low power and short follow up time. None of them 
provided conclusive evidence for regular screening in elderly 
people, although the Danish trial(72) suggested possible benefits 
in mortality and admission to hospital. Despite the lack of 
conclusive evidence, in 1990, the Department of Health 
introduced an annual screening assessment for anyone aged 
over 75 years. The annual assessment was very general but 
some broad areas suggested for evaluation were; sensory 
function, mobility, mental condition, physical condition including 
continence, use of medicines and social environment. The 
screening assessment formed part of the general practitioners 
contract of service and was thus compulsory. 
If disease is detected via a screening program there needs to be 
appropriate medical management pathways in place to deal with 
that disease. There is some evidence to suggest that hospital 
based care may offer advantages over primary care based 
management. A review of the available evidence and meta- 
analysis(76) suggested that hospital based multidisciplinary 
geriatric care offered advantages over other forms of 
management of older people. 
The MRC trial of the assessment and management of older people in the 
community 
In light of this compulsory screening assessment the MRC study 
was undertaken. Its primary aims were twofold; to determine 
whether an annual multidimensional screening assessment 
identified disease in the community and to assess optimal 
methods of management of disease identified. The MRC study 
included comparison of multidisciplinary geriatric care (GM) 
against primary care based treatment (PC). Therefore 
identification of disease was the first stage of the study and the 
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second stage was the method of clinical management; either GM 
or PC. There were 52401 people aged 75 or over who were not 
living in a nursing home and did not have a terminal illness invited 
to participate. Participants were cluster randomised by general 
practice to a targeted arm or a universal arm. There was no 
control group who received no screening whatsoever because an 
annual screening assessment was a requirement of all GPs and 
denying anyone a screening assessment was deemed unethical. 
All participants enrolled in the trial then underwent a brief 
assessment questionnaire. Following the brief assessment, 
practices randomised to the universal arm then conducted a 
detailed assessment. People in the targeted arm only underwent 
a detailed assessment if they "triggered" predetermined questions 
deemed to indicate unmet health or social needs. People enrolled 
into either arm of the trial were then followed for admission to 
hospital, admission to institutional care, quality of life and death, 
all of which were primary outcomes of the trial. There were 21128 
individuals originally randomised to the universal arm of the trial. 
It is these people who were considered for this thesis. Individuals 
originally randomised to the targeted arm did not have data 
collected relating to diabetes. Individuals undergoing detailed 
assessment having been "triggered" from the targeted arm are no 
longer randomised and thus liable to selection bias. These 
individuals no longer form a representative sample. See appendix 
1 for a diagrammatic representation of the MRC trial structure. 
The health aspects of the detailed screening questionnaire were 
extensive, covering many areas. These included physical health, 
such as the Rose angina questionnaire(77) and mental health, 
with a 30 point mini mental state examination (MMSE)(78). As 
well as questions there were physical measures taken, including 
37 
Chapter 2 Methods 
body mass index and other anthropometric data, pulse rate and 
blood pressure. The social status of individuals was assessed 
with various estimates of socio-economic status and social 
isolation. Current drug history was collected, which included the 
name, dose, frequency and potential interactions of all 
medications(79). Blood tests for haematology, urea and 
electrolytes were performed. Routine urine dipstick analysis was 
also performed. The detailed questionnaire can be seen in its 
entirety in appendix 2. The questions relating to physical health 
contained 15 questions specifically regarding diabetes. It was 
these 15 questions which formed the basis for much of this 
thesis. They are shown on page 15 of appendix 2, questions 38a 
to 38m. 
Due to its size, the range of the information collected and the 
nature of the outcome variables (admission to hospital and death) 
the MRC trial of the assessment and management of older 
people in the community provided an extensive resource for 
studying diabetes in the older person. 
In 2004 the full results of the original trial were published(80). 
2.1.2 MRC GP Research Framework 
The MRC general practice research framework (MRC GPRF) is a 
resource used for medical research throughout the UK. It was first 
established in the early 1970s and subsequently expanded 
throughout the 1980s. The cross section of general practices now 
represents the full spectrum of different practices seen throughout 
the UK; urban and rural locations, large and small practice size, 
poor and affluent locations. It now consists of over 1000 practices 
representing approximately 10% of the UK population. Practices 
who form part of the GPRF are invited to participate in trials 
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conducted by the MRC and choose which they would like to 
participate in. The MRC trial for the assessment and 
management of elderly people in the community took place in 
practises belonging to the GPRF. 
2.1.3 Outcome measures used in the MRC trial. 
The primary outcome measures used in the MRC trial were 
admission to hospital, admission to institutions (hospitals, 
residential homes or nursing homes), quality of life and death. 
Quality of life data was collected on a sub sample of the trial 
population. The quality of life data was collected via interview 
prior to the detailed assessment, at 18 months and again at 36 
months. This data formed the basis of the PhD undertaken by Dr 
Elizabeth Breeze at the London School of Hygiene and Tropical 
Medicine (LSHTM), the results of which are presented 
elsewhere(81; 82). Quality of life was not considered further in this 
thesis. 
Admission to hospital was collected for each trial participant for 
the two years immediately after they had completed the brief 
assessment. Nurses based within each participating general 
practice carried out six monthly notes searches on admission to 
hospital, based on the hospital discharge letter. The information 
recorded included speciality, date of admission, date of discharge 
and diagnosis. The hospital discharge summary has been 
established as a reliable method of recording discharge 
information(83-85). 
Mortality follow up was collected for all participants in the trial. 
This was done by registering all trial participants with the Office of 
National Statistics in Southport, UK. Whenever any trial 
participant died and the death certificate arrived in Southport 
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(where every death certificate in the U. K. is recorded) the details 
would be collected. Cause of death for all mentioned causes, 
including the underlying cause, was coded by ONS initially using 
ICD 9 and ICD 10 from October 2002. The results in this thesis 
were based on deaths collected until October 2003. 
2.1.4 The Egton Medical Information System (EMIS) 
The majority of general practitioners in the UK use clinical 
software to record clinical events and prescriptions. Of those who 
do use clinical software over 55% use software known as the 
Egton Medical Information System or more commonly EMIS. It 
was developed by two general practitioners in Egton, UK during 
the 1980s. The system forms an electronic record of each patient 
event and forms the basis of the patients medical record, held by 
the general practitioner. Practices in the MRC study gave their 
consent for their EMIS records to be accessed. EMIS data 
relating to the participants in the MRC trial has been collated at 
Nottingham University, UK. The EMIS data has been collated 
from the time that the general practice began using EMIS 
software and for the entire follow up period of each individual who 
participated in the original trial. EMIS data is still being updated 
by participating general practices for those individuals who are 
still alive. For approximately half of the participants in the MRC 
study further information regarding their health was available from 
the EMIS system. The EMIS data is not available for all the trial 
participants because not all the GP practices who were involved 
in the MRC trial use the system and three practices who did use it 
did not agree to its use in the MRC trial. 
The EMIS data had two major functions; firstly it provided another 
method of identification of individuals with diabetes who were not 
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identified from the detailed questionnaire and secondly as a 
validation tool. The EMIS data, where available, forms a 
representative sample of MRC trial participants. It was used to 
provide a sensitivity estimate for people who self reported as 
having clinically diagnosed diabetes. EMIS entries relating to 
diabetes or the use of any diabetic medication before recruitment 
into the MRC trial indicated that person had diabetes when they 
entered the MRC trial. All these people should have responded 
positively to the questions regarding diabetes when they 
completed the detailed questionnaire. Comparing the numbers of 
people who did actually respond positively to having diabetes in 
the trial questionnaire enabled a sensitivity and specificity 
estimate to be calculated for the question "Have you ever been 
told by a doctor that you have sugar diabetes? " which was used 
to identify trial participants with diabetes (see Chapter 3.6.8 and 
appendix 2). 
2.2 Plan of analysis 
2.2.1 Cluster randomisation 
The MRC study was a cluster-randomised trial with a2x2 
factorial design i. e. practices were randomised to the universal 
arm then randomised to GM or PC or they were randomised to 
the targeted arm then randomised to GM or PC (see appendix 1). 
When healthcare interventions are conducted at a level higher 
than the individual, such as organisations, regions, towns or 
schools, they are often randomised at the group level rather than 
the individual level; this is known as cluster randomisation. For 
example, whole schools may be allocated to intervention A and 
compared with schools allocated to intervention B. The MRC trial 
was implemented at the level of the general practice and 
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therefore was a cluster randomised trial. There are a number of 
reasons why trials are conducted using cluster randomisation(86). 
The reasons for using cluster randomisation listed below were all 
applicable to the MRC study, they included; 
" Public health programmes, such as the evaluation of a 
screening program, are generally implemented at the 
organisational level (in the MRC study the general practice) 
rather than the individual level, so cluster level 
randomisation was more appropriate for the evaluation of 
the program. 
" It is potentially both unethical and/or unpractical to 
randomise individuals within an organisation to different 
treatments. It may therefore be preferable to allocate all 
individuals within an organisation to the same treatment. 
" If individuals are randomised to different treatments within 
an organisation then an intervention may be susceptible to 
contamination bias. For example, different health 
promotional messages within an organisation may be 
communicated between individuals making true 
comparisons of the different interventions more difficult. 
" There are practical advantages in terms of cost and time 
when interventions are allocated at a cluster level. Staff 
within each cluster have to familiarise themselves with and 
conduct only one intervention rather than two or more. 
Likewise central administration is simpler if each cluster 
has one intervention. 
While the reasons above make cluster randomised trials seem 
attractive there are important statistical considerations which 
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must be taken into account during design and analysis of a 
cluster randomised trial(87). When a study is conducted at the 
cluster level, individuals may be more highly correlated within the 
cluster than with individuals within other clusters. The reasons for 
this are listed below and were all applicable to the MRC study; 
" Participants in a study have chosen the organisation to 
which they belong and therefore may have certain things in 
common. For example the general practitioner to which 
they are all registered. 
" Cluster level attributes may have a common influence over 
all the individuals within that cluster. For example, 
outcomes of an intervention may vary systematically 
between practice nurses, with outcomes for patients 
interviewed by one practice nurse being more similar to 
those interviewed by another practice nurse. 
" Individuals may interact within each cluster, leading to 
similarities between individuals within each cluster. 
This lack of independence affects the statistical analysis in two 
ways. Firstly, there can be a marked drop in power of the study. 
Secondly, if observations are correlated, standard errors 
generated may be underestimated unless clustering has been 
taken into account. 
To allow for the correlation between subjects, the sample size 
can be calculated by multiplying the formula for individually 
randomised trials by a quantity known as the design effect or 
variance inflation figure(88). The design effect can be calculated 
form the formula: 
Design Effect= 1+(nO- 1)p 
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Where nO is the average number of individuals within each cluster 
and p is the intraclass correlation coefficient. The intraclass 
correlation coefficient is the proportion of the total variation 
between the subjects within the same cluster attributable to the 
clustered sampling. The design effect for different outcomes was 
taken into account when calculating the number of clusters 
required for the MRC trial. 
To allow for the underestimation of the standard errors which are 
generated consideration needs to be taken at the time of 
analysis. If this is not done, any confidence intervals generated 
from the standard errors will be too narrow and p values too 
small. By incorporating the design effect into conventional 
standard error formulas used for hypothesis testing and 
estimating confidence intervals, the correlation between 
individuals in each cluster can be taken into account(89). All the 
statistical analysis conducted in the following chapters were 
performed to allow for this. Cluster randomisation also has 
implications when dealing with confounding. Regression methods 
for dealing with confounding need to be performed at the cluster 
level rather than the individual level. Random effects models 
(multilevel models) can take into account associations between 
individuals within clusters. These models control for both 
individual level and cluster level characteristics(89). 
In the MRC trial all the randomisation occurred at the general 
practice level by a computer generated randomisation. To ensure 
that the general practices did not differ in population 
characteristics, between randomisation groups, randomisation 
was stratified by Jarman Score and Standard Mortality Ratio 
(SMR). Practices had list sizes of between 200 and 700 patients. 
The sample size calculations were conducted using methods 
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developed for use in cluster randomised trials(90). Each general 
practice contained a large enough sample size to conduct the 
MRC trial. 
2.2.2 Missing data and outlying values 
Categorical values were tabulated to identify missing values. To 
minimise the decrease in power by loss of partial information, 
variables with over 100 missing values had a separate missing 
value generated which was used in the analysis. When a variable 
had less than 100 missing values, the missing values were 
ignored and the participants with missing data excluded from that 
part of the analysis. The justification for this was that the dataset 
was of sufficient size to enable exclusion of small numbers of 
variables to be of little affect on the final results. 
Continuous variables were visualised graphically to assess their 
distribution and outlying values were inspected to check their 
accuracy. Variables were discarded and treated as missing when 
they were found to be obviously wrong. For example, the date of 
diagnosis of diabetes stated as 1868 or diastolic blood pressure 
recorded as 15 mmHg. 
2.2.3 Statistical software 
All the analysis was conducted using Stata statistical 
software(91). The importance of cluster randomisation has been 
discussed above and this was accounted for when using Stata. 
The "svy" family of commands was used which were designed for 
multi-stage survey based clustered samples. This allowed for 
clustering within practices and generated the intracluster 
correlation coefficient. 
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2.2.4 Approaches to the analysis 
Chapters 3 and 4 are primarily descriptive and associations were 
calculated using univariate analysis. Using survey commands in 
Stata the prevalence of diabetes was calculated and univariate 
analysis used to identify associations with diabetic end points and 
the use of diabetic services. More complex analysis in these 
chapters that required controlling for explanatory factors was 
conducted using logistic regression. The population attributable 
risk fraction for each diabetic endpoint was calculated using 
Stata. Chapter 5 concentrated on the relationships between blood 
pressure and diabetes. Initially diabetic end points were tested for 
associations with blood pressure. Blood pressure was grouped 
and logistic regression used. In chapter 6 the relationship 
between diabetes and renal function was assessed using 
proteinuria and creatinine measurements. These were treated as 
binary variables and logistic regression analysis was performed. 
Admission rates were assessed in chapter 7 using Poisson 
regression comparing the rates of admissions between all 
diabetic individuals and non diabetic individuals. The Poisson 
regression was undertaken stratifying by five year age groups. 
The Poisson model was tested at the 5% significance level using 
likelihood-ratio testing after any addition to the model of potential 
confounding factors or interaction terms. Chapter 8 concentrated 
on all cause and cause specific mortality. The cause specific 
mortalities were circulatory and renal mortality. All survival 
analyses used Cox regression analysis. Step wise Cox 
proportional hazard models were constructed. Potential 
confounding factors and interaction terms were included in the 
model and tested with the addition of each term to the model. 
After each addition to the model the proportional hazards 
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assumption was tested to ensure it was still maintained. All 
variables that were left in the final model affected the hazard ratio 
generated by more then five percent and were significant for the 
Schoenfield residual test statistic at the 5% significance level. The 
Cox proportional hazard model was visually inspected to ensure 
that proportionality was maintained. 
2.2.5 Potential confounding factors 
Variables that were considered, a priori, as potential confounders 
were age, sex, socio-economic status measured using the 
Carstairs index, smoking history, alcohol intake, mini mental test 
score (MMSE), previous myocardial infarction, previous 
cerebrovascular disease, Body Mass Index (BMI) and Waist-Hip 
ratio (WHR). 
Age, sex, socio-economic class, smoking and alcohol are 
common confounders. Therefore these variables should be 
included as potential confounding factors in any analysis where 
that information is available. Age was grouped using five yearly 
intervals, up to the age of 90, when anyone aged above this was 
grouped together. The Carstairs index is a measure of social 
deprivation(92; 93). The Carstairs index is based on four 
component variables; overcrowding, male unemployment, social 
class and car ownership. The Carstairs index was obtained from 
postcode linkage of study participants addresses obtained from 
the 1991 census data. The Carstairs index was divided into 
quintiles, with the lowest quintile representing the poorest section 
of this population. Smoking, was grouped into never smokers, ex- 
smokers and current smokers, it did not assess pack years. 
Alcohol usage was classified according to the current 
recommendations of the Department of Health(94). It was 
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classified into men and women who drank less and those who 
drank more than upper limit currently suggested. This was 21 
units/week for men and 14 units for women. In 1997, the 
Rochester study showed that the risk of dementia is increased for 
both men and women with type 2 diabetes. Work conducted in 
the UK showed that older people with type 2 diabetes had an 
excess of cognitive dysfunction, associated with poorer ability in 
diabetes self-care and greater dependency(95). This study used 
a Mini Mental State Examination (MMSE) score of 23 or below for 
a threshold of cognitive impairment and therefore 23 was also 
used in this analysis. The MMSE was designed in 1975 by 
Folstein and collegues(78). It is a widely used and validated as a 
screening tool for cognitive impairment. However it is limited by 
the educational and language ability of participants. In addition 23 
is a cut off point, someone with a score above this level may still 
have cognitive impairment but this would not be detected using 
this measure. Both previous history of myocardial infarction and 
cerebrovascular accident were available. They were both 
assessed as potential confounding factors because they indicate 
specific disease and comorbidity. The Nurses Health Study found 
that Body Mass Index (BMI) was the strongest predictor for the 
development of diabetes(96) and it was therefore used in this 
analysis. It was divided into four groups, according to the WHO 
guidelines(97). The classifications were; below 18.5 Kg/M2 
underweight, 18.5-25 Kg/M2 normal weight, 25-30 Kg/M2 
overweight and over 30 Kg/M2 obese. Epidemiological evidence 
also links waist-hip ratio with the development of diabetes(98). 
The World Health Organisation report on the definition of diabetes 
defines an increased waist hip ratios to be >0.90 for males and 
>0.85 for females(99). These figures were used in this thesis. 
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Further variables which were available from the MRC trial and 
considered for analysis were; a fall within the last six months, 
taking more than five medications, living alone, difficulty making 
ends meet, anyone to call for help and poor self rated health. The 
justification for using these variables is that they represent 
general markers of health and social isolation, which could all 
potentially bias the results generated. For example, if someone is 
taking over five medications, they are likely to have a least a 
modest degree of underlying pathology. Likewise if someone has 
no one to call for help, then they must be socially isolated to 
some extent. 
The final four variables which were chosen a priori as potential 
confounding factors were blood pressure, systolic and diastolic, 
proteinuria and raised creatinine. Each of these factors are well 
established in the development of diabetic complications(31; 33) 
and therefore warranted inclusion and testing in any statistical 
model for which diabetes was an exposure. 
2.2.6 Effect modification 
The prevalence of diabetes changes with age and this was 
supported by the findings in this study (see chapter 3) therefore it 
was important to consider age as an effect modifier. 
Similarly the prevalence of diabetes is higher in men, again 
supported by this study (see chapter 3) and therefore sex was 
treated as a potential effect modifier when the analyses were 
performed. 
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Chapter 3. Identification of older people with 
diabetes and the prevalence of diabetic 
complications 
3.1 Summary of objectives 
To describe a large community based sample of older people, with 
and without diabetes; 
To assess the prevalence of diabetes and its complications in the 
older person. 
3.2 Background 
3.2.1 Prevalence estimates of diabetes 
There are numerous prevalence estimates of diabetes in the older 
person. Prevalence estimates, both diagnosed and undiagnosed, 
vary widely and are affected by a number of factors. These include 
age, ethnicity, the type of population studied (community, hospital or 
institution) and differences in the method of diagnoses(41; 100-104). 
The prevalence generally increases with age but stabilises or even 
decreases in the very elderly(7; 8; 105-111). A Canadian community 
based prevalence study is one of the best examples; the study 
demonstrated that the prevalence of diabetes decreased from 10.2% 
in people aged 65-74 years to 7.8% in people aged over 85 
years(111). Some examples of the differences in prevalence 
estimates which were available can be seen in table 3.1. 
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3.2.2 Estimations of the prevalence of microvascular complications among 
people with diabetes 
In the older diabetic adult the amount of information that is available 
regarding the prevalence of microvascular diabetic endpoints is 
sparse. Much of the available information has been generated from 
small scale local studies. There are also two large scale studies 
which assessed several diabetic end points. The first of these was a 
survey of the prevalence of diabetes complications conducted in 
South Glamorgan, Wales(112). This study identified 10709 people 
with type 1 and type 2 diabetes of all ages, including people aged 
over 75 years. Diabetic people were identified from both GP and 
hospital records. The study identified several diabetic complications; 
retinopathy, nephropathy, coronary and cerebrovascular disease. 
The second large study was carried out in France and published in 
2000. The French study identified 5548 patients with type 2 diabetes 
and assessed several micro and macrovascular end points(113). 
The French study population had a mean age of 63 years and were 
identified from electronic data records from a representative sample 
of French GPs. The French study considered the duration of 
diabetes and found that each complication increased in prevalence 
with increasing duration of diabetes. The prevalence of each diabetic 
end point derived from both these studies will be highlighted in the 
following paragraphs where they are appropriate in conjunction with 
the other available data. 
The Welsh study identified retinopathy or cataract and found that 
over 20% of diabetic people aged over 75 years had either of these 
complications(112). The French study found retinopathy to increase 
from 7.5% in people who had suffered from diabetes for under five 
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years to 30.0% in people who had diabetes for over 15 years, in 
people aged over 75 years(113). A study from Ireland, involving 150 
people, newly diagnosed with diabetes, showed a prevalence of 
14% for retinopathy, in patients over the aged of 70 years(l 14). The 
Wisconsin epidemiological study of diabetic retinopathy showed an 
overall prevalence of 39% in 151 patients aged over 70 years(115). 
A Welsh case control study found the prevalence of visual 
impairment to be 40% in older people with diabetes compared to 
31% in non diabetic people(116). In Italy, the prevalence of 
retinopathy was found to be 24.6% in diabetic people aged over 70 
years old(117) and Nathan and colleagues found similar prevalence 
levels of 25% in 185 diabetic people aged between 55 and 75 
years(118). The duration of diabetes, the use of insulin, chronically 
elevated blood sugar levels and raised blood pressure have all been 
associated with the presence of diabetic retinopathy(114; 115; 117- 
119). Previous work done by Dr Jenny Evans at the London School 
of Hygiene and Tropical Medicine, on the causes of visual 
impairment in the elderly used the MRC trial(120; 121). Using a 
subset of 1742 people identified with visual impairment, a hospital 
ophthalmologist detected diabetes as the underlying cause of visual 
impairment in 3.4% of cases. 
The Welsh study found nephropathy to be under 5% in people aged 
over 75 years(112). The French study found either proteinuria or 
raised creatinine (>150 pmol/I) in 23.1% of diabetic people aged 
over 75 years with a history of having diabetes for over 15 
years(113). In 821 patients aged between 50 and 75 years 
proteinuria was found in 29.2% of a diabetic population in South 
East London(122). In the same study 12.5% of the population had a 
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creatinine level greater than 120 pmol/1(122). In 2004, the DAI study 
(Diabetes and Informatics study group, Italian Association of 
Diabetologists, and Italian National Institute of Health) found the 
prevalence of microabluminuria to be 25.0% in men and 19.3% in 
women. Proteinuria was found to be 9.5% in men and 6.1 % in 
women. This was a large study which recruited 19468 participants. 
The average age in the study was 65 years for men and 67 years for 
women(123). 
3.2.3 Estimations of the prevalence of macrovascular complications among 
people with diabetes 
Macrovascular disease is associated with a triad of large vessel 
conditions; coronary artery disease, cerebrovascular disease and 
peripheral vascular disease. 
The Welsh study from South Glamorgan estimated all forms of 
coronary heart disease to be over 35% in diabetic people aged over 
75 years(112). The French study found "coronary insufficiency" in 
20.3% of over 75 year old diabetic people. This figure rose to 36.5% 
in people who had had the disease for over 15 years(113). In the 
DAI study mentioned above (n=19468) the prevalence of coronary 
artery disease was 11.0% and all acute myocardial events 
5.8%(123). In a population of 832 people admitted with a myocardial 
infarction, the prevalence of diabetes was found to be 9.7%, which 
was higher than an age matched group (6.1%)(124). A similar more 
recent study in 2050 people aged over 65 years found the 
prevalence of diabetes to be 28% of all myocardial admissions(125). 
The Minnesota Heart Survey found the prevalence of diabetes in 
people with myocardial infarction to be increasing since 1970 and to 
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be greater in women than men, 25.8% vs 16.8%(126). The 
Framingham study found that diabetic men were more likely to have 
a fatal myocardial infarction and women four times more likely to 
develop heart failure after a myocardial infarction(127). The UKPDS 
23 highlighted poor gylcaemic control, poor lipid profile, raised 
systolic blood pressure and a history of smoking as risk factors for 
the development of coronary artery disease(27). The UKPDS 66 
showed that myocardial infarctions were more likely to be fatal in 
people with higher glucose levels, increased age, increased blood 
pressure and albuminuria(128). 
For cerebrovascular disease, the Minnesota Heart Survey also 
estimated the prevalence of diabetes in people hospitalised for 
stroke. It was found to be 10.5% in men and 25.9% in women(129). 
Increased age, smoking, increased systolic blood pressure and the 
presence of atrial fibrillation have all been shown by UKPDS 60 to 
predict the risk of a first stroke(130). The largest study to date in the 
older person was that conducted by Barzilay and colleagues in the 
Cardiovascular Heart Study(131). This recruited 5712 people all 
aged over 65 years. They were screened for cardiac and 
cerebrovascular disease using several parameters. Each participant 
then underwent fasting glucose measurements. In people found to 
have known diabetes the prevalence of history of angina, myocardial 
infarction or cerebrovascular disease were 30.7%, 25.2% and 12.6% 
for men and 31.8%, 19.6% and 12.7% for women respectively. In 
each case the prevalence estimates were lower for those with newly 
diagnosed diabetes. In Wales, the South Glamorgan study identified 
cerebrovascular disease in approximately 20% of the population 
aged over 75 years(112). 
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When considering peripheral vascular disease, the prevalence 
increases with the duration of disease and was found to be 12.5% 
after 18 years in the UKPDS(132). Hyperglycaemia, hypertension, 
dyslipidemia and smoking were identified as risk factors for 
developing peripheral vascular disease in the UKPDS 59(132). 
Peripheral vascular disease itself contributes to mortality(133; 134) 
and lower limb amputation(135) in younger diabetic populations. The 
majority of problems caused by peripheral vascular disease occur in 
the lower limb and often manifests clinically with foot problems. The 
World Health Organisation define the diabetic foot as a group of 
syndromes in which neuropathy, ischaemia and infection lead to 
tissue breakdown with subsequent morbidity, including amputation. 
Estimates suggest that about 5% of diabetic patients have a foot 
ulcers, these studies included a large number of older people(136- 
138). Over 50% of foot ulcers are due solely or in part to peripheral 
vascular disease(138; 139). Risk factors for foot ulceration in people 
with diabetes of all ages include age, smoking, peripheral vascular 
disease, peripheral neuropathy, duration of diabetes, any injury, 
operation or trauma to the foot and renal disease(136; 138; 140; 141). 
3.2.4 Estimation of the prevalence of diabetic neuropathies 
Diabetes may affect the central nervous system, the peripheral 
nervous system or the autonomic nervous system. There are no 
universally agreed definitions. They are usually defined based upon 
abnormalities detected at clinical examination. There are many 
different clinical manifestations, such as cranial nerve lesions, motor 
nerve lesions or sensory neuropathies. Neuropathies may present 
with or without pain and can manifest as reduced reflexes. 
Peripheral neuropathy was estimated in a large Italian study and 
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found to be 32.3% in patients with an average age of 56 years(142). 
A smaller study in Rochester USA estimated some degree of 
neuropathy in up to 59% of people with type 2 diabetes(143). In an 
older population in Manchester UK the prevalence of neuropathy 
increased with age and the duration of diabetes In the participants 
aged between 70 and 79 years the prevalence of neuropathy was 
44.2%(144). 
The MRC study did not specifically assess or examine diabetic 
neuropathy. Therefore any estimates of the prevalence of these 
conditions were not possible. Diabetic neuropathy is not considered 
further in this thesis but their description was included for 
completeness. 
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3.3 Methods; Classification of trial participants with 
diabetes 
3.3.1 The World Health Organisation and the American Diabetes 
Association classification of diabetes 
In the late 1970s the National Diabetes Group(145) of the USA and 
the World Health Organisation (WHO)(146) produced reports which 
established new classification systems for diabetes. Apart from a 
small revision in 1985, by the World Health Organisation(147), these 
definitions remained unchanged for 12 years. By this time more data 
and aetiological information were available. Consequently in 1997 
the American Diabetes Association (ADA) produced a report(3) to 
discuss the definition of diabetes. At the same time the WHO also 
convened a similar report; the conclusions of which were published 
in 1998(2) with the final report published in 1999(99). The ADA 
recommended diagnosing diabetes based on a fasting glucose 
above 7 mmol/I. The WHO criteria was based on a glucose level 
greater than 11.1 mmol/l measured two hours after an oral glucose 
load of 75g. However there was much agreement between the 
reports. Both reports reduced the threshold level of glucose needed 
to be diagnosed as having diabetes. The aim of both was to 
maximise accurate and early diagnoses in an attempt to prevent 
morbidity and mortality. Nonetheless identification of people with 
diabetes may vary according to which criteria is used(18; 103; 148). 
For example, a famous study known as the DECODE study 
compared 13 populations in eight European populations(149). They 
concluded that using fasting glucose caused an increase in 
prevalence by 0.8%. Further work from the DECODE group 
suggested that abnormal fasting glucose levels are more often seen 
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in middle aged obese patients while thinner elderly people are more 
likely to have abnormal glucose levels after an oral glucose 
load(103). 
For epidemiological purposes the WHO recommends the use of the 
blood glucose measurements two hours after an oral glucose load 
but states that fasting glucose alone is also a satisfactory 
measure(99). 
3.3.2 Criteria used for the identification of diabetic individuals 
within the MRC trial of older people in the community 
Thorough identification of participants in the MRC trial with diabetes 
was essential to ensure the results and conclusions generated were 
accurate. All participants in the trial identified with diabetes were 
used throughout the subsequent analysis. 
To correctly identify all the trial participants with diabetes, using the 
universal questionnaire, they were identified according to their self 
reporting response, high random glucose and whether they were 
receiving diabetic medication. The EMIS database was then 
searched for any further trial participants diagnosed as having 
diabetes. Trial participants will ultimately be divided into those with 
diabetes (cases) and those without diabetes (non cases). 
Participants with diabetes (cases) were based on the self reporting 
of diabetes using the detailed questionnaire in the MRC trial, high 
random glucose, the use of diabetic medications and participants 
with diabetes identified from the EMIS database. 
59 
Chapter 3 Identification of people with diabetes 
All questionnaires with a positive response to the question "Have 
you ever been told by a doctor that you have sugar diabetes? " were 
examined, to ensure that the responder really did have diabetes. 
Using random glucose measurements (fasting glucose was only 
recorded in five individuals in the MRC trial) further trial participants 
were identified as having diabetes. These glucose measurements 
were not taken two hours after a 75g oral glucose load. Although this 
does not satisfy the WHO(99) or ADA(3) criteria for the classification 
of diabetes (see section 3.1.1 above) it is likely that many of these 
people will have diabetes. A cut of point off 11.1 mmol/l was used in 
the MRC study. The rational being that a random glucose of 11.1 
mmol/l or above in the presence of symptoms of diabetes is another 
criteria used for the diagnosis of diabetes(99). Unfortunately, while 
the MRC study collected large amounts of information, the specific 
presence of diabetic symptoms were not collated. 
The third method for the identification of diabetic individuals, from 
the universal questionnaire, was to find the trial participants who 
were receiving diabetic medication. In this age group diabetic drugs; 
insulin and oral hypoglycaemic drugs, are used exclusively in 
diabetic individuals. Anyone found to be taking these medications 
had diabetes. 
Finally the EMIS database was searched for diabetic terms to find 
any remaining trial participants who had been diagnosed with 
diabetes before they were entered into the trial. 
Failure to identify and treat individuals as having diabetes has 
several implications. It would have underestimated the true level of 
both diagnosed and undiagnosed diabetes in the community. It 
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would have also impacted on the survival analysis of the diabetic 
participants, leading to an underestimation of the affect of diabetes, 
as not all diabetic participants would have been included in the 
analysis. This is nondifferential (random) misclassification. The affect 
of this type of misclassification is to increase the similarity between 
the group with diabetes and the group without diabetes thus diluting 
or underestimating any associations. Any results obtained would 
have been biased towards the null value. 
3.4 Methods; Classification and identification of the 
complications of diabetes 
3.4.1 Microvascular complications 
Diabetic Retinopathy (Visual Impairment) 
Diabetic retinopathy is assessed using retinal visualisation. This can 
be done using direct fundoscopy, retinal photography or fluorescein 
angiography. These techniques detect well defined retinal disease 
caused by diabetes. However, none of these procedures were done 
in the MRC trial. Therefore, in order to detect diabetic retinal disease 
in the study population a proxy measured had to be used; visual 
acuity. The epidemiological consequences of using visual 
impairment as a proxy measure for diabetic retinopathy is 
considered in the discussion section of this chapter (section 3.9). 
To test visual acuity all participants who underwent the detailed 
questionnaire in the universal arm of the MRC study had their visual 
acuity measured at 3 metres with a Glasgow acuity chart. This 
measured the minimal angle of resolution on a logarithmic scale 
(logMAR). Binocular vision was measured, followed by vision in 
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either eye separately, using any spectacle correction. Trial 
participants with a IogMAR visual acuity more than 0.5 or more in 
either eye were retested with a pinhole occluder. A log MAR visual 
acuity of more than 0.5 is equivalent to less than 6/18 Snellen acuity. 
The International Classification of Diseases 10th Edition (ICD 10) 
defines low vision as a visual acuity less than 6/18 but equal or 
better than 3/60. It defines blindness as visual acuity less than 3/60 
in the better eye. The term visual impairment was used in this thesis 
to mean both low vision and blindness. Visual impairment is 
presented for trial participants with diabetes. 
Diabetic Nephropathy 
Diabetic nephropathy is a term used to describe abnormal renal 
function in people with diabetes. The MRC trial collected two 
measures which were useful in assessing the renal function of the 
diabetic population. These were proteinuria and raised creatinine 
levels. Both of these factors represent proxy measures for diabetic 
nephropathy. 
Diabetic nephropathy typically presents with proteinuria followed by 
rising blood creatinine levels as renal function worsens. Typically 
diabetic nephropathy begins with the loss of protein into the urine. 
The amount of protein lost into the urine tends to increase. Diabetic 
nephropathy is diagnosed (and defined) when more than 300 mg of 
protein is lost into the urine in a 24 hour period. All trial participants 
had a sample of urine tested for the presence of protein (yes or no). 
The exact diagnosis of diabetic nephropathy requires two samples to 
be positive for protein within one year. In addition, samples may be 
positive for protein in the absence of diabetic renal disease e. g. In 
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the presence of urinary infection. A blood sample was obtained 
during the detailed questionnaire, which was tested for creatinine 
(pmol/I). Typically 120pmol/I creatinine is used an upper limit of 
normal for renal function. Any level above 120 pmol/l was therefore 
used as a cut off point to determine any associations with diabetes 
and poor renal function. 
Creatinine measurements alone, while useful, are prone to variation 
between individuals. Several factors can lead to abnormal creatinine 
levels; kidney disease itself, reduced muscle mass (commonly seen 
in older people), ingestion of cooked meat, malnutrition and the use 
of certain medications (cimetidine and trimethoprim being 
examples). Consequently, since the 1950s, another measure of 
kidney function has been regarded as the gold standard of 
estimation of renal function; the Glomerular Filtration Rate 
(GFR)(150). GFR is estimated from the urinary clearance of an ideal 
filtration marker (a filtration marker is a substance freely filtered by 
the kidney, without secretion or reabsorbtion) and is defined by: 
Ci= UiV/Pi 
where Ci is the clearance of the ideal filtration marker (i), Ui is the 
urinary concentration of i, V is the urine flow rate, and Pi is the 
average plasma concentration of i during the time interval of urine 
collection. In clinical practice the precise measurement of GFR is 
difficult to achieve. It requires urine collection and the administration 
of filtration markers. Therefore extensive attempts have been made 
to estimate the GFR directly from creatinine levels, such as the 
commonly used Cockcroft and Gault formula(151). In 1999, Levey 
and colleagues developed several estimating equations for GFR 
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based on creatinine levels(152). These equations were adopted (in 
modified form) in 2002 by the National Kidney Foundation in 
America and are now widely established and form an accurate 
measure of GFR, surpassing previously used estimating 
equations(153; 154). The data on which the estimating equations 
was based was the Modification of Diet in Renal Disease Study and 
the equation is known as the abbreviated MDRD study equation. 
The formula is: 
GFR (ml/min per 1.73 m2) = 186 x (SCr)-1.154 x (Age)-0'203 x (0.742 if 
female) 
SCr is serum creatinine concentration (mg/dL), age in years. There 
is another correction factor for people of black origin (not shown 
here). The detailed questionnaire did not obtain information 
regarding ethnicity and therefore this additional correction factor was 
not used when calculating GFR. In 2005, the MDRD study equation 
was evaluated in two studies involving diabetic people and found to 
be more accurate than the Cockcroft-Gault formula(155; 156). The 
first study used 160 people with diabetes, 50 had typet and 110 type 
2 diabetes. The age ranged between 19 and 83 years with a mean 
age of 62.2 years(155). The second trial used the large cohort 
(n=1286) of diabetic people from the DCCT, therefore this population 
was exclusively comprised of type 1 diabetic individuals(156). Both 
studies noted imperfections with the MDRD equation but considered 
it to be more accurate at calculating GFR when compared to the 
Cockcroft-Gault formula. It was therefore the MDRD equation that 
was used to calculate GFR for diabetic participants in the MRC 
study. 
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The 2002 guidelines from the National Kidney Foundation(153) have 
highlighted two levels of GFR. The first was 60 ml/min per 1.73 m2. 
GFR measurements below this level represent the loss of at least 
half the normal adult level of normal kidney function(154). The 
second level was a GFR less than 15 ml/min per 1.73 m2, which in 
most cases will be accompanied by symptoms of uraemia. In the 
United States 98% of patients need to start renal replacement 
therapy when their GFR falls below this level(154). In the UK renal 
function is graded into five stages. GFR below 60 ml/min per 1.73 m2 
corresponds to stage 3 (moderate) disease and less than 15 ml/min 
per 1.73 m2 corresponds to stage 5 (established renal failure). The 
distribution of the GFR is presented here for the diabetic population. 
3.4.2 Macrovascular complications 
Coronary Heart Disease 
Coronary heart disease can present in a number of ways. These 
include angina (typically pain on exertion which is relieved with rest), 
myocardial infarction or sudden death. The WHO (Rose) chest pain 
questionnaire is a well validated and long standing method of 
defining and identifying angina and severe coronary ischemia for use 
in epidemiological studies(157; 158). Questionnaire responses 
accurately predict death due to coronary heart disease(77). In 1998 
Lampe and colleagues used a simplified version of the questionnaire 
to identify angina(159). They suggested that the use of three 
questions alone can be used to identify angina in epidemiological 
studies. A missing response for one or more questions precludes a 
diagnosis of angina. The three questions used to identify angina 
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were all included as part of the MRC trial and are shown in appendix 
2, (questions 9(a), 9(b) and 9(c)). The questions were: 
" Have you ever had any pain in your chest? 
" Do you get this pain or discomfort when you walk uphill or 
hurry? 
" Do you ever get it when you walk at an ordinary pace on the 
level? 
The same paper also suggested that recall of a doctor diagnosis of 
ischaemic heart disease is a very strong predictor for the presence 
of severe ischaemic heart disease(159). Therefore the question 
"Have you ever been told that you have had a heart attack? " was 
assessed to determine the prevalence of previous myocardial 
infarction in participants in the MRC trial. Therefore prevalence of 
angina and myocardial infarction are presented for trial participants 
with diabetes. 
Cerebrovascular Disease 
A diagnosis of cerebrovascular disease is usually a clinical one. 
Investigations such as computerised tomography of the brain are 
useful but not essential when making a diagnosis of stroke. The use 
of such imaging has only become routine in the past few years 
following initiatives such as the National Service Framework for 
Older People(37). Recruitment for the MRC study finished in 1997 
and it is likely that many of participants who had a stroke would not 
have undergone imagining. Therefore it is likely that responses to 
the question "Have you ever been told that you have had a stroke? " 
(yes or no) accurately represented the prevalence of 
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cerebrovascular disease within the diabetic population. The results 
for this question in trial participants with diabetes are given below. 
Peripheral Vascular Disease 
Peripheral vascular disease is a condition which affects the large 
blood vessels of the peripheral circulation, most typically the lower 
limb. It can result in pain, ulceration or amputation. Pain may be 
constant or associated with walking and relieved by rest, when it is 
known as intermittent claudication. The UKPDS 59 identified 
peripheral vascular disease if two of three of the following criteria 
were identified in either leg; 1. ankle-arm blood pressure index (ratio) 
<0.8,2. neither dorsalis pedis or posterior tibial pulses were palpable 
(these are pulses which should normally be felt in the foot and ankle) 
or 3. intermittent claudication was reported. The MRC study 
collected data on the presence of foot or leg ulcers, whether they 
were being treated and if they were healing (see appendix 2 
questions 47(a), 47(b) and 47(c)). The questions were: 
9 Have you ever had any leg or foot ulcers? 
" If yes, are they/is it being treated? 
" Are they/is it healing alright? 
The types and aetiology of foot ulceration are numerous and are not 
solely caused by peripheral vascular disease or diabetes. The MRC 
questionnaire regarding foot ulceration did not distinguish between 
different types of ulcer. Neither did it collect information regarding 
intermittent claudication, ankle-arm blood pressure indexes, 
peripheral pulses or amputation. Therefore the presence of foot 
ulcers in people with diabetes are presented. If ulceration was 
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present whether they were being treated and whether they were 
healing is also shown. 
Please note that occasionally the numbers involved in each sub 
group analysis were small. Where less than five individuals were 
present in each group the calculation of prevalence estimates 
became inaccurate. This was because the standard errors 
generated were very large. Consequently where this occurs the 
number of participants was given in the results tables without a 
prevalence estimate. 
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3.5 Results; Description of the participants who underwent 
detailed assessment in the MRC trial of older people in the 
community 
The full description of the MRC trial of the assessment and 
management of older people can be found in the methods section 
(Section 2.1.1). 
The following factors were used to describe the population. 
" Number of participants 
" Age 
" Sex 
" Additional descriptive factors, including those which were 
considered as potential confounders, are provided to give a 
fuller picture of the population. The factors assessed were the 
Carstairs index, living alone, reporting no one to call for help if 
required and reporting often or always having difficultly making 
ends meet. Measures of general health status were assessed 
by reporting one or more falls at home within the last six 
months, taking five or more medications and self reporting of a 
participants own health as either poor or fair. 
" Smoking, alcohol, mini-mental state examination (MMSE), 
previous myocardial infarction, previous cerebrovascular 
disease, body mass index (BMI) and waist hip ratio (WHR). 
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3.5.1 Description of the universal arm of the MRC trial 
The dataset comprised 21410 individuals aged 75 and over, who 
were eligible and invited to participate in the universal arm of the 
MRC trial. A total of 15095 (70.5%) of 21410 people randomised to 
the universal arm, completed the full assessment. 
The mean age was 81.30 years, with the median age 80.38 years. 
The age range was from 75.01 years to 108.04 years. The inter- 
quartile range was 77.23 years to 101.31 years. 
There were 5776 (38.26%) males and 9319 (61.74%) females. The 
women were older (p<0.001) with a median age of 80.98, the 
median age of the male trial participants was 79.76. 
Age group Male(%) Female(%) Total(%) 
75-79 years 3014 (52.2) 4028 (43.2) 7042 (46.7) 
80-84 years 1746 (30.2) 3012 (32.3) 4758 (31.5) 
85-89 years 820 (14.2) 1621 (17.4) 2441 (16.2) 
90 plus years 196 (3.4) 658 (7.1) 854 (5.6) 
Total 5776 100 9319 100 15095100 
Table 3.2. Age and sex distribution of participants who underwent detailed assessment 
The were 13846 participants who had sufficient information recorded 
to enable the Carstairs index to be completed. Participants in the 
lowest (most deprived) quintile were more likely to be male 
(p<0.001) and older (p<0.001). Those in the youngest age groups 
and men were more likely to be heavy drinkers, ex and current 
smokers, have the highest BMI and an increased hip waist ratio 
(p<0.001 for all). Women and those at increased age were most 
likely to have a MMSE=<23 (p<0.001). There was no missing data 
for alcohol or MMSE, 1992 participants had missing smoking data, 
1250 participants had missing body mass index, 314 men and 680 
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had missing waist hip ratio measurements. There were no 
differences between people with and people without missing data in 
terms of age and sex. The results for Carstairs index, MMSE, 
alcohol, smoking, body mass index and waist hip ratio are all given 
in table 3.3. 
Variable 
Whole 
Population 
n=15095 (%) 
Men 
n=5776 (%) 
Women 
n=9319 % 
Carstairs 1st (least deprived) 3264 (21.62) 1336 (23.13) 1928 (20.69) 
by quintile 2nd 3688 (24.43) 1454 (25.17) 2234 (23.97) 
3rd 3161 (20.94) 1181 (20.45) 1980 (21.25) 
4th 2268 (15.02) 856 (14.82) 1412 (15.15) 
5th (most deprived) 1465 (9.71) 506 (8.76) 959 (10.29) 
missing 1249 (8.27) 443 (7.67) 806 (8.65) 
MMSE <=23 3156 (20.91) 947 (16.40) 2209 (23.70) 
>23 11939 (79.09) 4829 (83.60) 7110 (76.30) 
missing 0 0 0 
Alcohol 0-21 units (-) 5585 (96.69) (-) 
>21 units (-) 191 (3.31) (-) 
0-14 units (-) (-) 9177 (98.48) 
>14units (-) (-) 142 (1.52) 
missing (-) 0 0 
Smoking Never 5117 (33.90) 968 (16.76) 4149 (44.52) 
Ex-smoker 6694 (44.35) 3500 (60.60) 3194 (34.27) 
Current 1292 (8.56) 633 (10.96) 659(707) 
missing 1992 (13.20) 675 (11.69) 1317 (14.13) 
BM I <18Kg/m2 261 (1.73) 58 (1.00) 203 (2.18) 
18-25 5643 (37.38) 2119 (36.69) 3524 (37.82) 
25-30 5616 (37.20) 2450 (42.42) 3166 (33.97) 
>30 2325 (15.40) 753 (13.04) 1572 (16.87) 
missing 1250 (8.28) 396 (6.86) 854 (9.16) 
WHR <0.90 (men) (-) 1418 (24.55) (-) 
>0.90 (men) (-) 4044 (70.01) (-) 
<0.85 (women) (-) (-) 4901 (52 59) 
>0.85 (women) (-) (-) 3738 (40.11) 
missing (-) 314 (5.44) 680 (7.30) 
Table 3.3. Characteristics of the whole population 
There were 7081 (46.91 %) individuals in the universal arm who lived 
alone and a total of 288 (1.91 %) participants stated that they had no 
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one to call for help. There were 423 (3.03%) participants who had 
difficulty making ends meet and there were 3144 (20.82%) 
participants who had at least one fall at home in the last six months. 
In all, 3307 (21.91%) participants were taking more than five 
medications and 2418 (16.18%) participants rated their own health 
as fair or worse. 
3.5.2 Description of the non responders 
Of the 21410 participants who were randomised to the universal arm 
of the trial. There were 6315 (29.5%) who did not complete the 
assessment. This group includes a small number (169) of people 
who were found to be ineligible, for example, aged under 75 at 
recruitment. It also includes a larger group who underwent the brief 
assessment but failed to complete the universal assessment. This 
group of non completers totalled 1601 (7.48%). For the purposes of 
this thesis anyone who failed to complete the full assessment, for 
whatever reason, will be termed a non responder. Age and sex were 
the only descriptive factors available for non responding participants. 
Men were more likely to respond than women (80.5% vs 76.7%, 
p<0.001), and this sex difference persisted after adjustment for age: 
the adjusted odds ratio for response comparing men with women 
was 1.22 (95% Cl 1.16-1.29, p<0.001). Responders were slightly 
younger than non responders (median 80.3 years vs 81.0 years, 
p<0.001). All non-responders were followed up for mortality. The 
mortality rates for the non responders are presented in chapter 8. 
3.6 Results; identification of individuals with diabetes 
Trial participants were identified who potentially had type 2 diabetes 
(see section 3.3.1-6 below). After the identification of any person 
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who may have had diabetes their original trial questionnaire was 
examined. Every questionnaire was examined at least once. The 
results are summarised in table 3.4 and figure 3.1 below. 
3.6.1 Identification of trial participants with type I diabetes 
The year of diagnosis of diabetes was used to identify any trial 
participant who may have had type 1 diabetes. Chapter 1 described 
the poor life expectancy for anybody diagnosed with type 1 diabetes 
mellitus in the early part of this century, even after the advent of 
insulin therapy in 1922(40). There were 18 trial participants identified 
as having diabetes who recoded their date of diagnosis as 1922 or 
before. Life expectancy before the advent of insulin therapy was only 
2.6 years, therefore it is extremely unlikely that this response is 
correct. All these people were assumed to have type 2 diabetes 
mellitus. In trial participants identified as having diabetes, who 
recorded a year of diagnosis, their age at diagnosis implied that they 
had type 2 diabetes i. e. they were all aged at least 40 years old. 
There were 197 participants with diabetes who had not recorded a 
year of diagnosis. None of these people was taking insulin alone 
which is prerequisite for a diagnosis of type 1 diabetes. Similarly 
these people were assumed to have type 2 diabetes. Ultimately 
there was no one in the universal arm of the MRC trial who was 
considered to have type 1 diabetes. 
3.6.2 Missing responses for diabetes mellitus 
There were 53 participants who had a missing response to the 
question "Have you ever been told by a doctor that you have sugar 
diabetes? ". All of these questionnaires were examined. More women 
(33) had missing data than the men (p=0.006). Individuals with 
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missing data were more likely to be older (p<0.001) than those 
without. 
Of the 53 questionnaires there were 49 questionnaires with no 
evidence of diabetes (no further questions relating to diabetes 
mellitus were completed, all of them had a normal random glucose, 
none of these participants were receiving diabetic medication and for 
those with EMIS records, none had any record of having diabetes). 
For all future analysis in this thesis these individuals were classified 
as not having diabetes. 
There was one person with a missing entry for diabetes who 
subsequently responded correctly to all the further questions relating 
to diabetes (appendix 2, page 15). In addition they had a random 
glucose greater than 11.1 mmol/l. This participant was classified as 
responding positively to having diabetes (true positive response) and 
was treated as having diabetes for future analysis. 
There was one entry who had a random glucose greater than 11.1 
mmol/l and had a missing response for diabetes. They had not 
answered any further questions relating to diabetes and they were 
not taking any diabetic medication. This person was treated as 
having high random glucose for the future statistical analysis 
There was one entry with a missing response for diabetes who had a 
random glucose greater than 11.1 mmol/I and was taking diabetic 
medication, although they had not answered any further questions 
relating to diabetes. This person was classified as responding 
negatively to having diabetes mellitus (false negative response), but 
for the analysis was treated as having diabetes. 
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There was one participant with a missing response for diabetes who 
had responded to a few, but not all of the other questions relating to 
diabetes mellitus (see appendix 2, page 15). This person did not 
have a high random glucose and they were not taking any diabetic 
medication. This person was classified as having responded 
negatively to having diabetes mellitus and was treated as not having 
diabetes mellitus for future statistical analysis. 
3.6.3 Self reporting of diabetes mellitus 
There were 992 individuals who responded positively to the question 
"Have you ever been told by a doctor that you had sugar diabetes? ". 
After inspection of each questionnaire, only three of these had no 
evidence to support the diagnosis of diabetes. All three had not 
responded positively to any of the further questions relating to 
diabetes (see appendix 2, page 15). None of these individuals were 
taking diabetic medication and none of them had a random glucose 
greater than 11.1 mmol/l. These three entries were recoded as not 
having diabetes for all subsequent analysis. These three individuals 
were false positive responders. There was one individual who was 
reclassified as responding to this positively to this question who 
originally had a missing response (see section 3.6.2 above). 
Therefore the total number of people identified from this question 
was 990 (see table 3.4). 
3.6.4 High random glucose 
There were a total of 129 individuals who had responded negatively 
to the question regarding a diagnosis of diabetes and one missing 
responder (see section 3.6.2 above) who had a random glucose 
greater than 11.1 mmol/I and were not taking diabetic medication. 
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None of them had responded positively to the further questions 
relating to diabetes (see appendix 2). All of these people were 
unaware of having diabetes and formed the basis of the prevalence 
estimate of undiagnosed diabetes in the community (see section 
3.6.7 below). 
All 130 individuals with a high random glucose were recoded as 
having diabetes (cases) for the purposes of future statistical analysis 
for the majority of this thesis. The exception being chapter 4. This 
chapter considered the understanding of diabetes and the use of 
diabetic services and individuals with a high random glucose were 
not considered as cases. This was because these people had not 
been diagnosed with diabetes and therefore would not have been in 
a position to receive diabetic education or to have been offered the 
opportunity to utilise diabetic services. 
3.6.5 The use of diabetic medication 
There were 15 individuals who had responded negatively when 
asked about a diagnosis of diabetes but who were receiving diabetic 
medication. All 15 were considered as false negative responders. 
For the statistical analysis in this thesis they were recoded as having 
diabetes (cases). 
3.6.6 Participants with diabetes Identified from the EMIS data 
There were a total of 6273 (41.56%) who entered the universal arm 
who had EMIS data available. A total of 42 people were further 
identified as having diabetes from the EMIS data. The EMIS 
database was searched for participants who were receiving diabetic 
medication or who had a diagnosis of diabetes before they were 
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entered into the MRC trial. All these individuals were considered as 
false negative responders. They were reclassified as having 
diabetes (cases) for the remainder of the thesis. 
3.6.7 Overall estimates for the prevalence of diabetes mellitus 
The total number of trial participants who were identified as having 
type 2 diabetes mellitus was 1177 out of 15095 who underwent 
detailed assessment. The prevalence of diabetes in men and women 
aged over 75 years was 7.80% (95%Cl 7.11-8.47). The results are 
shown in table 3.4 below. For the future statistical analysis these will 
be the cases and any trial participant without diabetes mellitus will 
now be considered as a non case. 
The majority (990) of participants with type 2 diabetes mellitus were 
identified directly from the screening questionnaire, 130 were 
identified due to a high random glucose and 15 because they were 
receiving drugs for diabetes. A further 42 participants with diabetes 
were identified from the EMIS data The prevalence of undiagnosed 
diabetes in the community is therefore 0.86% (95%Cl 0.96-1.02) 
(130 individuals with high random glucose divided by the total study 
population 15095). 
Different trial participants identified as having Number (proportion) 
diabetes mellitus 
Identified from the questionnaire 990 (84.11) 
Identified from high random glucose 130 (11.05) 
Identified from drug data 15 (1.27) 
Identified from EMIS data 42(357) 
Total 1177 (100) 
Table 3.4 Breakdown of the source of the participants identified as having diabetes mellitus 
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3.6.8 Sensitivity estimates for response to questions relating to 
diabetes mellitus. 
The responses of the trial participants were assessed. This allowed 
an estimation of the accuracy of the response to the question "Have 
you ever been told by a doctor that you have sugar diabetes? " to be 
tested. The responses to this question for each person identified as 
having diabetes were divided into the four groups shown below: 
1. Those who self reported as having diabetes and had evidence of 
having diabetes (true self report positive individuals). 
2. Those who self reported as having diabetes but who had no 
evidence of having diabetes (false self report positive individuals). 
3. Those who self reported as not having diabetes but who had 
evidence of having diabetes (false self report negative individuals). 
This group did not include individuals with a high random glucose. 
This was because these people were unaware of their condition and 
could not have been expected to report positively that they had the 
disease. 
4. Those trial participants who self reported as not having diabetes 
and who had no evidence of having diabetes (true self report 
negative). 
The EMIS data was used to provide sensitivity and specificity 
estimates for people who self reported as having diabetes. EMIS 
entries relating to diabetes or the use of any diabetic medication 
before recruitment into the MRC trial indicated that person had 
diabetes. All these people should have responded positively to 
having diabetes mellitus. Comparing the numbers of people who did 
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actually respond positively provided the sensitivity and specificity 
estimates. 
EMIS data was available for 6273 individuals who entered the 
universal arm of the trial. Of the 990 participants who responded 
positively when asked if they had diabetes 360 had EMIS data 
available. 
A sensitivity estimate was calculated for self reporting in detecting 
previously diagnosed diabetes. This figure was calculated from the 
360 positive responders to the question "Have you ever been told by 
a doctor that you have sugar diabetes? ", who had EMIS data 
available and 47 individuals who responded negatively to that 
question but were found to have diabetes (42 from the EMIS data 
alone and 5 people who were receiving diabetic drugs and had EMIS 
data available). The sensitivity estimate was therefore calculated to 
be 88.5%, (313/360). 
A specificity estimate was calculated for self reporting in detecting 
previously diagnosed diabetes. The specificity estimate was 
calculated from all the trial responders who appropriately said that 
they did not have diabetes and the three responders who said they 
diabetes when they actually had no evidence that they did have 
diabetes (all three had EMIS data available). The specificity estimate 
was calculated to be 99.9% (5863/5866). 
Table 3.5 shows the results, note that the numbers represent only 
those participants for whom EMIS data was available. 
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Evidence of diagnosed Total 
diabetes 
"Have you ever been told Yes No 
that you have sugar 
diabetes? 
Yes 360 3 363 
No 47 5863 5910 
Total 407 5866 6273 
Table 3.5. Responses to t he screenina auestion for diabetes. 
3.6.9 Individuals with glycosuria 
There was another group of participants within the MRC trial who 
warranted discussion. These were the trial participants who had 
glycosuria only without any other evidence of having diabetes. 
Glycosuria may be associated with renal glycosuria, a benign 
condition, tubular disorders such as Fanconi syndrome, cystinosis, 
Wilson disease, hereditary tyrosinemia, or oculocerebrorenal 
syndrome (Lowe syndrome). In a population aged over 75 years the 
presence of glycosuria may well reflect undiagnosed diabetes. 
However, glycosuria in isolation is not diagnostic of the condition and 
these people could not be classified as having diabetes with any 
certainty. There were 129 people with glycosuria. Glycosuria was not 
considered further in this thesis. 
3.6.10 Duration of diabetes 
It would have been useful to have known the length of time each 
diabetic participant had been suffering from the disease. Duration of 
disease is an unmodifiable risk factor, which correlates with the 
occurrence of diabetic end points. Unfortunately it was not possible 
to calculate accurately the duration of disease. Firstly, there were 
197 participants with diabetes who had not recorded a year of 
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diagnosis. Secondly, and more importantly, the date of diagnosis of 
the diabetic end point was not recorded. Therefore it was virtually 
impossible to correlate the duration of diabetes with the onset of 
diabetic end points. 
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3.7 Results; Description of the individuals defined as 
having diabetes mellitus 
The participants identified in the trial as having diabetes were then 
described using the same factors as the participants in the universal 
arm of the trial (see section 3.5). 
The mean age of participants with diabetes was 80.94 years, with a 
median value of 80.02 years, which was slightly younger than people 
without diabetes who's mean age was 81.33, with a median value of 
80.41 years, (p=0.007). There were more women with diabetes 633 
(53.78%) than men 544 (46.22%) p<0.001 (table 3.6). The 
prevalence of diabetes in men was 9.42% (8.44-10.50) and in 
women 6.79% (6.10-7.56) p<0.001. The age specific prevalence of 
diabetes was higher in men compared to women for people aged 75- 
79 years only (p<0.001). 
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The were 1087 (out of 1177) participants with diabetes mellitus who 
had sufficient information for the Carstairs index to be completed. 
The 90 diabetic people without Carstairs data available were missing 
either all or part of the information required to complete the Carstairs 
index. Like the main trial participants, those in the lowest quintile 
(indicating the greatest social isolation) were more likely to be male 
(p<0.001) and older (p<0.001). The odds ratio for MMSE less than 
23 was 1.33 (1.14-1.55) for participants with diabetes compared to 
those without diabetes. Both men and women with diabetes were 
less likely to drink above the recommended weekly amounts, odd 
ratios 0.57 (0.35-0.97) and 0.71 (0.51-0.98) respectively. There were 
430 (36.53%) participants who had diabetes and had never smoked. 
Participants with diabetes were more likely to be ex-smokers or 
current smokers than those without diabetes (test for trend p<0.001). 
Body Mass Index (BMI) greater than 30Kg/M2 was more common 
278 (23.62%) in those with diabetes than those without diabetes 
(p<0.001). Increasing BMI was also related to diabetes (test for trend 
p<0.001). Both men and women with diabetes had an increased 
odds ratio of having a waist hip ratio above 0.90 (p=0.04) and above 
0.85 (p<0.001) respectively. These results are shown in table 3.7. 
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Variable 
Non diabetic 
Population 
n=13918 (%) 
Diabetic 
Popualtion 
n=1177 
Odds ratio* 
(95% Cl) 
P value 
Carstairs 1st (least deprived) 3063 (22.01) 201 (17.08) 1 (-) 
by quintile 2nd 3398 (24.41) 290 (24.64) 1.31 (1.12-1.51) <0.001 
3rd 2889 (20.76) 272 (23.11) 1.45 (1.21-1.73) <0.001 
4th 2055 (14.77) 213 (18.10) 1.59 (1.24-2.04) <0.001 
5th (most deprived) 1354 (9.73) 111 (9.43) 1.28 (0.99-1.65) 0.06 
missing 1159 (8.33) 90 (7.65) (-) (-) 
MMSE <23 2874 (20.65) 282 (23.96) 1 (-) 
>23 11044 (79.35) 895 (76.04) 1.33 (1.14-1.55) <0.001 
missing 0 0 (-) (-) 
Alcohol 0-21 units (men) 5049 (96.50) 536 (98.89) 1 (-) 
>21 units (men) 183 (4.50) 8(1.11) 0.57 (0.35-0.97) 0.04 
0-14 units (women) 8546 (98.38) 631(99.68) 1 (-) 
>14units (women) 140 (1.62) 2 (0.32) 0.71 (0.51-0.98) 0.04 
missing 0 0 (-) (-) 
Smoking Never 4754 (35.16) 363 (30.84) 1 (-) 
Ex-smoker 6098 (43.81) 596 (50.64) 1.12 (0.95-1.32) 0.18 
Current 1212 (8.71) 80 (6.80) 0.76 (0.58-0.99) 0.04 
missing 1854 (13.31) 138 (11.72) (-) (-) 
BMI <18Kg/m2 348 (2.50) 15 (1.27) 1 (-) 
18-25 5205 (37.40) 336 (28.55) 1.41 (0.75-2.67) 0.28 
25-30 5182 (37.23) 434 (36.87) 1.78 (0.96-3.33) 0.07 
>30 2047 (14.71) 278 (23.62) 3.03 (1.61-5.68) <0.001 
missing 1136 (8.16) 114 (9.69) (-) (-) 
WHR <0.90 (men) 1306 (24.96) 112 (20.59) 1 (-) 
>0.90 (men) 3654 (69.84) 390 (71.69) 1.24 (1.01-1.54) 0.04 
missing 272 (5.20) 42 (7.72) (-) (-) 
<0.85 (women) 4648 (53.51) 253 (39.97) 1 (-) 
>0.85 (women) 3405 (39.20) 333 (52.61) 1.80 (1.52-2.12) <0.001 
missing 633 (7.29) 47 (7.42) (-) (-) 
Table 3.7. Characteristics and odds ratios for diabetic and non-diabetic populations 
*adjusted for age and sex 
There were 508 (43.16%) individuals who lived alone who were 
identified as having diabetes. Those with diabetes were less likely to 
live on their own than those without diabetes (p=0.007). A total of 18 
(1.53%) participants with diabetes had no one to call for help but no 
more than those without diabetes (p=0.58). There were 44 (3.74%) 
participants with diabetes who had difficulty making ends meet, no 
more than those without diabetes (p=0.14). There were 300 
(25.49%) participants with diabetes who had at least one fall at 
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home in the last six months which was more than those without 
diabetes (p<0.001). A total of 402 (34.15%) participants with 
diabetes were taking at least five medications, this was more than 
participants without diabetes (p<0.001) and 254 (21.58%) 
participants with diabetes rated their own health as fair or worse, 
again more than those without diabetes (p<0.001). 
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3.8 Results; The complications of diabetes mellitus 
3.8.1 Microvascular complications 
Diabetic eye disease 
Eye disease was grouped into those with low vision (Snellen<6/18) 
or blindness (Snelien<3/60), as described in section 3.4.1 above. 
There were a total of 523 (3.46%) individuals who completed the 
detailed questionnaire but had no visual acuity measure recorded for 
low vision or blindness. People with missing entries for low vision 
were more likely to be female (p<0.001), older (p<0.001) and have 
diabetes (p=0.02). For all participants, those with low vision or 
blindness were more likely to be female (p<0.001) and older 
(p<0.001). Diabetic people had a higher prevalence of visual 
impairment and blindness when compared to the non diabetic 
population: 12.66% (95%Cl 12.62-12.70) vs 9.80% (95%Cl 9.79- 
9.81) (p<0.001) for visual impairment and 3.01% (95%CI 2.91-3.11) 
vs 2.04% (95%Cl 2.03-2.05) (p<0.001) for blindness. For the 
diabetic participants sex did not affect the presence of low vision or 
blindness. In diabetic people low vision (p<0.001) and blindness 
(p<0.001) were all associated with increasing age. The amount of 
low vision and blindness attributable to diabetes (assuming complete 
causation), measured using the population attributable risk fraction 
(PAF), was 3.46% and 1.02% respectively. 
The full results can be seen in tables 3.8 and 3.9. Crude, adjusted 
odds ratios and PAF for low vision and blindness attributable to 
diabetes can be seen in table 3.12. 
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Diabetic renal disease 
Proteinuria was recorded as the presence of at least one plus of 
protein on a urinary dipstick testing (yes or no). There were a total of 
995 out of 15095 (6.59%) people who had a missing record for 
proteinurig. The response was more likely to be missing in women 
(p<0.001) and with increasing age group (p<0.001). However, 
diabetic participants were just as likely to have missing data 
compared to people without diabetes (p=0.77). For the 1177 
participants who were identified as having diabetes there were 1097 
(93.20%) participants who had a response. Diabetic participants with 
missing data were more likely to be older (p=0.004) than diabetic 
participants without missing data, although there was no difference 
in the number of missing responses between men and women with 
diabetes. 
There were a total of 1581/15095 (10.47%) non diabetic people who 
had proteinuria. Proteinuria was found in 188/1177 (17.14%) of the 
diabetic participants, which was more than those without diabetes 
(p<0.001). For all participants, women were more likely to have 
proteinuria (p=0.002) and participants were older (p<0.001). Diabetic 
participants with proteinuria were not more likely to be older or of 
different sex. 
Raised creatinine was defined as serum creatinine above 120pmol/I. 
There were 1942/15095 (12.87°/x) participants who had no creatinine 
measurement recorded. Participants without a creatinine 
measurement were both older and more likely to be women 
(p<0.001). For the diabetic participants 135/1177 (11.47%) had a 
missing creatinine which was not more than those without diabetes. 
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The diabetic participants with missing creatinine more likely to be 
women (p=0.008) but not older. 
There were 2404/15095 (18.28%) people with a creatinine greater 
than 120pmol/l. they were more likely to be men and older 
(p<0.001). There were 236/1177 (22.65%) diabetic participants with 
raised creatinine. Diabetic participants were more likely to have 
raised creatinine (p<0.001) than non diabetic participants. Diabetic 
participants with raised creatinine were more likely to be women 
(p<0.001) and older (p=0.002). 
The PAF for proteinuria attributable to diabetes was 6.99% and for 
raised creatinine the PAF attributable to diabetes was 5.35%. 
The results can be seen in table 3.10 and 3.11. Crude and adjusted 
odds ratios for proteinuria, raised creatinine and PAF are given in 
table 3.12. 
The glomerular filtration rate (GFR) was calculated for the 
participants in the trial. As creatinine was used to calculate this value 
there were the same number of missing values for GFR as for 
creatinine (1942/15095,12.87%). For the trial participants without 
diabetes the mean GFR was 58.30 ml/min per 1.73m2 (95%C. I. 
58.04-58.57). This was not significantly higher than participants with 
diabetes, whose mean GFR was 58.09 (95%C. I. 57.09-59.08), 
(p=0.65). For comparison the average creatinine measurements 
were compared in the diabetic and non diabetic populations. 
Creatinine was significantly higher in the diabetic population; 105.19 
(95%Cl 103.29-107.10) vs 101.36 (100.79-101.92), p=0.007. 
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Likewise, no differences were detected when GFR was assessed 
using the established cut off points of 60 and 15 ml/min per 1.73m2. 
People with diabetes were no more likely to be in either of these 
groups than people without diabetes, (p=0.89 and p=0.86, 
respectively). Visual inspection of the distributions of GFR for people 
with and people without diabetes showed both to be normally 
distributed and not skewed. 
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Number Proteinuria Number Raised creatinine 
% 95% CI % 95% CI 
All participants 1581 11.21 (8.72-13.7) 2404 18.28 (16.87-19.69) 
Missing 995 1942 
Men 669 12.23 (9.93-14.43) 1444 28.23 (25.78-30.68) 
Women 912 10.57 (8.27-12.87) 960 11.94 (10.73-13.15) 
75-79 years Men 315 10.98 (8.64-13.32) 630 23.38 (20.33-26.43) 
Women 350 9.21 (6.70-11.72) 268 7.53 (6.26-8.90) 
80-84years Men 216 13.01 (9.27-16.73) 473 30.54 (27.66-33.48) 
Women 280 10.07 (7.28-12.88) 354 13.64 (11.78-15.50) 
85-89 years Men 114 14.81 (10.57-19.06) 267 38.03 (34.49-41.57) 
Women 203 13.77 (9.89-17.65) 220 16.02 (14.22-17.82) 
90 plus years Men 24 14.04 (8.78-19.30) 74 43.53 (36.18-50.88) 
Women 79 13.76 (9.75-17.77) 118 22.91 (18.72-27.10) 
Table 3.10 Prevalence of proteinuria and raised creatinine 
with age and sex distribution of all participants 
Number Proteinuria Number Raised creatinine 
% 95% CI % 95% CI 
Diabetic participants 188 17.14 (13.26-21.00) 236 22.65 (19.79-25.49) 
Missing 80 135 
Men 89 17.32 (12.73-21.91) 151 30.44 (25.74-35.14) 
Women 99 16.98 (12.24-21.72) 85 15.57 (11.77-19.37) 
75-79 years Men 53 18.21 (12.78-23.64) 73 25.89 (19.30-32.48) 
Women 42 15.97 (10.80-21.14) 24 9.87 (6.19-13.55) 
80-84years Men 25 17.12 (8.16-26.08) 45 33.09 (25.43-40.75) 
Women 33 16.92 (10.16-23.68) 34 18.47 (12.30-24.64) 
85-89 years Men 9 14.51 (4.67-24.35) 29 47.54 (36.92-58.16) 
Women 20 22.47 (11.92-33.01) 19 22.61 (13.02-32.19) 
90 plus years Men 2 (-) 4 (-) 
Women 4 8 22.85 (8.46-37.42) 
with age and sex distribution of diabetic participants 
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Chapter 3 Identification of people with diabetes 
3.8.2 Macrovascular complications 
Cardiovascular disease 
The presence of angina was evaluated using the questions outlined 
in section 3.4.2. It used three questions relating to chest pain to 
establish a diagnosis of angina as proposed by Lampe et al(159). 
For a diagnosis, an answer needed to be present for each of the 
three questions. The first question was simply "have you ever had 
pain or discomfort in your chest? " It required a yes or no answer. A 
person answering no was not required to answer the following two 
questions. The vast majority of the respondents 13480 out of 15095 
(89.30%) answered no. Only 49/15095 (0.29%) people had a 
missing response for this question, this small number of missing 
responses (less than 100) will not be considered further. There were 
1566/15095 (10.41%) people who responded to all three questions 
relating to angina. Of the 1566 people with angina, they were more 
likely to have diabetes, be female and be younger (p<0.001, for 
each). Considering the people with diabetes and angina, they were 
no differences between sex or age. The results are shown in tables 
3.13 and 3.14. 
History of a previous myocardial infarction was ascertained from the 
detailed questionnaire. There were 138/15095 (0.91 %) people with a 
missing response for a previous history of myocardial infarction. 
Those with a missing response to this question were not older, 
different sex or more likely to have diabetes than those without a 
missing response. 
There were 1603/15095 (10.62%) people who had had a myocardial 
infarction and 190/1177 (16.14%) people with diabetes who had had 
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a myocardial infarction. People with diabetes were more likely to 
have had a myocardial infarction than those without diabetes 
(p<0.001). Women were more likely to have had a myocardial 
infarction than men (p=0.001) and participants were more likely to be 
older (p<0.001). Of the diabetic people, those who had had a 
myocardial infarction were not more likely to be older or of different 
sex than diabetic people who had not had a myocardial infarction. 
The PAF for angina attributable to diabetes (assuming complete 
causality) was 3.31 % and 4.82% for myocardial infarction. The 
results are shown in tables 3.13 and 3.14. 
Cerebrovascular disease 
A previous diagnosis of cerebrovascular disease was determined 
from the questionnaire. There were 119 out of 15095 (0.79%) people 
with a missing response for this question. People with a missing 
response to this question were not older, of different sex or more 
likely to have diabetes than those without a missing response. There 
were 1338/15095 (8.86%) people who had had a cerebrovascular 
accident and 163/1177 (13.94%) people with diabetes who had had 
a cerebrovascular accident. A cerebrovascular accident was more 
likely to have occurred in people with diabetes (p<0.001). Women 
were more likely to have had cerebrovascular accident than men 
(p=0.006), people who had suffered a cerebrovascular accident 
were also younger (p<0.001). In people with diabetes, those who 
had had a cerebrovascular accident were the same sex and not 
more likely to be older. The results are shown in tables 3.13 and 
3.14. The PAF for CVA attributable to diabetes was 2.56%. Crude, 
adjusted odds ratios and PAF for angina, myocardial infarction and 
cerebrovascular accidents can be seen in table 3.16. 
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Chapter 3 Identification of people with diabetes 
Peripheral vascular disease 
Individuals with foot ulceration were identified from the detailed 
questionnaire as described above (see section 3.4.2). Those with 
foot ulceration were then required to answer further questions 
relating to treatment and healing. There were 644 out of 15095 
(4.27%) missing responses to this question. People with missing 
responses were of similar sex, similar age and no more likely to 
have diabetes than those without missing responses. There were 
404/15095 (2.80%) people with foot ulceration. There were 303/404 
(75.00%) of this group who were receiving treatment for their foot 
ulcer and 280/404 (69.31%) reported that their foot ulcer was 
healing. People with foot ulceration were more likely to be female 
(p=0.013) and older (p<0.001). People with diabetes were more 
likely to have foot ulceration (p=0.004). There were 47/1177 (4.14%) 
people with diabetes and foot ulceration. There were 41/47 (87.23%) 
of this group who were receiving treatment for their foot ulcer and 
37/47 (78.72%) reported that their foot ulcer was healing. The 
diabetic people with foot ulceration were not older or of different sex 
than diabetic people without foot ulceration. The PAF for foot 
ulceration attributable to diabetes was 1.09. The results are shown in 
tables 3.15 and 3.16. Crude, adjusted odds ratios and PAF for foot 
ulceration can be seen in table 3.16. 
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All participants Diabetic participants 
Number Presence of foot Number Presence of foot 
ulceration ulceration 
(95% CI % (95% Cl) 
Overall 404 2.80 (2.42-3.24) 47 4.14 (2.74-5.54) 
Missing 644 42 
Men 131 2.36 (1.90-4.82) 20 
Women 273 3.06 (2.52-3.60) 27 
75-79 years Men 50 1.72 (1.23-2.24) 9 
Women 79 2.04 (1.46-2.72) 10 
80-84years Men 42 2.52 (1.66-3.38) 7 
Women 84 2.92 (2.15-3.65) 7 
85-89 years Men 29 3.71 (2.31-5.11) 3 
Women 74 4.82 (3.67-5.97) 6 
90 plus years Men 10 5.38 (2.08-8.71) 1 
Women 36 5.71 (3.70-7.72) 4 
Table 3.15 Prevalence of foot ulceration with age and sex 
all and diabetic participants 
3.82 (2.07-5.57) 
4.41 (2.61-6.21) 
3.01 (2.03-3.99) 
3.72 (1.71-5.73) 
4.82 (1.56-8.10) 
3.38 (1.61-4.77) 
6.45 (1.41-11.49) 
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3.9 Discussion 
The results from this chapter were used primarily for the analysis 
in the rest of the thesis. They also provided estimates for 
prevalence, descriptive factors associated with diabetes and 
diabetic complications and these factors are discussed below. 
The results from the description of the universal arm of the MRC 
trial show that the participants were distributed as expected for an 
elderly population. There were more women who were older than 
the men. The participants in the trial with diabetes had a similar 
distribution of age and sex, with more older women. The diabetic 
participants were also younger than the trial participants without 
diabetes. 
In the MRC trial all participants with diabetes were assumed to 
have type 2 diabetes. Typically, type 1 diabetes is thought of as a 
disease of young people with absolute pancreatic failure 
occurring at presentation of the disease to medical care. In 
clinical practice about 10% of people of middle and older age 
present with a clinical picture of diabetes which is similar. They 
present with rapidly progressive disease which requires the use 
of insulin for disease control within a matter of months. Therefore 
one can speculate the prevalence of type 1 diabetes is around 
10% in the older person. However, in the MRC trial no one was 
identified with any certainty as having type 1 diabetes and must 
therefore be treated as having type 2 diabetes mellitus. 
The prevalence estimates of type 2 diabetes found from the MRC 
study were broadly similar to other community based estimates. 
Like previous studies there was a decrease (or stabilisation) of 
prevalence with increasing age(7; 8; 102; 106-111; 160). This study 
represents by far the largest community based questionnaire of 
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the prevalence of diabetes in older people published in the world. 
The largest previously conducted study was conducted by 
Rockwood and colleagues and involved 9008 Canadian 
elders(161). The results, generated from the MRC trial, for the 
age groups 85-89 years and 90 plus years are the only estimates 
available anywhere for these specific age groups. Previous 
estimates have not agreed on whether men or women have a 
higher prevalence of diabetes(7; 110). The results from the MRC 
study demonstrated a higher prevalence of diabetes in men 
compared to women for each age specific prevalence estimate, 
although only the estimate for the age range 75-79 years reached 
statistical significance. 
However, it is likely that the estimates produced here 
underestimate the true figure. There are a number of factors that 
could have contributed to this underestimation. Firstly, it is likely 
that despite thorough searching of the available data sources not 
all of the participants with diabetes were identified because they 
self reported inaccurately, did not have a high random glucose at 
the time of the assessment and were not taking any diabetic 
medication. Further attempts to identify participants with diabetes 
were made using the EMIS database. This identified a further 42 
participants with diabetes. This number was also an 
underestimate because EMIS data was only available for 6273 of 
the trial participants and therefore not all records could be 
checked. Despite this, questionnaires based on interviews have 
been used previously to identify diabetic people for use in cohort 
studies and are commonly used for this type of research. For 
example, the National Health and Nutrition Examination Study 
(NHANES) which was a representative cohort study of 15374 
individuals aged 25-74 years identified diabetic people using a 
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similar method to the MRC study. It recruited 725 diabetic people 
based on an interview only. The cohort was, and still is, followed 
for mortality(162). The second factor that could have contributed 
to the underestimation of the true prevalence of diabetes is that 
older people with diabetes are more unwell than those without 
diabetes and therefore less likely to have participated in this 
study. Within the MRC trial it was not possible to identify and 
assess these individuals. Comparison of mortality rates between 
the non responders and the responders for the universal arm was 
conducted in chapter 8 to assess this and is discussed in more 
detail then. 
The estimation of undiagnosed diabetes (0.86%) seems very low 
compared to previous U. K. estimates of up to 2%. This may have 
been due to the lack of an OGTT. In studies that have identified 
diabetic people using an OGTT the prevalence of undiagnosed 
diabetes has been much higher(8; 109). 
For the whole population the quintiles of Carstairs index show 
that the population comes from a range of different social 
backgrounds. A large proportion (24.73%) of this elderly 
population came from the two lowest quintiles, which represent 
the most deprived population, with 21.62% coming from the 
highest. In both the population as a whole and in the participants 
with diabetes, men were more likely to come from the lowest 
quintile of the Carstairs index and those in the lowest quintile 
were older. These results for both all the participants and those 
with diabetes are consistent with published data relating to the 
distribution of elderly populations within the Carstairs 
index(92; 93). 
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When comparing the whole population and the population with 
diabetes there was no difference between the groups in terms of 
no one to call for help and difficultly making ends meets. This 
implies that people with diabetes are not necessarily more 
socially isolated than people without diabetes. Furthermore 
participants with diabetes were less likely to live alone, again 
implying less social isolation within the diabetic population. 
Participants from nursing homes have been excluded from entry 
into the trial. Therefore people with diabetes being more likely to 
live in nursing homes (and therefore less likely to live alone) 
would not account for the finding that people with diabetes were 
less socially isolated. It is possible that greater social networks 
develop around people with diabetes. Another explanation could 
be that the study population is biased. It is possible that our trial 
population, like all participants in medical studies, have increased 
health awareness and are generally more healthy. Such 
individuals may be more likely to take steps to prevent social 
isolation by developing greater social networks. Unsurprisingly 
trial participants with diabetes were more likely to be taking at 
least five medications and that they rated their health as being 
worse than people without diabetes. There was also an increased 
risk of falls in those with diabetes. There are two possible medical 
explanations for the increased number of falls; firstly 
hypoglycaemia induced by diabetic medication or secondly as a 
result of the disease process itself e. g. increased falling 
associated with diabetic neuropathy. For example subgroup 
analysis of a large prospective study of older women with 
osteoporosis found that the chances of having a fall were higher 
in any woman who had diabetes and even higher in those 
diabetic women who were taking insulin(163). However the 
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authors concluded that this was because of a generally increased 
prevalence of falls risk factors rather than any one specific factor. 
The results for smoking were interesting. It shows that 
participants with diabetes were more likely to be current smokers 
or ex-smokers than those without diabetes. The increased 
number of ex-smokers could be attributable to smoking cessation 
advice which is heavily aimed a diabetic individuals but why there 
should be greater numbers in the first place is unclear. Smoking 
increases the risk of several long term complications of the 
disease but is not strongly implicated in the aetiology of the 
disease itself. Cross sectional studies have shown greater insulin 
resistance in smokers, although HbAlc levels have not been 
found to have been raised(164). It is possible that smoking itself 
may have a greater aetiological role in diabetes in the older 
person. 
People with diabetes had lower MMSE scores than people 
without diabetes; odds ratio 1.33 (1.14-1.55). This result is in 
agreement with those obtained previously in Wales and 
America(95; 165). The decreased MMSE reflects the increased 
risk of dementia, of all types, in people with diabetes(165). 
It has long been established that obesity contributes to the 
aetiology of diabetes in the younger person and the results in this 
elderly population support the association between obesity and 
risk of diabetes. The age and sex adjusted odds ratio for having a 
BMI over 30 Kg/M2 was 3.03. There was also a significant trend 
for increasing BMI in people with diabetes. The adjusted odds 
ratios for having diabetes and an increased waist hip ratio (WHR) 
were increased for both men and women; 1.24 (1.01-1.54) and 
1.80 (1.52-2.12) respectively. These results implied that even at 
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older age an increased WHR still predisposed an individual to 
having diabetes. 
Unsurprisingly, in the diabetic population each of the 
complications assessed in this study was found to have higher 
prevalence than in the non diabetic population. After adjustment 
for age and sex, the odds ratio for each complication remained 
raised when comparing the two groups. 
When considering the prevalence estimates overall, they seemed 
to be lower for each specific complication than had previously 
been estimated from other studies. While the differences seen 
may have been due to chance the generally lower prevalence 
estimates seen were probably due to an underestimation of the 
overall diabetic prevalence detected from the MRC study. An 
underestimation of the true figure for the prevalence of diabetes, 
which is discussed above, will result in bias. There will be a non 
random misclassification. This will result in a dilution of the effect 
of diabetes and hence the prevalence of diabetic complications 
Specific complications and their prevalence estimates are 
discussed and compared in more detail to previous studies 
below. 
The studies of diabetic eye disease have previously assessed 
diabetic retinopathy rather than visual impairment and above the 
age of 75 years few studies have been conducted. The estimates 
of prevalence highlighted in the introduction to this chapter 
(section 3.2.2) ranged between 7.5% for diabetes of five years 
duration to above 40%(112-117). The studies from South 
Glamorgan, Wisconsin and Italy all found the prevalence of 
retinopathy to be over 20%(112; 115; 117). 
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The prevalence of visual impairment among people with diabetes 
obtained from the MRC trial was 13.27%. However the MRC trial 
did not assess diabetic retinopathy, making direct comparisons 
with previous studies difficult. Retinopathy may be present 
without deterioration in vision. It was likely that some of the 
diabetic population in the MRC trial had diabetic eye disease 
which had not yet affected their vision. In epidemiological studies 
which perform fundoscopy, retinopathy may be more likely to 
exhibit a higher prevalence than decreased visual acuity. 
However, the higher prevalence of visual impairment in the 
diabetic group and PAF of 3.46%, indicate that diabetes does add 
to the burden of visual impairment. The overall prevalence of 
visual impairment but not blindness was slightly higher in women 
than men, but there was not any difference between the age and 
sex specific prevalence measures. 
In South East London, 29.2% of their diabetic clinic population 
had proteinuria and 12.5% of the population had a creatinine level 
greater than 120 pmol/1(122). The prevalence level of proteinuria 
obtained from the MRC trial (17.14%) was less than this. Our 
estimate is higher than those obtained from the DAI study in 
Italy(123). This study found proteinuria to be 9.5% in men aged 
on average 65 years and 6.1 % in women aged on average 67 
years. The MRC trial population was older than both of these 
studies suggesting that proteinuria may increase with age. The 
raised PAF detected in the MRC study (PAF=7.0%) implied that 
diabetes contributes to the burden of proteinuria in older diabetic 
people. A large percentage of the older diabetic population in the 
MRC trial had raised creatinine 22.65%. This figure is much 
higher than the 5% estimate of nephropathy obtained from South 
Wales, for reasons for which were not clear(112). While diabetes 
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seems to have contributed to raised creatinine (adjusted odds 
ratio 1.25), this was not reflected in reduced glomerular filtration 
rate in this age group. In fact, there was no difference in the GFR 
calculated for the diabetic and the non diabetic group using the 
Modification of Diet in Renal Disease Study (MDRD) 
equation(152; 154). The MDRD equation has only been validated 
in younger diabetic populations(155). It was surprising that no 
differences were found between the diabetic and non diabetic 
groups because the creatinine levels were higher in the diabetic 
group. It is therefore possible that the MDRD equation becomes 
less reliable at the extremes of age in diabetic (and possibly all) 
populations. Furthermore, when the GFR was assessed by 
grouping, either less than 60 or less than 15 ml/min/1.73m2, 
people with diabetes did not exhibit worse renal function. This 
may have also reflected inaccuracies in the calculation of GFR 
using the MDRD in the older diabetic person. Visual inspection, of 
the distributions of GFR, showed that both the non diabetic and 
the diabetic populations were normally distributed. If the 
distribution had not been normal, a non parametric test should be 
used to test any differences between the means of the diabetic 
and non diabetic populations. Therefore a non normal distribution, 
occurring after the generation of GFR using the MDRD equation, 
does not account for the lack of difference observed. 
The MRC trial estimated the prevalence of angina among people 
with diabetes to be 12.10% and myocardial infarction to be 
16.26%. These estimates were community based using a well 
validated method of recall(159). The results therefore represent 
slightly different estimates to some of those which were 
discussed in the introduction to this chapter (section 3.2.3). For 
example; a study in 2050 people aged over 65 years in 
99 
Chapter 3 Identification of people with diabetes 
Connecticut, U. S. found the prevalence of diabetes to be 28% of 
all myocardial admissions(125), slightly lower than the 35% seen 
in South Wales, which included both in patients and out 
patients(112). The Minnesota Heart Survey estimated the 
prevalence of diabetes in people hospitalised for myocardial 
infarction. It was found to be 16.8% in men and 25.8% in 
women(129). 
Perhaps the most comparable study to the MRC trial was the 
Cardiovascular Heart Study(131). This recruited 5712 people all 
aged over 65 years, from 4 study sites in America. Each 
participant then underwent fasting glucose measurements. In 
people found to have diabetes, the prevalence of history of 
angina and history of myocardial infarction were 30.6% and 
25.2% for men and 31.8% and 19.6% for women respectively. 
The overall prevalence of angina and myocardial infarction in our 
diabetic population were lower than these figures and did not vary 
between men and women; 12.10% and 16.26% respectively. The 
higher prevalence seen in the Cardiovascular Heart Study may 
reflect a higher underlying prevalence of diabetes, detected 
because each participant underwent fasting glucose 
measurement. In the DAI study from Italy (n=19468) the 
prevalence of coronary artery disease was 1.1% and all acute 
myocardial events 5.8% in type 2 diabetic patients of all ages in a 
hospital outpatient setting(123). This may be a comparable 
survey to the MRC trial and the differing results obtained reflected 
the younger age of the Italian population. The increased PAF for 
each complication shows that diabetes contributes to the burden 
of macrovascular disease in older age, especially myocardial 
infarction. 
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The prevalence of cerebrovascular disease was very similar 
between the Cardiovascular Heart Study and the MRC trial(131). 
The Cardiovascular Heart Study demonstrated a prevalence of 
12.6% for men and 12.7% for women. The MRC trial showed an 
overall prevalence of 13.94%. The sex specific prevalence was 
15.47% for men and 12.62% for women. This figure is less than 
the 20% seen in South Wales but this study identified both in 
patients and out patients(112). 
The prevalence of peripheral vascular disease was found to be 
12.5% after 18 years in the UKPDS(132) in whose population 
was younger. We did not have the capacity to estimate peripheral 
vascular disease itself Equally, there are detailed classification 
systems available for foot ulcers, such as the Wagner 
classification. Therefore, the self reporting of foot ulceration was 
taken as representing, however crudely, the presence of 
peripheral vascular and foot disease. Over 50% of foot ulcers are 
due solely or in part to peripheral vascular disease(138; 139). 
Estimates suggest that about 5% of diabetic patients have a foot 
ulcers (these studies included a large number of older 
people) (136-138). The prevalence estimate recorded in the MRC 
trial is slightly below that figure, 4.14%, but broadly similar. 
It is likely that the prevalence estimates of diabetic complications 
produced by this survey underestimate the true figures because 
not everybody with diabetes was identified due to the reasons 
outlined above. This is nondifferential (random) misclassification. 
This increases the similarity between the group with diabetes and 
the group without diabetes thus diluting or underestimating any 
associations. Any results obtained will be biased towards the null 
value. 
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It is also likely that not all diabetic complications were detected. 
Physical measurements by trained study personnel were taken 
for visual acuity, proteinuria and creatinine, while there is always 
the possibility of bias, these measures probably reflect accurate 
reproducible results. The identification of cardiac disease, 
cerebrovascular disease and foot ulceration required self 
reporting. All self reporting is subject to recall bias, although the 
cardiac measures have been well validated(157-159). The others 
have not been so well validated and this must be noted as a 
limitation. Another factor contributing to the underestimation of 
the true prevalence of diabetic complications is that older people 
with diabetes and complications are more unwell than those with 
diabetes without complications. Diabetic people with 
complications are therefore less likely to have participated in this 
study. Within the MRC study it was not possible to identify and 
assess these individuals beyond comparing mortality rates 
between responders and non responders which was performed in 
chapter 8. 
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Chapter 4. The management of diabetes in the older 
person and patient understanding of their diabetes 
4.1 Summary of objectives 
To assess the: 
Source of medical advice and treatment regimes; 
Degree and type of home glucose testing; 
Hypoglycaemia and individual understanding of diabetes 
management; 
Utilisation of diabetic services; 
Affect of management and understanding on diabetic endpoints. 
4.2 Background 
4.2.1 Introduction 
Modern diabetic management is multi-disciplinary and life long. 
Once a diagnosis of diabetes has been established the daily 
management is largely patient based, with patients taking 
responsibility for their own care. Therefore a high degree of 
emphasis is given to self management by patients themselves, 
through diabetes education and empowering individuals. 
There are several components of successful long term patient based 
management of diabetes. These include; diet, self-medication, 
monitoring blood glucose, regular medical review and the use of 
specialties allied to diabetes. The aim of which are to reduce 
morbidity and mortality from diabetes. The National Service 
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Framework for diabetes (NSF)(4) first published in December 2001, 
provided a blueprint for care, which formalises the standard of care a 
diabetic person can expect. Three of those standards are especially 
relevant to this chapter; standards 3,4 and 10. Each of them and 
their subsequent recommendations concern the routine 
management and understanding of the condition; 
Standard 3 is dedicated to empowering individuals to manage their 
condition themselves. 
Standard 4 states "All adults with diabetes will receive high-quality 
care throughout their lifetime, including support to optimise the 
control of their blood glucose, blood pressure and other risk factors 
for developing the complications of diabetes". 
Standard 10 states "All young people and adults with diabetes will 
receive regular surveillance for the long-term complications of 
diabetes. " 
Within the NSF clinical guidelines and pathways have been 
developed by the National Institute for Clinical Excellence (NICE) for 
management of diabetic retinopathy(166) and by the Royal College 
of General Practitioners for the management of foot care(167). 
4.2.2 The diabetic annual review 
An important part of the NSF is the diabetic annual review, which is 
the recommended minimum frequency for diabetic consultations(4). 
The annual review is solely centred around diabetes, rather than 
other health issues. It provides a point of contact for the diabetes 
services and an environment for the systematic review of an 
individuals diabetic care. A typical annual review would include 
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blood glucose levels, blood pressure, renal function, examination of 
eyes and feet and any diabetic issues relevant to the consultation. 
The annual review may be conducted in hospital or within the 
primary care setting. The exact local model will vary between 
different hospitals and primary care trusts. Thus, the majority of 
people with diabetes are under the care of a medical professional; 
either a hospital based consultant, their general practitioner, a 
diabetic specialist nurse or a combination of all three. Current 
estimates suggest that at least half of diagnosed diabetic patients 
attend hospital for their diabetes(168). A study from Leeds of 100 
elderly diabetic inpatients found that 19% did not receive any 
medical supervision for their condition(169). General Practitioners 
may also provide specialist clinics, if they have a particular interest in 
diabetes. A literature review from 1996 suggested that between 13% 
and 20% of general practices provide specialist diabetic care(170). 
The results in this chapter provide an assessment of the medical 
management and treatment regimes that the older diabetic person 
undergoes in the U. K. 
4.2.3 Home glucose testing 
Home glucose testing is designed to maximise a persons ability to 
mange their own disease; tightly regulating blood sugar while at the 
same time preventing hypoglycaemia. As discussed above (see 
section 1.1.5) chronic hyperglycaemia contributes to the long term 
complications of diabetes. It follows that it is important to monitor 
blood glucose levels, attempting to maintain blood sugar as low as 
possible, in relation to diet and medication, while avoiding 
hypoglycaemia. 
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Therefore many individuals, young and old, are taught how to 
perform home glucose testing, a common method of testing blood 
sugar quickly and accurately. This can be either testing of blood or 
urine. The testing of blood is done via a small pin prick to the finger 
and testing the resulting drop of blood. Hand held meters provide a 
measure of current blood glucose to one tenth of one mmol/I of 
glucose. Home glucose testing is time consuming, requires dexterity 
and can be painful. Urine testing detects the presence of glucose in 
the urine. It provides a graded estimate recording the amount of 
glucose in the urine (a reflection of the glucose in the blood) using 
an increasing series of "+"s. The minimum threshold for identification 
of urinary glucose is a blood glucose concentration of approximately 
10mmol/I. Below this level glucose is reabsorbed in the kidney and 
not excreted into the urine. It does not provide as accurate a 
measure as blood testing and also does not record hypoglycaemia. 
It simply detects the presence, and to a less accurate extent, the 
degree of hyperglycaemia. Blood testing has now largely 
superceded urine testing, although urine testing is an older and 
simpler method. Therefore many older people, particularly if 
diagnosed several years ago, still test their urine. 
While many diabetic people test their glucose levels at home, limited 
benefits in the older person have so far been identified. It has also 
not been established that blood glucose testing confers additional 
benefits to urinary glucose testing. One of the few studies to show 
benefit from regular blood testing was conducted in Italy, in non 
insulin treated type 2 diabetic people aged up to 75 years(171). In 
988 patients they showed a small improvement in long term blood 
glucose levels in people who performed at least six blood tests per 
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week, when followed up for six months. However, in 2005, another 
Italian group found no benefits in a larger population of non insulin 
treated type 2 diabetic people(172). This trial contained more people 
(n=1896) aged 62.4 years, who were followed up for much longer (3 
years). The same Italian group had previously demonstrated in a 
study of 3567 people with type 2 diabetes of all ages that only 
people who were able to adjust their insulin doses (which requires 
regular glucose testing) had better glycaemic control. Other 
participants who tested their blood glucose at least once per day had 
higher levels of stress, worry and depressive symptoms, without 
improved glycaemic control(173). In 1993, a retrospective study of 
229 patients conducted on Veterans in the U. S., did not show any 
improvement in overall blood glucose measurement using either 
urine or blood testing(174). A further cohort study of 8668 Veterans 
published in 1997 did not demonstrate any overall benefit in glucose 
levels in those who used intensive glucose regimes, although each 
trial participant conducted over 300 home glucose tests per 
year(175). Two studies from Britain which assessed different 
treatments did not find any benefit in overall blood glucose level or 
quality of life in people treated with insulin. The UKPDS 37 which 
assessed quality of life in a sub group of the trail population showed 
that the presence of microvascular or macrovascular complications, 
rather than the type of treatment, affected quality of life (176). 
Another study from Salford, UK which studied 1000 diabetic people 
aged over 60 also showed quality of life was not improved with 
intensive treatment options(177). A study from Bournemouth (U. K. ) 
which assessed only newly diagnosed type 2 diabetic people, found 
no difference between levels of glycosolated haemoglobin, at 12 
months between those people testing their urine and those testing 
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their blood for glucose(178). A meta analysis by Coster et al (179), 
compared blood or urine monitoring with no monitoring and 
compared blood monitoring with urine monitoring. Using data from 
four randomised controlled trails comparing urine or blood glucose 
testing against no testing, there was a non significant decrease in 
glycated haemoglobin of -0.25% (95%Cl, -0.61-0.10%). When three 
trials were used to compare blood glucose and urine glucose 
monitoring the estimated reduction in glycated haemoglobin 
obtained using blood testing was -0.03% (95%Cl, -0.52-0.47%). 
For glucose testing to be affective, it is presumed that it should be 
performed regularly. It appears, however, that most diabetic people, 
regardless age, do not test their glucose regularly. This has been 
confirmed by three large epidemiological studies(172; 180; 181). The 
2005 Italian study (previously mentioned above) demonstrated that 
most diabetic people tested their blood glucose less than once per 
day(172). The NHANES study found that 58.9% of their cohort 
tested their blood glucose either never or less than once per 
month(180). The Kaiser Permanente diabetic study showed that 
people in their cohort aged over 65 years, tested their blood glucose 
less than once per day, odds ratio 1.3 (1.1-1.5), (less than daily vs 
daily)(1 81). 
Due to the lack of conclusive benefits and the high financial cost of 
blood glucose testing there have been suggestions for the increased 
use of urinary glucose testing(182). Urine testing may be particularly 
appropriate in diabetic people on diet or tablet treatment alone(182) 
who do not have the ability to regulate their treatment in conjunction 
with any glucose results obtained. It should be noted that some 
diabetic people have been found to hold strongly negative views 
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about urine glucose testing(183) and that blood glucose testing has 
the ability to empower diabetic individuals(182). 
4.2.4 Hypoglycaemia 
Hypoglycaemia is defined as a blood glucose measurement below 
3.3 mmol/l. Symptoms of hypoglycaemia may be experienced at this 
level or below. Levels less than 2.5 mmol/l will almost always be 
symptomatic. The MRC trial did not ask about hypoglycaemia 
confirmed by blood glucose measurement. It simply asked whether 
an individual had ever experienced hypoglycaemia. 
As well as preventing hyperglycaemia, the use of diabetic 
medication (sulphonlyurea medications and insulin) can produce 
hypoglycaemia. Patients need to be aware of the symptoms of 
hypoglycaemia, how it arises, how to prevent it and how to treat it. 
Hypoglycaemia is of particular importance in the elderly and can be 
particularly hazardous. Older people are particularly susceptible to 
hypoglycaemia and often are not aware of the symptoms(184). In a 
study of 80 year olds from Marsala (Italy), 124 different people were 
hospitalised for hypoglycaemia over a two year period(185). Only 10 
of these people performed regular blood glucose testing. In the 
study authors opinion greater numbers of severe hypoglycaemic 
episodes could have been prevented by teaching the principles of 
blood glucose measurement. 
Older diabetic people at risk of hypoglycaemia need to know how to 
manage their disease if they are unwell. The reasons for this are two 
fold. The intake of food causes blood glucose to rise, normally 
counteracted by oral medication or insulin. If an individual is not 
eating or is vomiting the intuitive response to a lack of intake would 
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be to decrease medication to prevent hypoglycaemia. The natural 
physiological response of any individual when they become ill is, 
however, to produce more glucose through a combination of 
different physiological pathways. In a non diabetic person, their own 
insulin production would continue to regulate their blood glucose 
concentration. In a diabetic individual they do not have the ability to 
do this. Therefore, the combined action of potentially decreasing 
medication, in an environment where medication should be 
maintained or often increased, can easily lead to ever increasing 
glucose levels. The days which diabetic people are unwell are 
commonly known as "sick days". What to do on "sick days" is 
therefore very important. Diabetic people on medication need to be 
aware they should never stop their medication, may need to 
increase their medication and should be aware that they may need 
to seek diabetic advice. Consequently a high degree of 
understanding is required by diabetic individuals to safely manage 
their disease. The level of diabetes understanding among an elderly 
population has never been assessed on this scale before and this 
thesis provided an interesting insight into the degree of 
understanding of the disease in an older diabetic population and the 
factors that were associated with it. It is likely that some older 
diabetic individuals have poor understanding of the every day 
management of their condition, which may be exacerbated in those 
with cognitive impairment(95; 186; 187). In diabetic populations of all 
ages a critical review of 19 studies concluded that it was likely that 
diabetes was associated with an increased risk of cognitive 
dysfunction(186). A community based survey in the U. K showed that 
older diabetic people were more likely than non diabetic people to 
have cognitive impairment(187). Sinclair et al(95) studied 396 
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diabetic people aged over 65 years and compared them with 393 
age matched controls. The study showed diabetic people were more 
likely to have cognitive impairment than non diabetic people (OR 
0.54, p<0.001). People with cognitive impairment were less likely to 
be involved in diabetes self care (self medication and self 
monitoring) or attend a diabetes clinic. 
4.2.5 The use of specialities allied to diabetic care 
The use of specialists allied to diabetic health care, such as diabetic 
specialist nurses, dieticians, eye specialists and chiropodists are 
widely believed to aid in the overall quality of care of the diabetic 
patient and increase patient knowledge about the condition(188). 
Diabetes specialist nurses provide a wide range of support for 
people with diabetes, especially at the time of diagnosis. They 
educate patients about injection technique, the correct use of home 
glucose monitoring, all aspects of hypoglycaemia, education for "sick 
days" and are a point of patient contact for any aspect of diabetic 
care. Dieticians provide advice regarding weight loss and suitable 
diet. Both diabetic specialist nurses and dieticians form an integral 
part of the diabetic team recommended by the NSF(4). While the 
exact service provision will vary locally, all diabetic people should 
have access to these services, if appropriate. 
The foot is susceptible to disease in diabetic people, as discussed in 
section 3.2.3. The guidelines produced by the Royal College of 
Physicians for the management of the diabetic foot, suggested that 
in the uncomplicated diabetic foot, yearly surveillance is 
required(167). The same report admits that due to the disparity of 
the services available, little reliable data on the use of health care 
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facilities for the diabetic foot exists(167). Adequate monitoring, self 
care, foot hygiene, awareness of fungal infections, cutting toe nails 
regularly and correctly, wearing properly fitting shoes and identifying 
early disease in the foot are all important(167; 189). Chiropody aids 
in correct foot management of the diabetic person in all of these 
areas. Evidence from two small studies in the UK suggested that the 
elderly, including those in institutional care, have a particularly low 
uptake of foot care services. In Leeds, 100 elderly inpatients with 
diabetes were surveyed and only 50% had seen a chiropodist within 
the last 12 months(169). Only 20 of 109 (18%) of residents with 
diabetes in institutional care in Liverpool had had their feet examined 
in the last year(190). 
Diabetic eye disease is easily detectable and is often treatable, 
especially diabetic retinopathy. The exact management of diabetic 
eye disease may vary locally between different health care 
providers; with regular screening from either optician, 
ophthalmologist or diabetologist. The guidelines developed by the 
National Institute for Clinical Excellence(166), as part of the NSF(4), 
recommended examination of the eyes at diagnosis of diabetes and 
then annually for individuals without pre-existing eye disease. The 
presence of diabetic eye disease requires review by an 
ophthalmologist, the frequency of which depends on the type and 
severity of the diabetic eye disease(166). Screening for diabetic 
retinopathy is both cost effective and leads to decreased morbidity 
from diabetic eye disease(46; 191-193). Proliferative diabetic 
retinopathy, the most severe form of diabetic retinopathy, is a very 
serious disease. Depending on the exact location within the eye, 
over 50% of people with this condition will be blind within two 
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years(194; 195). Retinal laser treatment, which is the treatment of 
this condition, is also extremely affective, with up to a 60% reduction 
in the rate of severe visual loss expected(194; 195). Diabetes also 
contributes to other forms of eye disease. For example, cataracts 
are more common in people with diabetes. Regular eye examination 
would therefore also detect additional eye disease associated with 
diabetes. The frequency of eye examination in a large community 
based diabetic population has not been assessed in an older age 
group. The Leeds survey of 100 inpatients with diabetes found 52% 
underwent annual eye examination(169) and in the Liverpool survey 
of diabetic people in institutional care, 72% had had an eye 
examination within the last year(190). 
Ultimately, the aim of diabetes care is to prevent morbidity and 
mortality. The point of home glucose testing and dietician review is 
to improve glycaemic control and minimise microvascular, 
macrovascular and hypoglycaemic end points. Likewise, regular foot 
and eye examination is designed to prevent foot ulceration and 
diabetic retinopathy. There is little evidence that the use of home 
glucose testing, foot and eye examination actually achieves those 
aims in patients of any age. In the older person, however, the 
evidence is sparser still and this thesis provided an ideal opportunity 
to assess those aims. 
4.3. Methods; Classification and identification of the 
management and patient understanding of diabetes 
This section only included the 1047 participants who were aware 
that they had diabetes. This figure included diabetic people who did 
not correctly report diabetes but not individuals identified as having 
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diabetes using a high random glucose. The 130 individuals with 
diabetes identified using high random glucose were unaware of their 
health status and therefore would not see anybody about their 
condition or utilise any health care provision available for diabetes. 
They were therefore not included in the analysis in this section. The 
questions 38c to 38m of the detailed questionnaire were used in this 
chapter (see appendix 2, page 15). 
There were two basic questions regarding diabetes management; 
who was looking after the individuals diabetes and what treatment 
they were taking. The questions and responses were; 
" 'Who do you normally see about your diabetes (can be more 
than one person)? " The responses were "Family doctor/GP", 
"Hospital doctor", "Practice/District nurse" and "No one". 
" "What treatment are you on for your diabetes? (Tick all that 
apply)". The potential answers were; "diet alone", "tablets", 
"insulin injections" or "no treatment". 
Two questions related to home glucose testing, the answers were 
"yes" or "no"; 
" "Do you ever test your blood for sugar? " 
" "Do you test your urine for sugar? " 
The results were then combined to show participants who did any 
form of testing. As highlighted above, the benefits of any home blood 
testing have not been fully established, the type of testing even less 
so. It was important to determine whether or not a difference existed 
between blood testing, urine testing or indeed, any form of testing. 
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Therefore, the groups used for home glucose testing in the 
remainder of the chapter were; blood testing (any), urine testing 
(any) and any testing. Blood testing included people who only tested 
their blood or blood and urine. Likewise, urine testing included 
people who only tested their urine or urine and blood. Any testing is 
the group that includes any form of testing (blood, urine or a 
combination of both). The frequency of testing was then assessed. 
It is unlikely that a person with a MMSE below 23 could meaningfully 
conduct and/or understand the result of home blood testing. The 
detailed assessment could be completed by a proxy responder, 
either partially or totally. In an individual with cognitive impairment 
proxy response is likely to indicate a closely involved carer. Proxy 
responses were therefore assessed in the people with cognitive 
impairment. The degree of cognitive impairment for people who 
tested home glucose was then assessed. 
The questionnaire instructed the nurse conducting the interview to 
only ask participants who were receiving tablets or insulin to answer 
the following set of questions. These questions related to 
hypoglycaemia and its management. The responses were "yes", "no" 
or "don't know". The questions were; 
" "Have you ever had a low blood sugar (a"Hypo")? " 
" "If you have a low blood sugar, should you increase your 
diabetes treatment? " 
" "If you have a low blood sugar should you take a sugary drink 
or snack? " 
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" "If you have the flu, should you stop taking your diabetes 
tablets/insulin? " 
Regardless of whether an individual has had a hypoglycaemic 
attack, all of these responders should still be aware of what to do if 
they ever did have one and know what to do if they became unwell. 
The use of specialities allied to diabetic health care was then 
assessed for the diabetic population. The three questions contained 
within the detailed questionnaire were; 
" "in the last year have you had your feet examined? " 
" "In the last year have you had your eyes examined? " 
" "In the last year have you discussed your diet with a 
dietician? " 
For each question, the possible responses were "yes", "no", "don't 
know" or missing. If a response to any of these questions was don't 
know or missing, it assumed that no meaningful examination had 
taken place. The responses were then assumed to be no. 
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4.4. Results 
The results are presented for the 1047 people who had a diagnosis 
of diabetes. 
4.4.1 Source of medical advice and treatment regimes 
Table 4.1 shows the medical supervision that participants were 
receiving and the treatments which the diabetic participants were 
taking. It was possible for participants to record more than one 
response to either of these questions. Multiple responses occurred if 
more than one person was responsible for their care or they were on 
a combination of treatments. 
The results for the people who saw only one medical practitioner for 
their diabetes care demonstrated that 229 (21.87%) people only saw 
their general practitioner for their diabetes care, 100 (9.55%) only 
saw the hospital doctor and 155 (14.80%) only saw a nurse for their 
diabetes management (not shown in the table). 
There were 645, out of the population of 1047, people who were 
taking either tablets, insulin or a combination of both. All of these 
people had the ability to become hypoglycaemic. There were 
501/1047 (47.85%) people taking tablets alone, 112/1047 (10.70%) 
taking insulin alone and 32/1047 (3.06%) taking a combination of 
tablets and insulin. These results are not shown in the table. 
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4.4.2 Type and frequency of home glucose testing 
In total 681/1047 (65.04%) people did some form of glucose testing 
at home. The results are given for blood testing only, urine testing 
only, testing of both blood and urine; "blood any", "urine any" and 
"any testing". The results for home glucose testing are presented in 
table 4.2. The age distribution, sex and cognitive impairment 
(MMSE<=23) are also presented for people who did any form of 
testing. Those who tested their glucose at home were younger 
(p=0.001) and less likely to have a MMSE under 24 (p<0.001) than 
those who did no form of testing. There were 130 (19.09%) people 
with a MMSE<=23 who reported testing their blood at home. The 
proportion with cognitive impairment is less in this sub population 
than the whole diabetic population (p<0.001). There were 235 
(22.45%) within the whole diabetic population with a MMSE<=23. 
Proxy responses were made for 42/235 (17.87%) of the diabetic 
people with cognitive impairment. These results are shown in table 
4.3. 
Considering only the 645 individuals who were receiving diabetic 
medication capable of inducing hypoglycaemia the degree of 
glucose testing was higher than the overall diabetic population 
(p<0.001). There were 493/645 (72.39%) people testing their 
glucose (blood or urine) in this group. Of these people, 225/645 
(34.88%) were testing their blood glucose. 
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Type of glucose testing Number (%) 
In=1047 
(Missing=O) 
None 
Blood only 
Urine only 
Blood and urine 
Blood (any) 
Urine (any) 
366 (34.96) 
169 (16.14) 
406 (38.78) 
106 (10.12) 
275 (26.27) 
512 (48.90) 
Any testing 1681 (65.04) 
Table 4.2. Type of glucose testing for diabetic participants 
who were aware of their condition 
Sex Male 
Female 
Age group 75-79 years 
80-84 years 
85-89 years 
90 plus years 
318 (46.70) 
363 (53.30) 
364 (53.45) 
203 (29.81) 
82 (12.04) 
32 (4.70) 
Cognitive impairment (MMSE<23)1130 (19.09) 
Table 4.3 Sex, age and cognitive impairment for diabetic participants 
who underwent any form of home testing 
Overall, 592 out of 1047 (56.5%) of participants tested either urine or 
blood once per week or more. Only 178/1047 (17.0%) of people with 
known diabetes tested their blood or urine once per month or less. 
Considering the 275 participants who measured their blood glucose, 
there were 101/275 (36.7%) participants who tested about once per 
day, 101 (36.7%) who measured it weekly and 73/275 (26.4%) 
participants who measured their blood glucose less than once per 
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month. In the 512 people who tested their urine, 137/512 (26.8%) 
tested their urine daily, 253/512(49.4%) tested their urine weekly 
and 122/512 (23.8%) who tested their urinary glucose less than 
once per month. Age and sex were unrelated to the frequency of 
testing for either blood (p=0.32 for age and p=0.87 for sex) or urine 
(p=0.09 for age and p=0.89 for sex). 
4.4.3 Hypoglycaemia and individual understanding of diabetes 
management 
Table 4.4 shows the prevalence of hypoglycaemia. It also 
demonstrates the level of understanding of the management of 
hypoglycaemia within this population. The results are shown for the 
645 people who were taking diabetic medication or insulin and 
therefore had the potential to become hypoglycaemic. The incorrect 
response, don't know or a missing response, all indicate that person 
possessed inadequate knowledge. As such, they all represented an 
incorrect response and are shown under the incorrect heading. 
Of the 645 people who were taking hypoglycaemic medication, 143 
(22.17%) had cognitive impairment (MMSE<=23). There were 
21/143(14.68%) of people with cognitive impairment who were 
taking hypoglycaemic medication who had a proxy response. 
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Number (%) 
n=645 
'Have you ever had a low blood sugar or "hypo"? Yes 151 (23.41) 
No 425 (65.89) 
Don't know 20 (3.10) 
Missing 49 (7.60) 
If you have a low blood sugar, Yes 38 (5.89) 
should you increase your diabetes treatment? No 331 (51.32) 
Don't know 230 (35.66) 
Missing 46 (7.13) 
Incorrect 314 (48.68) 
If you have a low blood sugar, Yes 439 (68.06) 
should you take a sugary drink or snack? No 32 (4.96) 
Don't know 131 (23.31) 
Missing 43 (6.67) 
Incorrect 206 (31.94) 
If you have the flu, Yes 29 (4.50) 
should you stop taking your diabetes tablets/insulin? No 424 (65.74) 
Don't know 148 (22.95) 
Missing 44 (6.82) 
Incorrect 221 (34.26) 
Table 4.4. Understan inq of hypoglycaemia in patients taking ta blets or insul 
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4.4.4 Utilisation of diabetic services 
Table 4.5 shows the results for foot examination, eye examination 
and discussion regarding diet with a dietician within the last year. 
The sex and age distribution of these people is also given in table 
4.5. Men were more likely to undergo eye examination (p=0.03) and 
have seen a dietician in the last 12 months (p=0.02) when compared 
to women. Men and women were equally likely to undergo foot 
examination (p=0.25). Participants undergoing eye examination 
(p<0.001) and seeing a dietician within the last 12 months (p<0.001) 
were younger than people who did not use these services. Those 
undergoing foot examination were the same age as those not 
undergoing foot examination (p=0.37). 
There were 729/1047 (69.49%) people who underwent both foot and 
eye examination within the last year and 263/1047 (25.12%) people 
who had undergone both examinations and seen a dietician within 
the last 12 months. 
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4.4.5 Affect of management and understanding of diabetes on 
diabetic endpoints 
Any home glucose testing (either blood or urine) was assessed in 
relation to the diabetic end points defined in section 3.4. In those 
who were taking diabetic medication or insulin, the presence of 
hypoglycaemia was assessed in relation to home glucose testing. 
Individuals with missing responses for home glucose testing were 
assumed to be not testing their glucose. The results are presented in 
table 4.6. The table shows crude odds ratios for diabetic end points 
and hypoglycaemia in relation to home glucose testing. The odds 
ratios were then adjusted for age, sex and poor cognitive function. 
The questions regarding eye examination and annual foot 
examination were compared to the defined end points of poor vision 
or blindness, and foot ulceration respectively and are shown in table 
4.7. The odds ratios have been adjusted for age, sex and cognitive 
function. 
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Examination Outcome I Crude Odds Ratio Adjusted Odds Ratio' P value 
(95% Cl) (95% Cl) (adjusted Wald test) 
None 1 
Foot examination Foot ulceration 1.44 (0.66-3.14) 
Eye examination Vision <6/18 0.80 (0.51-1.28) 
Vision <3/60 0.62 (0.26-1.49) 
*Adjusted for sex, age and cognitive impairment 
1 
1.47 (0.69-3.13) 0.316 
1.12 (0.66-1.89) 0.671 
0.77 (0.29-2.10) 0.617 
eye examination and selected o 
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4.6 Discussion 
The results from this chapter provide one of the most 
comprehensive studies into the management and individual 
understanding of diabetes in the older person conducted in the 
U. K. 
The results show that the majority of older diabetic people are 
under some form of medical supervision. Although the frequency 
of supervision is not recorded, 1015 out of a population of 1047 
(96.94%) people were seeing either a doctor, a nurse or a 
combination, for their condition. Encouragingly, only 32/1047 
(3.06%) participants were not seeing a medical professional of 
any description. This figure is much lower than the 19% of elderly 
people receiving no medical supervision seen in the Leeds in 
patient study(169). While our survey is community based, this still 
represented a more encouraging response and involved far 
greater numbers of diabetic participants. The results for treatment 
also showed that elderly people are widely and actively treated in 
the community, using a combination of diabetic treatment 
regimes. Only 27 (2.58%) participants were on no treatment 
whatsoever. Diet was listed as a treatment (either alone or in 
combination) in 439/1047 (41.93%) people. This shows that these 
individuals understand that correct diet formed an integral part of 
their diabetic management. 
Hypoglycaemia was recorded using only questionnaire responses 
about symptoms and they were not confirmed by blood glucose 
measurements. It is therefore possible that not all of the positive 
responses were definitely true episodes of hypoglycaemia. 
However, hypoglycaemia is often relatively easy to. identify from 
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symptoms alone. Nonetheless, potential misclassification of 
hypoglycaemia must be noted as a limitation. 
In people who were at risk of hypoglycaemia, there was a far 
higher amount of blood glucose testing (34.88%) than seen in a 
similar Italian population. In the Italian study, less than 10% of 80 
year olds admitted with hypoglycaemia tested their blood(185). 
Previous studies have found the frequency of blood testing to be 
less than daily within diabetic cohorts and the frequency of testing 
to decrease with age(172; 180; 181). While these results can not 
be compared directly because the MRC trial assessed the 
frequency of testing of blood and urine, our results show that a 
large number of older diabetic people test their glucose regularly. 
For example, the NHANES study found that 58.9% of their 
participants tested blood glucose less than monthly(180) and the 
Kaiser Permanente study showed that people over 65 years 
tested their glucose less than people under 65 years(181). The 
MRC trial involved large numbers of subjects (681 (75.04%)) who 
did some form of home glucose testing. Overall, 56.5% of 
participants tested their glucose at least weekly and only 17.0% 
tested their glucose once per month or less. The MRC trial results 
also suggested that younger people were more likely to test their 
glucose, however, in people who tested their glucose the actual 
frequency of testing was not affected by age. 
The degree of reported hypoglycaemia was 23.41% in those 
taking hypoglycaemic medication. This shows clearly that 
hypoglycaemia is a major problem affecting one in five older 
people on hypoglycaemic medication. The severity and frequency 
of hypoglycaemia, however, was not estimated in the MRC study. 
In relation to the questions regarding the understanding of 
hypoglycaemia management and "sick days", large numbers 
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gave an incorrect answer. Nearly 50% gave an incorrect answer 
regarding increasing treatment in the presence of hypoglycaemia. 
The majority of this figure was comprised of a "don't know" 
response which was regarded as an incorrect response for the 
purposes of this study. Over 30% of people did not know how to 
correctly manage hypoglycaemia by taking a sugary drink or 
snack and nearly 35% gave an incorrect answer regarding "sick 
day" management. These figures suggest that education 
regarding these aspects of diabetes management was either not 
occurring or was ineffective in the older person. 
There were 235/1047 (22.45%) people identified as having 
cognitive impairment. A large proportion of the 681 subjects who 
tested their glucose had marked cognitive impairment 
(MMSE<=23). In all, 130 (19.09%) of these people had a MMSE 
below this level. There were 143 (22.17%) people taking 
hypoglycaemic medication who also had a reduced MMSE. This 
suggests that cognitive impairment was high among older 
diabetic people who have the capacity for hypoglycaemia and 
that home testing is unlikely to be reliable. Not only is cognitive 
impairment common in our study, it has previously been shown to 
be associated with poor diabetes self care(95). While some of 
these individuals may have carers, without cognitive impairment, 
who manage their condition for them, many will not. The 
measurement of proxy response supported this assumption. The 
results from the MRC study showed that only 17.87% of the 
people with diabetes and cognitive impairment had a proxy 
responder. This figure for proxy response was even lower 
(14.86%) when the 143 people who were receiving 
hypoglycaemic medication and had cognitive impairment were 
considered. On the basis of these results it would seem sensible 
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to recommend regular Mini Mental State Examinations (MMSE) to 
all diabetic individuals aged over 75 years in order to detect 
cognitive impairment. Identification of people with poor cognitive 
function, especially if they are receiving hypoglycaemic 
medication, must be beneficial to the individual. 
Both eye examination and foot examination showed a high 
uptake, with 77.65% having an eye examination and 79.85% 
having a foot examination within the last year. In terms of the 
recommendations by NICE(166) and the Royal College of 
General Practitioners(167) regarding annual screening, the MRC 
trial results suggest a very good uptake. The results should help 
to form a more accurate picture of the amount of screening 
occurring in the older diabetic person. Both figures are above 
those seen in smaller studies from Leeds(169) and 
Liverpool(190), although neither of these two studies were 
community based. The number of diabetic people seeing a 
dietician within the last 12 months to discuss their diet is lower 
(31.14%) than the numbers undergoing eye or foot examination. 
This is less surprising because, while the dietician is an important 
part of the diabetic team, annual visits are not currently 
recommended by the NSF for diabetes(4). 
The high uptake of eye examination, foot examination, dietician 
use and regular medical supervision when compared to other 
studies is interesting. One potential explanation is possibility that 
participants in the trial, in keeping with all medical trials were 
more health aware and therefore more likely to utilise medical 
services than non trial participants. 
There have been numerous studies which have shown little, if 
any, benefit in outcome with regular home glucose testing(173- 
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177). While some limited benefit in glycaemic control has been 
found in subgroups of patients, higher levels of stress, worry and 
depressive symptoms are also reported. No study has so far 
identified benefits in microvascular or macrovascular end points. 
The results from the MRC study also show limited benefit in home 
glucose testing. It is possible that the lack of positive results seen 
was due to the sample being too small too detect any benefits, as 
these were not primary endpoints of the original trial. Also, the 
assessment of the occurrence of micro or macrovascular end 
points in relation to home testing is cross sectional and continued 
longitudinal follow up may have showed benefit. It may also be 
the case that no benefits in micro and macrovascular outcome 
are conferred by home testing in older people. The only positive 
association seen for home testing, was between a raised 
creatinine and urinary testing; the adjusted odds ratio for having 
raised creatinine in people who tested their urine for glucose was 
0.56. The reasons for this are unknown, however, one 
explanation would be that people with a raised creatinine 
constitute an advanced form of diabetic end stage disease. As 
such, they are likely to have been in regular contact with health 
care professionals, take hypoglycaemic medication and therefore 
more likely to have been taught how to perform blood testing 
rather than urinary testing. End stage renal failure also causes an 
increased renal glucose loss and patients often require 
decreased dosage of diabetic medication at this stage of their 
disease. They are therefore at increased risk of hypoglycaemia, 
another reason that individuals with raised creatinine are unlikely 
to solely test their urine and to have been taught home blood 
glucose testing. 
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Urine testing was associated with a significantly lower adjusted 
odds ratio for hypoglycaemia. As urinary testing does not detect 
hypoglycaemia it is possible that this is an incorrect result. 
Individuals who test their urine are simply unaware that they are 
hypoglycaemic as urinary testing will not show this. Conversely, 
any testing or blood testing was strongly associated with having 
ever had a hypoglycaemic attack. Obviously it is not the testing 
itself causing the hypoglycaemia, but that fact that those at risk 
are taught how to perform blood testing and therefore able 
confirm the presence of hypoglycaemia using their hand held 
meter. 
Finally, neither annual foot or eye examination was associated 
with significant changes in the amount of foot ulceration or 
reduced vision or blindness found in the trial population. It is 
again possible that these results are spurious due to the lack of 
diabetic trial participants and the cross sectional nature of the 
survey. They do, however, suggest that further studies are 
required to confirm any benefits. 
This chapter provided one of the largest community based 
assessments of the management and understanding of diabetes 
in the older person ever undertaken worldwide. It shows that the 
majority of older diabetic people see a medical professional and 
undergo some form of treatment. It provided an interesting 
summary of community based provision for elderly diabetic 
people, an area noted for lack of evidence(167). As this study 
was conducted before the introduction of the NSF for diabetes, it 
will be particularly interesting to see if these figures change as the 
NSF continues its development and implementation. In keeping 
with previous studies, our results did not show any major benefits 
in diabetic end points in relation to home glucose testing. While 
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these results may be spurious, further studies should be 
recommended. 
Perhaps the most important results generated from this chapter 
concerned hypoglycaemia and cognitive impairment. The level of 
understanding of hypoglycaemia and its management in this 
population was poor. In addition there was a high prevalence of 
cognitive impairment throughout the whole diabetic population, 
including those at risk of hypoglycaemia. Both are areas for 
concern and potential improvement. 
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Chapter 5 The relationship between hypertension 
and diabetes in the older person. 
5.1 Summary of objectives 
To assess the: 
Relationship between hypertension and diabetes in the older person; 
Affect of systolic and diastolic blood pressure on diabetic endpoints. 
5.2 Background 
5.2.1 Introduction 
Hypertension and diabetes occur commonly together. Estimates 
vary, with between 20-80% of people with diabetes being reported 
as having hypertension(31; 196), both during the course of the 
disease and at the initial presentation of the disease to medical 
care(197). Hypertension is a major independent risk factor for 
cardiovascular events, stroke, renal disease and diabetic 
complications(31; 198). In people with diabetes affective blood 
pressure control has been shown conclusively to prevent the 
diabetic complications associated with hypertension (33; 199; 200). 
Epidemiological studies have helped to define the level of 
appropriate blood pressure(32; 201) and assessed different 
treatment regimes(202-206). The results of these studies suggested 
that aggressive treatment of hypertension in individuals with type 2 
diabetes should be recommended. However, the bulk of these trials 
were conducted in middle aged adults, the evidence base for the 
older adult, with and without diabetes, is far smaller. Furthermore, 
whether blood pressure (systolic or diastolic) has the same 
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associations with diabetic end points in older people has yet to be 
established, let alone specific thresholds for treatment. 
5.2.2 Hypertension in the older person 
Over the past two decades increasing epidemiological information 
has become available regarding the benefits of treating hypertension 
in the older person; both the diastolic and the systolic components. 
However, there is still debate about the merits of treating 
hypertension in very elderly populations. The evidence of the 
benefits for treatment in the "young" elderly and the concerns 
regarding the treatment of the "very" elderly are presented below. 
In 1991, the Swedish Trial in Old Patients with Hypertension Study 
(STOP-Hypertension)(207) was one of the first to show benefits of 
blood pressure reduction in the general older population. It recruited 
1627 elderly patients aged between 70 and 84 years. A mean 
difference in blood pressure of 19.5 mm Hg systolic and 8.1 mm Hg 
diastolic was achieved, between the active treatment and placebo 
groups. Compared with placebo, active treatment significantly 
reduced the number of primary endpoints (myocardial infarction, 
stroke and other cardiovascular death) (55.5 vs 33.5 events per 
1000 patient years, p=0.0031) and non-fatal stroke or myocardial 
infarction (31.3 vs 16.8 events per 1000 person years, p=0.0081). 
Although not a primary endpoint, a reduced number of total deaths 
in the active treatment group was observed (35.4 vs 20.2 events per 
1000 person years, p=0.0079). 
Mulrow and colleagues conducted a large survey of 13 trials 
involving 16564 elderly persons (age 60 years and older) which 
further supported the benefits of treating hypertension in elderly 
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people(208). They concluded that 18 subjects (95% Cl, 14 to 25) 
needed to be treated to prevent one cardiovascular event 
(cerebrovascular or cardiac), and found a significant decrease in 
cardiovascular mortality, with 78 (95% Cl, 50 to 180) older people 
requiring treatment to prevent one fatal cardiac event. A subsequent 
Cochrane review by the same author concluded that anti 
hypertensive drug therapy was beneficial. The review compared 15 
trials including 21908 elderly subjects, with most subjects aged 60 to 
80 years. Cardiovascular morbidity and mortality was reduced; 177 
vs 126 events (95% Cl of the difference 31 to 73) for cardiovascular 
morbidity and 69 vs 50 deaths (95% Cl of the difference 9 to 31) 
cardiovascular mortality. Total mortality was reduced; 129 vs 111 
deaths (95% Cl of the difference 4 to 28)(209). 
Until recently, reducing systolic blood pressure was considered to be 
of less importance than reducing diastolic blood pressure but this no 
longer appears to be the case(42). The Systolic Hypertension in 
Europe (Syst-Eur) Trial showed that a reduction in isolated systolic 
hypertension reduced cardiovascular morbidity and mortality in all 
older subjects (210; 211). Syst-Eur was a double blind trial 
comparing placebo and combinations of active anti hypertensive 
medications (starting initially with the long acting calcium channel 
blocker nitrendipine). All trial participants were aged over 60 years at 
entry, with a mean age of 70.3 years in the active treatment group. 
The Systolic Hypertension in the Elderly Program (SHEP) also 
provided evidence that reducing isolated systolic hypertension was 
beneficial for persons aged over 60 years(212). A total of 4736 
people with a mean age of 72 years were randomised to receive 
either a diuretic (plus a ß-blocker if needed) against placebo. The 
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relative risk for total stroke (the primary outcome) was 0.63 (95% Cl 
0.49-0.82, p=0.0003) for the treated group. The relative risk of all 
cause mortality was non-significantly reduced 0.87 (95% Cl 0.73- 
1.05). 
Whether the benefits of treating hypertension in the older adult apply 
to the very elderly is not clear. There are even concerns that the 
treatment of hypertension in the very elderly person may be 
detrimental, especially in those aged above 80 years(213). In STOP, 
older patients who were randomised to active treatment received 
less benefit, than their younger counterparts. Participants who were 
aged over 73 years no longer received significant benefit when 
compared to their younger counterparts(207). Likewise, the Syst-Eur 
trial did not postpone death in participants older than 75-80 
years(210). In contrast SHEP did find a continued benefit in mortality 
in patients treated for hypertension who were aged over 80 
years(212). In the results of the meta-analysis reported by Gueyffier, 
the authors identified 1670 people with hypertension aged over 80 
years old from seven different trials (including STOP, Syst-Eur and 
SHEP). (49). The results suggested treatment of hypertension was 
associated with a 34% reduction in the rate of fatal and non-fatal 
stroke. Major coronary events showed a non-significant trend 
towards treatment benefit but there was a non-significant trend of 
increased total mortality, with a 6% relative excess of death from all 
causes (95% Cl -5 to 18). Bulpitt and Fletcher(214), reported that 
the positive relationship between blood pressure and mortality at the 
age of 60 to 69 years changes to become a negative relationship in 
men over 75 years old and in women over 85 years old, with 
hypertensive individuals actually living longer. They suggest that the 
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negative relationship in very old people reflects underlying terminal 
disease (cardiac, respiratory or malignant) in those with low blood 
pressure, and reflects good cardiac function in those with high blood 
pressure. The authors were unable to conclude that in very elderly 
hypertensive people lowering blood pressure would be beneficial. 
They highlighted the lack of evidence from, and the need for, clinical 
trials of antihypertensive treatment in the elderly. In a longitudinal 
study, in 2002, Lernfelt and Svanborg published the effect of blood 
pressure changes between ages 70 and 90 years(215). It showed 
people with the lowest blood pressure at 70 survived longest but that 
this relationship changed with increasing age. Individuals alive at 93 
years had higher blood pressures at age 90 years than those who 
had died. Furthermore, people who had a greater individual systolic 
blood pressure at age 79 years than at age 70 or 75 years were 
more likely to survive to the age of 90 years. In order to resolve 
some of these issues the Hypertension in the Very Elderly Trial 
(HYVET) was set up in 1994(48). The aim of this trial was to 
investigate the affect of different treatments (no treatment, a diuretic 
or an angiotensin converting enzyme inhibitor) on stroke incidence in 
hypertensive patients over the age of 80 years. Secondary end- 
points include total cardiovascular mortality and morbidity. The target 
blood pressures were 150 mmHg systolic and 80 mmHg diastolic. 
The results of the pilot study were published in 2003(216). The 
results showed in the combined actively treated groups, the 
reduction in stroke events (hazard rate) was 0.47 (95%Cl 0.24 to 
0.93) and the reduction in stroke mortality (hazard rate) was 0.57 
(95%CI 0.25 to 1.32). However, as was suggested by the Gueyffier 
meta-analysis(49), the estimate of total mortality supported the 
possibility of excess deaths in the active treatment group (hazard 
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rate) 1.23 (95%Cl 0.75 to 2.01). The HYVET trial protocol has been 
slightly revised and now compares placebo against indapamide, plus 
additional perindopril(217). The full trial is currently underway and 
in the results will be published due course. 
5.2.3 The treatment of hypertension in the older person 
There has been a large amount of debate regarding the class of 
drug which should be used in the treatment of hypertension. In non 
diabetic adult populations there appears to be no clear benefit 
between medications over and above the benefit of simply lower 
blood pressure. For example, a large meta-analysis of 9 randomised 
trials involving over 62000 people of all ages found no benefits 
between different antihypertensive medications(218). Another 
survey, conducted on behalf of the Blood Pressure Lowering 
Treatment Trialists' Collaboration, used data from 29 trials and 
162341 participants and similarly failed to find any difference 
between medications, in addition to the protection conferred by 
blood pressure lowering alone(219). 
There has been concern that certain antihypertensive medications 
may actually predispose to the development of diabetes itself(220- 
222). Thiazide diuretics and ß-blocking medications were thought to 
be especially likely to predispose to its development, with other 
drugs exerting a neutral, or even protective, effect(220-222). Several 
large randomised controlled trials of the treatment of hypertension 
found that new onset diabetes occurred up to 15% more often in the 
groups receiving combinations of n-blockers and 
diuretics(206; 223; 224). In 2004, Padwal and Laupacis performed a 
large systematic review of this subject and concluded that there was 
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weak evidence to support these claims but that the data was far from 
conclusive and further well designed trials specifically addressing 
these issues were required(225). 
Consequently the British Hypertensive Society have developed 
recommendations for the which drugs should be use for the 
treatment of hypertension. The treatment algorithm they have 
produced adds medication in a step-wise fashion, based on the best 
available evidence(226). For people aged over 55 years (or any age 
for people of black origin) a diuretic or calcium channel blocker are 
recommended first line treatments. This is based on the 
Anti hypertensive and Lipid-Lowering Treatment to Prevent Heart 
Attack Trial (ALLHAT)(223). In a population aged over 55 years, 
these two drugs lowered blood pressure to a greater extent than 
ACE-Is. Further trials are currently awaited comparing angiotensin II 
receptor blocking drugs (ARBs) and ß-blocking drugs with Calcium 
Channel Blockers(226). 
The British Hypertension Society also highlighted certain specific 
points relating to the elderly(226). They noted that much of the 
evidence base for hypertension in the elderly is derived from the 
SHEP and the SYST-EUR trials(211; 212). As these trials used 
diuretics and calcium channel blockers as the primary active 
medications, then these are the medications that should be 
promoted as beneficial. They also highlight the meta-analysis from 
Messerli which suggested that ß-blockers may not be as affective at 
reducing strokes, coronary heart disease and all cause mortality 
when compared to diuretics in older populations(227). Subsequently 
Losartan (an ARB) has also been shown to be more affective at 
reducing stroke and cardiovascular mortality in older people with 
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systolic hypertension than 0-blockade(224). Therefore the British 
Hypertension Society suggest that the use of ß-blocking medication, 
as an antihypertensive agent, should be limited in the older 
person(226). 
5.2.4 Hypertension in the diabetic person 
The prevalence of hypertension in the diabetic population is roughly 
twice that of a non diabetic age matched population(62). Ritz 
estimated that up to 80% of people with type 2 diabetes will suffer 
from raised blood pressure at some time(31). Hypertension is often 
present when diabetes in first diagnosed. The UKPDS contained a 
sub-study, specifically designed to assess blood pressure, known as 
the Hypertension in Diabetes Study (HDS)(14). The first paper 
published from the HDS confirmed the high prevalence of 
hypertension in people presenting with newly diagnosed type 2 
diabetes(197). Of 3648 new diabetes presentations, 35% of men 
and 46% of women had mean blood pressure >= 160 mmHg systolic 
and/or >= 90 mmHg diastolic. 
In the second paper published from the HDS, which considered 
diabetes endpoints in relation to hypertension, hypertension was 
found to be a major risk factor for cardiovascular morbidity and 
mortality(198). The hypertensive group had a mean systolic/diastolic 
blood pressure of 150/92 mmHg compared to 125/78 mmHg in the 
normotensive group. The mean age of hypertensive participants was 
52 years. The authors suggested that patients with hypertension and 
diabetes have approximately four times the cardiovascular risk of 
death than non diabetic non hypertensive subjects. 
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The beneficial affect of lowering blood pressure on diabetic end 
points was shown convincingly from the UKPDS 38(33). As part of 
the UKPDS study, 1148 hypertensive people, with a mean age of 56 
years, were allocated to either tight control of blood pressure or to 
less tight control and followed up for 8.4 years for macrovascular 
and microvascular endpoints. The 758 patients who were assigned 
to the tight blood pressure control group achieved a mean blood 
pressure of 144/82 mm Hg compared to 154/87 mm Hg in the less 
tight group. In the tight blood pressure group there was a reduction 
of 24% (95%Cl, 8%-38%) in diabetes related end points, 32% (6%- 
51%) reduction in diabetes related deaths, 44% (11%-65%) 
reduction in strokes and 37% (11 %-56%) reduction in microvascular 
endpoints. There was a non significant reduction in all cause 
mortality; 22.4 vs 27.3 deaths per 1000 patients years (p=0.17). 
Using the same population, the UKPDS 69, published in 2004, 
showed that tight blood pressure reduced the clinical complications 
of all aspects of diabetic eye disease(35). The benefits of treatment 
are reflected in Standard 4 of the National Service Framework for 
Diabetes which states "controlling raised blood pressure in people 
with diabetes who have co-existing hypertension reduces their risk of 
developing both microvascular complications and cardiovascular 
disease"(4). 
The British Hypertension Society currently states that the highest 
level of acceptable blood pressure in people without diabetes is 150 
mmHg systolic and 90 mmHg diastolic, although it suggests 
treatment goals of below 140 mmHg and 80 mmHg(226). In people 
with diabetes the situation is less clear and no lower threshold for 
treatment has so far been identified, with several trials showing 
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additional benefits below 130 mmHg and 80 mmHg(32; 201). In 
1998, the Hypertension Optimal Treatment (HOT study) confirmed 
that there appears to be no optimum lower limit; the lower the blood 
pressure the better(201). The diabetic people in the HOT study 
remained at increased risk for cardiovascular endpoints compared to 
those without diabetes who had similar blood pressure(228). The 
UKPDS 36 examined the association between systolic blood 
pressure and macrovascular and microvascular complications. In the 
study each decrease in mean systolic blood pressure of 10 mm Hg 
was associated with reductions in risk of 12% for any complication of 
diabetes, 15% for deaths related to diabetes, 11 % for myocardial 
infarction and 13% for microvascular complications(32). The study 
did not find any threshold of systolic blood pressure below which the 
complications of diabetes did not occur. The lack of a lower 
threshold and continued benefit with decreasing blood pressure 
have led to lower blood pressure treatment targets in the diabetic 
person compared to the non diabetic person. The average blood 
pressures achieved in the UKPDS are now considered too high. In 
the UKPDS the "tight" blood pressure control group aimed for blood 
pressure of <150/<85 mm Hg(229). The mean blood pressure level 
achieved was 144/82 mm Hg; above today's recommendations(45). 
In 2004, the American Diabetic Association annual guidelines for the 
management of hypertension in adults with diabetes recommended 
130 mmHg systolic and 80 mmHg diastolic as the maximum levels of 
blood pressure(196). Diabetic individuals with repeated blood 
pressure readings higher than these levels are advised to have their 
blood pressure treated. 
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5.2.5 The treatment of hypertension in the diabetic person 
In people with diabetes weight loss, moderate exercise, moderation 
of alcohol and stopping smoking have all been shown to reduce 
blood pressure(230). Current American Diabetic Association 
guidelines recommend lifestyle measures as the first line of 
treatment for mild hypertension (130-139 mmHg systolic or 80-89 
mmHg diastolic) for the initial three months(196). The addition of 
drug treatment is recommended when these limits are exceeded, 
with lifestyle changes encouraged as a continued adjunct to drug 
therapy(196). 
Within diabetic populations much debate has centred around the use 
of angiotensin converting enzyme inhibitors (ACE-I) (or angiotensin- 
II receptor blocking drugs (ARBs), derivatives of ACE-I) compared to 
other forms of antihypertensive drugs. Due to specific effects upon 
the renin-angiotensin system, additional benefits are believed to be 
attributable to these classes of drug, over and above simply lowering 
blood pressure. There is now evidence to suggest that ACE-I and 
ARBs retard the development and progression of albuminuria and 
the development and progression of neuropathy(231-234). These 
drugs are discussed in more detail in chapter 6. 
Whether there are additional benefits from the use of ACE-I and 
ARBs with regards to cardiovascular disease is not clear. The Heart 
Outcomes Protection Study found benefits in cardiovascular events 
which were attributed to the drug Ramipril (an ACE-I)(45). It is 
important to note that this trial was a cardiovascular risk trial, not a 
hypertension trial and it is not established conclusively that the 
benefits seen were not simply due to lowering blood pressure rather 
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than the drug itself(230). The Losartan Intervention For Endpoint 
reduction in hypertension study (LIFE study), which used an ARB, 
showed evidence of reduced cardiovascular and all-cause mortality 
when compared to ß-blockade(224). Conversely, the UKPDS 39, 
found no difference between captopril (an ACE-I) and atenolol (a ß- 
blocker) in either drugs ability to successfully reduce diabetic 
endpoints(235). This finding was supported by the ALLHAT study, 
that included 12000 people with type 2 diabetes and hypertension 
and found no addition benefits from the using an ACE-I(223). 
Therefore in the hypertensive diabetic person, the key issue remains 
the treatment of hypertension, regardless of the drug. But, if a choice 
needs to be made, especially in the presence of diabetic renal 
disease, an ARB would currently be the drug of choice(226). 
5.2.6 Hypertension in the older diabetic person 
The evidence base for the older hypertensive diabetic person is 
primarily based on sub group analysis of the diabetic participants 
within hypertension trials. In the very elderly the evidence base is 
less well established 
There were 492 people with diabetes in the Syst-Eur study and 
separate analysis showed particular benefits of treatment in older 
people with diabetes (aged at least 60 years old). Overall mortality 
was lowered by 55%, cardiovascular mortality by 76% and strokes 
by 73% in diabetic people in the active treatment group, which 
achieved a lower systolic blood pressure, than the placebo 
group(200). Within the SHEP trial there were 583 people with "non- 
insulin treated" diabetes. In a separate analysis of these people 
benefits were seen(199). The five year rate of major cardiovascular 
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events was reduced by 34% in the treated group compared to the 
untreated group, although the all cause mortality was not 
significantly reduced (relative risk 0.74 (0.46-1.18 95% Cl)). 
5.2.7 The treatment of hypertension in the older diabetic person 
The recommended blood pressure for people with diabetes of 130 
mm Hg systolic and 80 mmHg diastolic applies to all age groups. 
The American Diabetic Association recommendations simply add in 
elderly hypertensive patients, blood pressure should be lowered 
gradually to avoid complications"(230), without further elaboration. 
Which complications are to be anticipated is not stated. Likewise the 
British Hypertension Society make no specific reference to age with 
regards to their recommendations for the treatment of the diabetic 
hypertensive person(226). Recently the European Union Geriatric 
Medical Society (EUGMS) have reviewed the currently available 
guidelines(39). They suggest that following comprehensive 
cardiovascular assessment and the exclusion of secondary causes 
of hypertension treatment should be recommended. They 
recommend treating blood pressure above 140/80 mmHg in most 
older diabetic people. In frail elderly people they suggest treatment 
targets of 150/90 mmHg. No organisation recommends specific 
hypertensive drugs in the older diabetic person above what is 
suggested for younger people. The treatments are diuretics and 
calcium channel blockers as an initial treatment in people aged over 
55 years and ACE-I or ARBs in individuals with diabetic renal 
disease(39; 226). 
There is little evidence, beyond what is known from younger 
populations, to suggest that hypertensive medications may cause 
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diabetes in older people. Padwal conducted an observational study 
into the affects of different classes of anti-hypertensive medications 
in the elderly (aged at least 66 years). They assessed a total of 
76176 older people from 5 large datasets in Canada. His team 
concluded that in the elderly there was no evidence to support an 
increased incidence of diabetes with different anti hypertensive 
medications(236). 
The currently recommended levels of acceptable blood pressure 
would until very recently been considered extremely low, especially 
the systolic component(42). Whether elderly people are able to 
tolerate such "low" blood pressure remains to be seen, with adverse 
drug reactions, such as postural hypotension, a concern amongst 
clinicians (213). 
In order to achieve the ambitious blood pressure targets that are 
recommended it is often necessary to use combinations of 
antihypertensive drugs(226). In the HDS over 25% of participants in 
the "tight" blood pressure group required the use of three or more 
anti-hypertensive medications to control their blood pressure(237). 
Polypharmacy in the elderly is common. The affect of large numbers 
of different anti hypertensive drugs adding further to this burden in 
the older diabetic adult has not been extensively evaluated. Some 
evidence supports the use of polypharmacy in the younger diabetic 
person. In patients with a mean age of 56 years, the UKPDS 37 
provided evidence that tight blood pressure control did not adversely 
affect the quality of life when compared to the less tight group(176). 
In the tight blood pressure group 29% were taking three or more 
medications compared to 11% in the less tight group(33). Any 
potential benefits of treatment in relation to diabetic outcomes must 
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be weighed against the many disadvantages of drug treatment. A 
situation which is especially important in the older person due to the 
high incidence of adverse drug reactions. 
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5.3 Methods; Classification and identification of systolic 
and diastolic blood pressure 
5.3.1 Derivation of systolic and diastolic blood pressure using 
the detailed questionnaire from the MRC trial 
Blood pressure readings were an important part of the MRC trial and 
attempts were made to measure this in all people undergoing 
detailed assessment. Page two of the detailed questionnaire 
addresses and records blood pressure (see appendix 2). In order to 
standardise blood pressure readings between trial participants all 
trial nurses were instructed in the procedure by the regional training 
nurse. Detailed instructions on how to measure blood pressure were 
included in the trial manual of operations provided to each trial 
nurse. The blood pressures were recorded using Hawksley Random 
Zero sphygmomanometers. Repeated readings were performed and 
the zero error of each sphygmomanometer recorded. All blood 
pressure readings were recorded to the nearest 2 mmHg. Both 
seated and standing blood pressure readings were taken. Seated 
readings were taken after at least 3 minutes rest and repeated after 
another 3 minutes rest. The average of these 2 readings, adjusted 
for the zero error, was calculated by the trial nurse who conducted 
the blood pressure measurement. The results were all inspected 
before data entry at the London School of Hygiene and Tropical 
Medicine and any obvious errors were corrected if possible. The 
standing blood pressure readings did not undergo the same degree 
of data cleaning and had not been corrected for the zero error after 
entry into the dataset. There were also a large number of missing 
entries, presumably because standing presented difficulties in some 
older people. Therefore the standing blood pressure data was 
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deemed to be potentially unreliable. In the clinical setting seated 
blood pressure readings are used for the basis of treatment 
decisions and while standing blood pressures are important in the 
detection of certain specific conditions, their role in diabetes 
management is less important. It was for these reasons that only the 
corrected seated average blood pressure readings were used for the 
remainder of this thesis. 
5.3.2 Groupings of blood pressure used for analysis 
Both the systolic and the diastolic blood pressures were grouped. 
The rationale behind this was to attempt to define discernable, 
clinically useful and convenient cut off points for the affect of 
hypertension on diabetic endpoints. The groupings chosen were 
based around increasing increments of 10 mmHg for both systolic 
and diastolic blood pressure. The systolic group included all systolic 
pressures up to 100 mmHg, then increasing groups of 10 mmHg up 
to 160 mmHg and then all systolic pressures above this. The 
diastolic group included all pressures up to 70 mmHg, increasing 
groups of 10 mmHg up to 100 mmHg and then all diastolic pressures 
above this. The systolic and diastolic groupings and numbers of 
participants within each group are shown in the results section of this 
chapter (table 5.1). Systolic and diastolic blood pressures were also 
treated as a binary variable using the most aggressive currently 
accepted levels for treatment in the younger diabetic person (130 
mmHg systolic and 80 mmHg diastolic(196)) as cut off points. 
In the detailed questionnaire question 37 asked participants about a 
range of previous medical conditions, one of which was high blood 
pressure (see appendix 2, page 14). Question 37 stated: 
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"Has a doctor ever told you that you had any of the following? If yes, 
was that with the last year? " 
For high blood pressure the responses were no, yes (within the last 
year) and yes (but before the last year). To simplify the outcome and 
to increase statistical power the responses were then regrouped into 
no or yes (either before or within the last year). 
5.3.3 Identification of the anti hypertensive medications used 
All the medications that individuals were taking were recorded in the 
detailed questionnaire. The process of recording drug histories has 
already been discussed in detail in section 2.1.1. Medications 
participants were taking at the time of the detailed questionnaire 
were also available for a limited sample of the trial population from 
the EMIS dataset. For more detail about this process see section 
2.1.4. Both of these datasets were searched for any medication 
which would lower the blood pressure. While some of these 
medications may not have been prescribed for hypertension itself 
they all would have had the affect of lowering blood pressure and 
hence have a treatment effect. For example, ß-blocking medication 
(which lowers blood pressure and slows the heart rate) should have 
been prescribed for all suitable patients following a myocardial 
infarction since the mid 1980s, when the first convincing evidence of 
the benefits of this treatment became available(238). The drugs 
identified which could lower blood pressure were diuretics, a- 
blocking drugs, ß-blocking drugs, angiotensin-converting enzyme 
inhibitors (ACE-I), angiotensin-II receptor blocking drugs (ARBs), 
long acting nitrate medications and calcium-channel blockers. All 
drugs within each class were considered as an antihypertensive 
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medication with no distinctions made between dose, method of 
delivery, type or make of drug. The number of anti hypertensive 
medications was collated, from zero to three or more. 
Due to the potential additional benefits of ACE-Is and ARBs, in 
respect of diabetic renal disease and the treatment of hypertension, 
a record was made of the number of people who were receiving 
these medications. The results are given in section 5.4.3. These 
results were then discussed in section 6.5, which focused on renal 
disease in the older diabetic person. 
5.3.4 Analysis 
The diabetic population with systolic blood pressure above 130 
mmHg and diastolic blood pressure above 80 mmHg were 
described. This was a univariate analysis using the same variables 
which had previously been used to describe the whole population in 
chapter 3. 
Forward fitting logistic regression models were then created. 
Potential confounding factors were incorporated into those models if 
they were found to be associated with increased blood pressure in 
diabetic individuals from the univariate analysis. Every attempt was 
made to keep the models as parsimonious as possible. The factors 
which affected the model by at least five percent were included in 
the final model. 
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5.4 Results 
5.4.1 Distribution of systolic and diastolic blood pressure 
Systolic blood pressure was normally distributed and showed 
minimal skewness (skewness=0.18). The range was 60 mmHg to 
258 mmHg, which was considered to represent a normal distribution 
of true readings. The mean systolic blood pressure for all 
participants was 148.63 mmHg (standard deviation 22.39), using 
14912 readings. The distribution is shown in figure 5.1 below. A 
normal distribution curve has been overlaid on the figure. Evidence 
of digit preference can be seen in the marked drop in readings at the 
160 mmHg point. 
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Figure 5.1 Distribution of systolic blood pressure for all participants in the MRC 
trial 
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There was a non significant difference (p=0.29) in the systolic blood 
pressure between people with and without diabetes; 149.3 mmHg 
(148.27-149.99) versus 148.57 mmHg (148.20-148.95) respectively. 
Diastolic blood pressure data revealed 18 readings less than 30 
mmHg. These were deemed to be inappropriately low and 
reclassified as missing diastolic blood pressure readings. 
Regardless, diastolic blood pressure still appeared to be normally 
distributed (skewness=0.02), using 14885 valid readings. The three 
central readings (70,75 and 80 mmHg) are all lower than expected, 
which may reflect digit preference. See figure 5.2. A normal 
distribution curve has been overlaid on the figure. 
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Figure 5.2. Distribution of diastolic blood pressure for all participants in the MRC 
trial 
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The range of values was 30.5 mmHg-144 mmHg. The mean for the 
whole population was 74.59 mmHg (standard deviation 12.75). 
When comparing those with and those without diabetes the diastolic 
blood pressure was lower in people with diabetes (p<0.001); 73.16 
mmHg (72.46-73.87) versus 74.72 mmHg (74.51-74.93) 
respectively. 
There were only 183 (1.21%) participants with missing systolic blood 
pressure, of whom 13 had diabetes. There were 192 (1.27%) 
participants with missing diastolic blood pressure, of whom 13 had 
diabetes. There were no differences between age and sex between 
either diabetic or non diabetic people with and without missing data 
(systolic or diastolic). 
5.4.2 The different blood pressure groupings used for analysis 
The groupings are shown for the non diabetic and diabetic 
participants within the trial. There was no difference in systolic blood 
pressure groupings between the diabetic and the non diabetic 
participants for the systolic blood pressure grouping. However, for 
the diastolic grouping, diabetic participants were more likely to be 
found in the lower blood pressure groups (p<0.001, test for trend). 
The results are shown in table 5.1. 
When blood pressure was treated as a binary variable most 
(approximately 80%) of both the diabetic and non diabetic 
populations had a systolic blood pressure above 130 mmHg. A lower 
proportion of the total population (approximately 30%), had diastolic 
blood pressure above 80 mmHg. The results are shown below in 
table 5.1. 
156 
Chapter 5 Hypertension and diabetes in the older person 
All participants 
n=14912 % 
Non diabetic 
participants 
n=13748 
Diabetic participants 
n=1164 
Systolic "10" grouping 
upto 100 mmHg 146 (0.98) 134 (0.97) 12 (1.03) 
100-109 mmHg 354 (2.37) 336 (2.44) 18 (1.55) 
110-119 mmHg 897 (6.02) 832 (6.05) 65 (5.58) 
120-129 mmHg 1530 (10.26) 1408 (10.24) 122 (10.48) 
130-139 mmHg 2305 (15.46) 2134 (15.52) 171(14.69) 
140-149 mmHg 2550 (17.10) 2341 (17.03) 209 (17.96) 
150-159 mmHg 2507 (16.81) 2306 (16.77) 201 (17.27) 
160 mmHg and above 4623 (31.00) 4257 (30.96) 366 (31.44) 
Systolic "binary" grouping 
upto 130 mmHg 2927 (19.63) 2710 (19.71) 229 (19.67) 
130 mmHg and above. 11985 (80.37) 11038 (80.29) 935 (80.33) 
Diastolic "10" grouping 
n=14885 (%) n=13722 (%) n=1164 
upto 70 mmHg 5087 (34.18) 
70-79 mmHg 4608 (30.96) 
80-89 mmHg 3437 (23.09) 
90-99 mmHg 1403 (9.43) 
100 mmHg and above 350 (2.35) 
Diastolic "binary" grouping 
upto 80 mmHg 9695 (65.13) 
80 mmHg and above 5190 (34.87) 
Table 5.1 Groupings of systolic and diastolic bic 
4636 (33.79) 452 (38.78) 
4235 (30.86) 373 (32.07) 
3210 (23.39) 227 (19.52) 
1311 (9.55) 92 (7.91) 
330 (2.40) 20 (1.72) 
8871 (64.65) 850 (73.02) 
4851 (35.35) 314 (26.98) 
pressure 
5.4.3 Past history and drug history of hypertension of trial 
participants 
The results of the responses to the question regarding a past 
medical history of hypertension were 9899 (65.58%) "no", 5029 
(33.32%) "yes" and 167 (1.11%) missing. After searching the drug 
histories from the detailed questionnaire and the drug histories 
available from the EMIS data there were 9334 (61.84%) people out 
of the total trial population of 15095 taking no blood pressure 
lowering medication and 5761/15095 (38.16%) people taking one or 
more blood pressure lowering medications. The people taking one or 
more medication comprised 3518 (23-31%) taking one medication, 
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1693 (11.22%) taking two medications and 550 (3.64%) taking three 
or more medications. When a history of blood pressure was 
compared with whether individuals were taking any blood pressure 
medications 1964 (19.84%) of the 9899 people who responded no to 
a history of hypertension who were in fact taking at least one blood 
pressure lowering medication. While it is possible that the 
medication was prescribed for other reasons it made any results 
generated using this variable subject to potential bias. Therefore 
only the drug history information was used in subsequent analysis, 
not the results from the question regarding a recalled history of 
hypertension. 
There were 559 (47.49%) out of 1177 diabetic individuals taking one 
or more blood pressure lowering medication compared to 5202 
(37.38%) of the 13918 non diabetic population, (p<0.001). The 
diabetic population was also more likely than the non diabetic 
population to be taking a larger number of blood pressure lowering 
medications; 315 (26.76%) vs 3203 (23.01%) were taking one only, 
187 (15.89%) vs 1506 (10.82%) were taking two and 57 (4.84%) vs 
493 (3.54%) were taking three or more, (p<0.001, test for trend). To 
ensure that this difference was not a reflection of diabetic people 
attending their GPs more often than non diabetic people, and thus 
having an increased rate of detection of hypertension, a comparison 
was made with the use of a hearing aid. Deafness is associated with 
increased visits to the GP. Therefore people with a hearing aid 
would be more likely to have treated hypertension than people 
without a hearing aid, simply because they attend their GP more 
frequently. The results showed that this was not the case. People 
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with a hearing aid were as likely as people without hearing aid to 
have treated hypertension (p=0.78). 
There were 929 (6.7%) people in the non diabetic population who 
were taking an ACE-I. In the diabetic population there were 167 
(14.2%) of people taking an ACE-I, (p<0.001). There were only 12 
people in the entire population who were taking an ARB. 
5.4.4 Description of the hypertensive diabetic population 
There were 1164 diabetic people with systolic and diastolic blood 
pressure readings available. Each group had 13 missing entries. 
This population was described in terms of systolic blood pressure 
above and below 130 mmHg and diastolic blood pressure above and 
below 80 mmHg. 
Diabetic women were more likely than men to have systolic blood 
above 130 mmHg, adjusted odds ratio 2.67 (1.97-3.61, p<0.001). 
Women also had a higher adjusted odds ratio for diastolic blood 
pressure above 80 mmHg, 1.46 (1.10-1.94, p=0.01). Age had no 
clear affects on either systolic or diastolic blood pressures, (p=0.38 
and 0.57 respectively, test for trend). Age and sex were both found 
to affect the logistic regression models constructed in this chapter 
and were both included in the final model. 
The other associations are all shown in table 5.2 below. The 
significant associations were between smoking and BMI. When 
these to variables were tried in the logistic regression models only 
smoking remained significant. The number of hypertensive 
medications was also significant within the model. Therefore the 
models used in the remainder of this chapter for the associations 
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between systolic and diastolic blood pressure and diabetic endpoints 
were age group, sex, smoking and the number of hypertensive 
medications used. 
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5.4.5 Associations between diabetes and hypertension 
Crude and adjusted odds ratios for the association of 10 mmHg 
levels of systolic blood pressure and diabetes are shown in table 5.3. 
After grouping systolic blood pressure as a binary variable, there 
was no association between systolic blood pressure and diabetes. 
The results were adjusted for age, sex, smoking and the number of 
blood pressure lowering medications taken. 
Outcome Crude Odds Ratio 
(95% Cl) 
Adjusted Odds Ratio* 
(95% Cl) 
P value 
(adjusted Wald test 
Diabetes 
Systolic 10" grouping 
upto 100 mmHg 1 1 (-) 
100-109 mmHg 0.59 (0.28-1.29) 0.63 (0.29-1.36) 0.23 
110-119 mmHg 0.87 (0.49-1.54) 0.86 (0.48-1.55) 0.61 
120-129 mmHg 0.96 (0.54-1.75) 0.97 (0.54-1.77) 0.93 
130-139 mmHg 0.89 (0.49-1.63) 0.90 (0.49-1.64) 0.72 
140-149 mmHg 0.99 (0.56-1.77) 1.01 (0.57-1.81) 0.95 
150-159 mmHg 0.97 (0.55-1.62) 1.00 (0.57-1.74) 0.99 
160 mmHg and above 0.96 (0.54-1.70) 1.02 (0.57-1.79) 0.95 
Systolic "binary" grouping 
upto 130 mmHg 1 1 (-) 
130 mmHg and above 1.07 (0.93-1.23) 1.12 (0.98-1.28) 0.1 
Table 5.3 Association between systolic blood pressure groupings and diabetes 
* Adjusted for age, sex, smoking and the number of blood pressure medications 
Crude and adjusted odds ratios for the association of diastolic blood 
pressure and diabetes are shown in table 5.4. Increasing diastolic 
blood pressure was protective for diabetes. What was noticeable 
were the trends seen for the "10" grouping. The significantly reduced 
odds ratios were seen for the middle levels of blood pressure and 
not for the lowest and the highest levels of blood pressure. There 
was a highly significant result for the "binary" diastolic variable using 
a cut point of 80 mmHg. Those with diastolic pressures above this 
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were significantly less likely to have diabetes. The results were 
adjusted for age, sex, smoking and the number of blood pressure 
lowering medications taken. 
Outcome I Crude Odds Ratio Adjusted Odds Ratio* P value 
(95% Cl) (95% Cl) (adjusted Wald test) 
Diabetes 
Diastolic "10" grouping 
upto 70 mmHg 
70-79 mmHg 
80-89 mmHg 
90-99 mmHg 
100 mmHg and above 
1 1 (-) 
0.91 (0.79-1.03) 0.93 (0.81-1.06) 0.27 
0.73 (0.63-0.84) 0.74 (0.65-0.86) <0.001 
0.72 (0.58-0.90) 0.75 (0.59-0.95) 0.02 
0.62 (0.36-1.09) 0.66 (0.38-1.15) 0.14 
Diastolic "binary" grouping 
80 mmHg and above 0.75 (0.66-0.86) 0.77 (0.67-0.88) <0.001 
Table 5.4. Association between diastolic blood pressure groupings and diabetes 
* Adjusted for age, sex, smoking and the number of blood pressure medications 
5.4.6 Associations between microvascular endpoints and 
hypertension 
The association between hypertension and poor vision 
The associations between the different groupings of systolic blood 
pressure and poor vision (<6/18) are shown in table 5.5. The trial 
participants without diabetes showed a trend towards a reduced 
association with each increase in blood pressure group especially for 
systolic blood pressure >130 mmHg, adjusted odds ratio 0.82 (95% 
Cl 0.72-0.95) p=0.007, i. e. people with higher blood pressure had 
less visual impairment. There were no significant associations seen 
within the diabetic population. For the diastolic blood pressure 
reduced odds ratios were also seen in the whole population, 
especially at higher levels of diastolic pressure (p=0.03, test for 
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trend). Diastolic blood pressure greater than 80 mmHg was also 
associated with poor vision in the non diabetic population, adjusted 
odds ratio 0.84 (95% Cl 0.73-0.97) p=0.02. For participants with 
diabetes, diastolic blood pressure was not associated with poor 
vision. The results are shown in table 5.6. 
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The association between hypertension and proteinuria 
The associations between systolic and diastolic blood pressure 
values and proteinuria are shown in tables 5.7 and 5.8 respectively. 
For participants with and without diabetes there were no significant 
associations seen between systolic blood pressure and proteinuria. 
For diastolic blood pressure, no associations between diabetes and 
proteinuria were seen in the non diabetic population (p=0.11). Within 
the diabetic population increasing diastolic blood pressure showed a 
significant trend towards predicting proteinuria (p=0.02). This was 
also seen in diabetic people with a diastolic blood pressure over 80 
mmHg, adjusted odds ratio 1.49 (95% Cl 1.05-2.14) p=0.03. 
The association between hypertension and raised creatinine 
The associations between systolic and diastolic blood pressures and 
creatinine are shown in tables 5.7 and 5.8 respectively. In the non 
diabetic population increasing systolic blood pressure was 
associated with less raised creatinine (p<0.01, test for trend). In 
people with systolic blood pressure over 130 mmHg the adjusted 
odds ratio was significantly lower than those with blood pressure 
below this level, 0.82 (95%CI 0.72-0.92) p<0.01. For the non 
diabetic population diastolic blood pressure did not seem to be 
associated with hypertension. There were no associations seen in 
the diabetic population between either systolic or diastolic blood 
pressure and raised creatinine. 
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5.4.7 Associations between macrovascular endpoints and 
hypertension 
The association between hypertension and angina 
For the systolic blood pressure the only significant result recorded 
was a reduced effect, for individuals in the non diabetic population, 
with blood pressure above 130 mmHg, adjusted odds ratio 0.77 
(95%Cl 0.69-0.85, p<0.001). The results are shown in table 5.9. 
The diastolic results, shown in table 5.10, showed a decreasing odds 
ratio for angina with increasing group of diastolic blood pressure, 
within the non diabetic population (p<0.001, test for trend). This 
affect remained, in the non diabetic population, with a diastolic blood 
pressure above 80 mmHg, adjusted odds ratio 0.77 (95%Cl 0.68- 
0.86) p<0.001. For the diabetic people the results were less striking 
but still present to some extent, for both the grouped blood 
pressures and when blood pressure was treated as a binary 
variable. 
The association between hypertension and myocardial infarction 
Increasing systolic blood pressure was strongly associated with a 
decreasing odds ratio for myocardial infarction. The association was 
strongest in the non diabetic population but was still seen in the 
diabetic population, p<0.001 and p=0.03 respectively. Systolic blood 
pressure greater than 130 mmHg was associated with a decreased 
adjusted odds ratio of 0.67 (95%Cl 0.56-0.80) p<0.001 for the non 
diabetic population and 0.46 (95%Cl 0.29-0.72) p=0.001, for elderly 
people with diabetes. The results are shown in table 5.9. 
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Within the non diabetic population increasing diastolic blood 
pressure was associated with a lower odds ratio for myocardial 
infarction (p<0.001, test for trend). A diastolic blood pressure above 
80 mmHg showed an adjusted odds ratio of 0.65 (95%Cl 0.57-0.76) 
p<0.001 for myocardial infarction. For the people with diabetes no 
trend was seen with increasing the diastolic blood pressure. 
However, having a diastolic blood pressure above 80 mmHg was 
significantly associated with a lower adjusted odds ratio for 
myocardial infarction, 0.64 (95%Cl 0.43-0.97) p=0.04. The results 
are shown in table 5.10. 
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The association between hypertension and cerebrovascular disease 
Increasing systolic blood pressure was not associated with 
cerebrovascular accidents in either the diabetic or the non diabetic 
population. The results do not show that significance was being 
approached for either population; none of the p values approach 
0.05 and all of the confidence intervals easily encompass one. The 
results are shown in table 5.11. Within the non diabetic population 
there was no association with diastolic blood pressure and 
cerebrovascular accidents. The diabetic population did show an 
association with increasing diastolic blood pressure and 
cerebrovascular accidents, (p=0.04, test for trend). The association 
was not seen when treating diastolic blood pressure as a binary 
variable (above 80 mmHg), adjusted odds ratio 1.05 (95%Cl 0.62- 
1.77) p=0.86. The results are shown in table 5.12. 
The association between hypertension and foot ulceration 
There was no association between foot ulceration and systolic blood 
pressure for either the non diabetic population or the diabetic 
population, in any of the groupings. The results are shown in table 
5.11. Increasing diastolic blood pressure did not show any 
association with foot ulceration in either population. When diastolic 
blood pressure was treated as a binary variable reduced adjusted 
odds ratios were seen for both the diabetic and the non diabetic 
population in people with diastolic blood pressure above 80 mmHg. 
The adjusted odds ratios were 0.65 (95%Cl 0.57-0.76) p<0.001 for 
the non diabetic population and 0.64 (95%CI 0.43-0.97) p=0.04 for 
the diabetic population. The results are shown table 5.12. 
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Chapter 5 Hypertension and diabetes in the older person 
5.5 Discussion 
5.5.1 The relationship between blood pressure and diabetes 
The distribution of blood pressure within both populations was 
normal with apparently lower mean values in the diabetic population. 
There was no difference between the systolic blood pressure in the 
non diabetic and the diabetic populations but the diabetic population 
had lower diastolic blood pressure. The diabetic population was 
taking more blood pressure lowering medications and taking a larger 
number of them. It is therefore possible that the lower diastolic blood 
pressure in the diabetic population was a reflection of the increased 
number of blood pressure medications being taken. Using the 
example of hearing aids, it appears that the increased treatment of 
hypertension was the result of more active treatment of diabetic 
people by medical practitioners. There were several examples of 
digit preference in all the blood pressure readings. This is a 
phenomenon common to trials which record blood pressure 
manually, leading to systematic bias(239). The problem has 
diminished somewhat recently due to the increased use of 
automated blood pressure recordings in clinical trials. But it should 
be noted as a limitation in the MRC trial but not a serious one. 
When the blood pressure was grouped (either in 10 mmHg groups or 
as a binary variable) systolic blood pressure did not vary between 
the two populations. For diastolic blood pressure the diabetic 
individuals were more likely to be in the lower groupings and more 
likely to have diastolic blood pressure under 80 mmHg. From these 
results it appeared that hypertension is no more prevalent with the 
older diabetic population and the diastolic component actually 
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appears to be lower, although probably due to an increased number 
of medications. 
There were just over 80% of (all) participants with a systolic blood 
pressure over 130 mmHg. Previous estimates suggested that up to 
80% of diabetic people will be hypertensive at some point in their 
illness(31; 196). The high number of hypertensive individuals shown 
by our results reflects the decreasing threshold for the diagnosis of 
hypertension. The previous estimates were conducted before 130 
mmHg was suggested as the upper limit for treatment. If over 80% of 
the elderly diabetic population are hypertensive then this will have 
implications if the current guidelines for treatment are to be enforced. 
All of these people should be treated, either via the initiation of 
hypertensive medications or additional medications added to their 
current regime. This would represent a major and potentially 
detrimental undertaking for many reasons; the financial cost of the 
drugs, the increased workload of the doctor, increasing 
polypharmacy and the potential for an increased number of adverse 
drug reactions. It is important to note that 130 mmHg systolic was 
used, as a figure of reference, throughout the analysis and the 
discussion. This figure is the most aggressive target of systolic blood 
pressure available, and is currently used in America(l 96). The use 
of the most aggressive target was justified because the most 
detrimental effects of excessive treatment, such as polypharmacy, 
drug interactions and postural hypotension, are more likely to be 
seen with lower blood pressures (and the increased number of 
medications needed to achieve those blood pressures). Therefore in 
order to justify such low blood pressures in the older diabetic person, 
there needs to be tangible benefits. There did not appear to be any 
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benefit identified from the MRC trial. The EUGMS guidelines suggest 
140 mmHg as an upper limit for systolic blood pressure in the older 
diabetic person(39). The results from the MRC trial did not present 
any convincing reasons to change the European recommendations. 
Increasing systolic blood pressure did not predict the presence of 
diabetes when it was grouped or treated as a binary variable, 
although the odds ratios for the higher systolic blood pressures 
remained over one. It is possible that these results reflect the known 
higher prevalence of systolic hypertension seen in diabetic 
populations. Diastolic blood pressure was shown to be protective for 
diabetes when diastolic blood pressure was treated as a binary 
variable. When grouped a "J" shaped relationship was seen, with the 
middle two groups exhibiting protective effects. The results seen for 
the diastolic blood pressure could again be the result of Increased 
numbers of diabetic people receiving treatment. 
5.5.2 The relationship between blood pressure and diabetic 
microvascular endpoints 
Within the non diabetic population there was apparently a marked 
protective affect between increasing blood pressure and 
microvascular diabetic end points. Hypertension is established as a 
risk factor for the development of diabetic eye disease(46) and these 
results argue against such strong associations in the older person. 
However, poor vision itself may have prevented people from 
attending the original trial resulting in under representation and 
hence selection bias. Another explanation of the results is that 
diabetic people with poor vision were more likely to be attending 
medical care than diabetic people without poor vision. Therefore the 
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results seen in the MRC trial were a reflection of increased 
treatment, due to increased medical attendance in this group. 
Increasing diastolic blood pressure showed an association with 
proteinuria in the diabetic population. Hypertension is an established 
risk factor for renal disease(33). One would have expected to see 
the association between proteinuria and systolic blood pressure 
maintained and the absence of a positive result was surprising. 
Higher systolic blood pressure was associated with less raised 
creatinine. Proteinuria is a precursor of end stage renal disease and 
hence raised creatinine. The lack of association seen may simply 
reflect patient selection. People with a raised creatinine were more 
likely to be unwell and hence not take part in original study. Another 
explanation would be that in the older person, proteinuria is less 
predictive of the development of renal failure. 
5.5.3 The relationship between blood pressure and diabetic 
macrovascular endpoints 
In both populations (people with and without diabetes), increasing 
blood pressure, systolic and diastolic, grouped or binary, was 
associated with reduced odds ratios for having angina and 
myocardial infarction. These associations were lessened for the 
diabetic persons, but not entirely lost. One possible explanation for 
these results is that higher blood pressure (systolic or diastolic) 
reflects a healthy and well functioning myocardium, as suggested by 
Bulpitt and Fletcher(214). The results argue against lowering blood 
pressure excessively in the older diabetic person. 
Cerebrovascular accidents have been conclusively linked to 
hypertension and shown to have a decreased incidence with 
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lowering blood pressure(205; 207; 21 1). This relationship was only 
shown from our results for increasing diastolic blood pressure in the 
diabetic people, with an increasing association seen between stroke 
and diastolic blood pressure. The higher the diastolic blood pressure 
the more likely the risk of stroke. The reasons for the lack of 
association seen between increasing systolic blood pressure and 
stroke are unclear. In the larger non diabetic population, due to the 
large sample size, one certainly would have expected to see the 
association between hypertension and cerebrovascular accident 
upheld. A possible explanation would have been a lack of trial 
participation in people who had suffered a stroke, because 
attendance will have been difficult for these people. More aggressive 
treatment of hypertension itself in people with a history of stroke 
seems an unlikely explanation because the results were adjusted for 
the number of blood pressure medications taken. However, it is 
possible that people who were deemed at risk of a stroke i. e. people 
with hypertension, had undergone thorough cardiovascular 
investigation, including lifestyle advise, lipid profiling and prescribed 
preventative medications, such as aspirin. 
Foot ulceration showed no associations with systolic blood pressure 
in either population. For both populations there were associations 
with a decreased odds ratio for increasing diastolic blood pressure. 
The likely explanation is that this reflects a good cardiac output 
needed to maintain adequate circulation to the lower limb. 
5.5.4 Inherent weaknesses; hypertension and diabetes 
The first point of discussion was the use of drug histories to identify 
people with hypertension. By doing this the hypertensive group 
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should more accurately be described as "the group taking blood 
pressure lowering medication". Individuals within this group do not 
necessarily have high blood pressure. Although they all have a 
treatment effect. Dosage and exact subclass of drug was also 
extremely hard to analyse with accuracy. It was also impossible to 
tell by how much blood pressure had been lowered, if at all. 
It was also likely that despite thorough attempts to identify people 
using this method some people will have been missed. These 
people would have been those whose medications were not 
correctly identified at the detailed assessment, either through 
participant error e. g. if they forgot to bring their correct medications 
with them or through nurse error e. g. a transcription error when 
entering the drugs. It was also likely that some of the EMIS data may 
be erroneous if any drug had failed to have been entered into the 
EMIS records and hence not identified. Even so identification of 
participants with hypertension using drug histories still appeared to 
be more representative than using the question relating to a 
previous medical diagnosis of hypertension. This was shown by the 
large number of individuals (19.84%) who denied a history of 
hypertension who were found to be taking blood pressure lowering 
tablets. Using drug histories conveyed another advantage. The 
analysis of the drug history showed that more ACE-I were prescribed 
in the diabetic population. This implied that the medical profession 
are aware of potential health benefits of these drugs in diabetic 
people, and they are being prescribed in elderly populations. The 
use of ACE-Is and ARBs is discussed in more detailed in section 
6.5. 
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The MRC trial did not recruit people with terminal illness. As has 
been argued Bulpitt and Fletcher(214) terminal illness was likely to 
have been associated with the lowest blood pressures. Excluding 
these people will remove people with low blood pressure and 
potentially bias the results seen. The extent to which this has 
affected this dataset is hard to estimate but the distributions of both 
systolic and diastolic blood pressure were normal. They did not show 
any obvious absence of lower blood pressure readings. 
5.5.5 Cross sectional data 
Many of the results obtained in this chapter contradict the 
established patterns seen in younger patients. Broadly the results of 
the MRC trial showed that higher blood pressure was associated 
with less microvascular endpoints and less ischaemic heart disease. 
The only association which was found to reflect established research 
was between hypertension and cerebovascular accidents, whose 
prevalence was associated with an increasing diastolic blood 
pressure. Several possible explanations for these results have been 
discussed above in this chapter, however, another explanation 
which needs to be considered is the nature of the data itself. 
The MRC trial used cross sectional data, collected at the time of the 
detailed screening assessment. This data was used in this chapter 
to determine the associations between diabetes, hypertension and 
diabetic endpoints. Cross sectional analysis of diabetes and its 
complications does not have the power or subtlety to detect 
differences between the diabetic population and the non diabetic 
population. A cohort study would have been far more suitable. It 
would have had the ability to follow diabetic people with and without 
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hypertension and identify any differences in the outcome of diabetic 
end points. The cross sectional nature of the data analysis may have 
contributed to the unexpected associations seen between diabetes, 
hypertension and many of the diabetic end points. 
5.6 Conclusions and recommendations 
The study shows that a very large number of British elderly diabetic 
people meet the criteria for treatment of their blood pressure using 
currently suggested guidelines. However, hypertension did not 
appear to be more prevalent than in the older non diabetic person 
and may even be lower, possibly due to increased treatment. 
Increasing systolic blood pressure seemed to offer protective affects 
to the diabetic person and no benefits were conferred for individuals 
with a systolic blood pressure under 130 mmHg. For the diastolic 
component, levels above 80 mmHg were predictive of proteinuria 
only and were protective for other conditions, although the presence 
of proteinuria and stroke started to increase substantially with 
diastolic blood pressures over 90 mmHg. 
This study did not show conclusive proof of benefits in treating the 
older hypertensive diabetic person and certainly found no 
advantages in using the American guidelines, which are the most 
aggressive. Based on the findings from the MRC study it would be 
sensible to suggest the use of the European guidelines. However 
these questions can only be conclusively answered from a 
randomised controlled trial and this should be the primary 
recommendation of this chapter. 
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Chapter 6 The relationship between proteinuria, 
renal impairment and diabetes in the older person. 
6.1 Summary of objectives 
To assess the: 
Relationship between proteinuria and diabetic end points in the older 
person; 
Relationship between raised serum creatinine (greater than 120 
pmol/I) and diabetic end points in the older person; 
Relationship between GFR and diabetic end points in the older 
person. 
6.2 Background 
6.2.1 Introduction 
End stage renal failure (ESRD) is increasing in prevalence(50). Type 
2 diabetes is the commonest cause of end stage renal failure and 
subsequent dialysis in Western Europe(31). Advanced age, male 
sex and ethnicity have been identified as risk factors for developing 
renal disease and the progression to end stage renal failure among 
diabetic people(47; 101; 104). Established modifiable risk factors 
include elevated blood pressure, proteinuria, poor glycaemic control 
and smoking(47; 52). Once end stage renal failure has developed in 
patients with type 2 diabetes the life expectancy is very poor, with 
higher death rates than non diabetic people. This is due in part from 
the increased prevalence of cardiovascular disease(50; 240). The 
five year survival rate of ESRD in Germany is 6% and in Australia it 
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is 27%(50). Once ESRD is established the mainstay of treatment is 
dialysis; either peritoneal dialysis or haemodialysis. Either form of 
dialysis is a hardship for any age group. This is especially so in the 
older person and is associated with high morbidity in addition to high 
mortality(42). 
Renal function is measured using blood testing, commonly creatinine 
and urea. Raised blood levels, of either, indicate an inability of the 
kidney to excrete them and therefore poor renal function (overt 
nephropathy). Raised creatinine is regarded as an indicator of 
chronic renal failure. The Glomerular Filtration Rate (GFR) is a 
measure of renal function which is derived directly from the 
creatinine levels, age and sex, and is considered to be a more 
accurate measure of renal function. Decreasing GFR, reflects 
worsening renal function. It has been described in more detail in 
section 3.4.1. This measure is discussed throughout this chapter in 
conjunction with creatinine. It is important to note that in diabetic 
renal disease, proteinuria precedes a raised creatinine, that 
persistent proteinuria is virtually diagnostic of diabetic renal disease 
and raised creatinine levels (and decreasing GFR) Indicate a 
relatively late stage of disease progression. 
The National Service Framework (NSF) for Diabetes(4) does not 
discuss diabetic renal disease in detail. Diabetic renal disease is 
simply implicit throughout the document because correct 
management of the condition is an integral part of two main pillars of 
the NSF for Diabetes; clinical care of adults with diabetes and the 
detection and management of long term complications. For example, 
the NSF for diabetes states, as a key intervention, that treatment of 
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microalbuminuria with ACE-Is reduces the rate of progression to 
nephropathy. 
6.2.2 Renal disease and renal failure, In diabetes 
Pathogenesis 
Diabetic individuals are at increased risk of non diabetic renal 
disease(31), with up to 25% of diabetic people undergoing 
haemodialysis having some known chronic non diabetic disease. It is 
likely but not certain, that these individuals have worse morbidity and 
mortality than non diabetic people with the same type of renal 
disease(31). However, the majority of type 2 diabetic patients have a 
similar morphological pattern of renal damage and associated micro 
and macroalbuminuria (proteinuria)(51; 241). Microalbuminuria is 
caused by thickening of the glomerular basement membrane and 
abnormal function of podocytes within the kidney(51). This is first 
detected as protein (albumin) in the urine, which leaks through the 
basement membrane. In the absence of other disease 
microalbuminuria is diagnostic of diabetic renal disease. Initially a 
small amount of protein is lost into the urine (microalbuminuria, 30- 
300mg/day). Without treatment this process can worsen with larger 
and larger amounts of protein lost into the urine (macroalbuminuria, 
>0.5g/day). It should be noted that microalbuminuria has been 
reported to have spontaneously regressed(19) and is not always 
present in diabetic renal disease(241). Microalbuminuria is, however, 
the strongest and one of the most easily detectable signs of diabetic 
renal disease(51). Continuing microalbuminuria reflects continuing 
structural damage to the kidney. As this process progresses the 
overall function of the kidney deteriorates (overt nephropathy). 
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Diabetic renal disease is a condition which occurs over a long period 
of time, usually many years. Progression varies between individuals 
but up to 40% of patients with microalbuminuria progress to overt 
nephropathy(240). The UKPDS 64 estimated the rate of progression 
from microalbunimuria to macroalbuminuria as 2.8% per year and 
from macroalbuminuria to raised creatinine as 2.3% per year(34). 
Once overt nephropathy has been established the rate of decline in 
GFR is between 2 and 20 ml/min/year(240). After 20 years, 20% of 
diabetic people with overt nephropathy will have developed 
ESRD(240). However, with improvements in life expectancy and 
decreasing mortality from cardiovascular disease more and more 
people are surviving long enough to develop ESRD(50). 
Factors associated with diabetic renal disease 
Hyperglycaemia contributes to the development of diabetic renal 
disease(242) but hyperglycaemia is not a primary focus of this thesis 
and is not considered further. Hypertension also contributes to the 
development of diabetic renal disease(33). The diabetic kidney does 
not regulate intraglomerular pressure correctly allowing systemic 
hypertension to be transmitted to the glomerulus(242). There can be 
up to a 20 mmHg increase in glomerular pressure. Flow pressure, 
renin, angiotensin and cytokines are all thought to contribute to this 
process and the subsequent renal damage. In mouse models 
several of the abnormal cellular responses seen in the diabetic 
kidney are reversed by the use of angiotensin 11 blockers (ARBs) 
providing evidence in support of their potential therapeutic benefits 
(see section 5.2.5 and below)(242). Smoking is also an established 
modifiable independent risk factor for the development of diabetic 
renal disease(47). Smokers progress to ESRD approximately twice 
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as quickly as non smokers(47). Unlike other forms of renal 
disease(243), restriction of dietary protein intake has not been 
shown conclusively to slow the progression of diabetic renal 
disease(244). 
Prevention of diabetic renal disease 
There is growing evidence that the progressive renal impairment 
seen in diabetes is preventable(47) and potentially reversible(242). 
In type 2 diabetes the use of ACE-I, given in adequate dosage(245), 
has been established as a preventative medication but the evidence 
base for doing so, while substantial, is less than for type 1 diabetes. 
For example, a study involving 156 people, with normotensive, 
normoalbuminuric type 2 diabetes showed that progression to 
albuminuria and decline in renal function was less in people 
receiving Enalapril compared to placebo. The patients were all under 
60 years, with a mean age of 54.9(246). A recent, large, randomised 
control trial, the Bergamo Nephrologic Diabetes Complications Trial 
(BENEDICT), also concluded that the use of an ACE-I decreased the 
incidence of microalbuminuria. They compared ACE-Is alone or in 
combination with a calcium channel blocker against placebo. The 
patients were hypertensive, but non microalbuminuric. They enrolled 
a total of 1204 subjects. The mean age was 61.6 years In the 
treatment group(247). The diabetic substudy of the Heart Outcomes 
Prevention Evaluation Study (Micro-HOPE), while primarily a 
hypertension study, also showed a reduction in progression to overt 
nephropathy in those receiving Ramipril(45). Weighed against this, 
the UKPDS 39, found no additional benefits in the use of an ACE-I 
when compared to ß-blockade(235). Also the Appropriate Blood 
Pressure Control in Diabetes (ABCD) trial found no differences 
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between progression to microalbuminuria and overt albuminuria, 
when ACE-I and nisoldipine (a calcium channel blocker) were 
compared to placebo. Both had an equal affect in slowing progress, 
in both normotensive and hypertensive populations(202; 248). Much 
of the current evidence is summed up by a systematic review of the 
use of ACE-Is and renal outcomes published in 2004(53). Before 
describing the results it is important to note some limitations of this 
review. The analysis used trials which contained patients with both 
type 1 and type 2 diabetes, subgroup analysis of type 2 analysis was 
limited due to differences between the trials and each analysis was 
dominated by the Micro-HOPE study, which contained by far the 
largest number of participants (1140 in total). The results showed 
that ACE-Is increased the rate of regression from microalbuminuria 
to normoalbuminuria (relative risk 3.42,95% Cl 1.95-5.99), using 15 
trials and 1888 participants. ACE-I reduced the relative risk for 
progression from microalbuminuria to macroalbuminuria (0.45,0.28- 
0.71), using 16 trials and 2010 participants. The doubling of 
creatinine was non significantly reduced (relative risk 0.60,0.34- 
1.05) using 8 studies and 1868 participants. The development of 
ESRD was also not reduced (relative risk 0.64,0.40-1.03), when 9 
studies were considered using 1907 participants. The New England 
Journal of Medicine published three papers consecutively In 2001 
which highlighted the benefits of angiotensin II receptor blockade 
(ARBs) in type 2 diabetic people(232-234). In the first of these 
studies hypertensive patients with diabetes and urinary protein 
excretion of at least 900 mg/24hours, aged between 30 and 70 
years were studied. The results showed that treatment with 
Irbesartan conveyed additional benefits, over and above that of 
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simply lowering the blood pressure. The people who received the 
ARB had a 33% lower (p=0.02) risk of doubling of creatinine than 
those not receiving the ARB(234). The second study assessed 
Losartan (an another ARB) in people aged between 31 and 70 
years, with diabetic nephropathy irrespective of their blood pressure. 
The study again showed a reduced incidence of the doubling of the 
serum creatinine concentration (risk reduction 25%, p=0.006) and 
reduced progression to ESRD (risk reduction 28%, p=0.002)(233). In 
the final study, ARBs were shown to reduce the progression of 
microalbuminuria in patients with hypertension and existing 
microalbuminuria(232). Patients who received the highest dosage of 
Irbesartan (300 mg) were less likely to have worsening proteinuria 
than those on lower doses (150 mg) or placebo. This effect was 
independent of the blood pressure lowering effect. The authors 
reached this conclusion because the difference in systolic and 
diastolic blood pressures between the two treated groups was 
minimal. The average blood pressures were 144/83 mmHg in the 
placebo group, 143/83 mmHg in the 150 mg group and 141/83 
mmHg in the 300 mg group. They also adjusted for these minimal 
effects and found that the benefits of higher dose Irbesartan 
remained. The combination of ACE-I and ARBs have also been 
assessed and there is currently weak but increasing evidence for 
additional benefits in preventing renal disease in diabetic 
people(242; 249; 250). 
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6.2.3 Non renal disease In the diabetic person with renal 
impairment 
Diabetic eye disease, cardiovascular and to a lesser extent 
cerebrovascular disease are all associated with diabetic renal 
disease. It is estimated that up to 75% of people with diabetic renal 
disease will also have diabetic retinopathy, with the severity of 
retinopathy increasing with the degree of albuminuria(251). 
Retinopathy, has also been linked to the rate of decline in renal 
function, as an independent risk factor. Small observational 
studies(252; 253) identified a link, which has subsequently been 
confirmed by a recent large randomised controlled study; the 
Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist 
Losartan (RENAAL) study (254). The authors of this study 
conducted a separate analysis of the baseline characteristics of 
1513 type 2 diabetic patients with nephropathy. They performed 
ophthalmoscopy or fundus photography on 1456 (96.5%) 
participants at baseline to identify retinopathy. Patients with 
retinopathy had a 52% increase in doubling of serum creatinine 
(p<0.001) and a 47% increased risk of ESRD (p=0.002) compared to 
those without retinopathy. 
It has been well established that diabetic renal disease is an 
independent risk factor for both cardiovascular disease and 
cardiovascular death(50; 240). Microalbuminuria predicts death, an 
association which strengthens with increasing proteinuria and raised 
creatinine. Diabetic people with raised creatinine show the largest 
association with death(65), especially cardiovascular death(128). 
Cardiovascular death in part accounts for the especially high 
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mortality rates seen in type 2 diabetic people who enter ESRD(50). 
Therefore much emphasis is placed upon cardiovascular risk 
management in these people. In a study of people with type 2 
diabetes and microalbuminuria intensive intervention aimed at 
treating multiple cardiovascular risk factors reduced cardiovascular 
events by 50 percent(255). There is less available evidence linking 
diabetic renal disease and cerebrovascular disease. Subgroup 
analysis of the HOPE study(45), found that microalbuminuria was 
associated with a composite primary endpoint which included stroke. 
The composite end point consisted of a combined cardiovascular 
end point of myocardial infarction, stroke and cardiovascular 
death(256). The UKPDS did not find associations between 
cerebrovascular disease and diabetic renal disease. The UKPDS 29 
found that microalbuminuria did not significantly effect the estimated 
hazard ratio for the occurrence of stroke(257). The UKPDS 60, 
which designed a risk engine for the likelyhood of stroke in diabetes, 
did not include renal disease in their final risk model and does not 
state whether it was tested(130). 
The UKPDS 59 showed that peripheral vascular disease was not 
associated with albuminuria.. This finding was present both the initial 
presentation to medical care and following re-assessment at 6 years. 
6.2.4 Renal disease in the older person 
Increasing age is a risk factor for the development of ESRD of all 
types. The incidence continues to rise as age increases even into 
the extremes of old age(258). The increasing prevalence is due to 
the aging population and improvements in survival leading to renal 
patients living longer and surviving to older age(259). There is also 
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evidence to suggest that renal replacement therapy, including 
transplantation, is affective in the older person(260; 261). 
Comparable survival rates have been experienced by "healthy" 
people aged over 75 years and younger people aged under 40(261). 
However, there does appear to be prejudice towards the older 
person when referral rates to renal specialist centres are studied and 
treatment is often based, in the UK at least, on the quality of life that 
an individual can expect following treatment(259). Nonetheless, it is 
encouraging that the rate of renal replacement therapy being offered 
to the older person is increasing(259). 
Cardiovascular disease has also been linked to renal insufficiency in 
the older person(262). In a large community based survey 5888 
adults all aged over 65 years were assessed as part of the baseline 
assessment in the Cardiovascular Health Study. The authors 
showed that in people with renal insufficiency compared to people 
without renal insufficiency, the adjusted odds ratio for clinical or 
subclinical cardiovascular disease was 1.43 (1.18-1.75)(262). 
6.2.5 Renal disease in the older diabetic person 
The prevalence of diabetes is increasing, the population is aging and 
survival in diabetes is improving(60; 161). Each of these factors has 
contributed to diabetic nephropathy becoming a disease of the older 
person, in a similar manner to which renal disease in general has 
increased in the elderly population. However, like the majority of 
issues in the care of the diabetic older person, clinical understanding 
and practice is based on the extrapolation from younger populations. 
For example, the current position statement of the American 
Diabetes Association regarding diabetic nephropathy, makes no 
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specific references to the older person, regarding aetiology or 
general treatment(240). With the lack of evidence in mind, Wasen 
and colleagues attempted to characterise renal disease in the 
elderly(263). Using a cross sectional survey of people aged between 
64 and 100 years (mean age 74 years) they identified 187 people 
with diabetes out of a total population of 1260. They divided the 
population in two; those under and those over 80 years. In the older 
age group, simply having diabetes, when compared to hypertension, 
was a greater determinate for decreased renal function. They 
suggested that in the older person hypertension may be of less 
importance to the development of diabetic renal disease than in the 
younger person. 
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6.3 Methods 
6.3.1 The classification and identification of proteinuria, raised 
creatinine and Glomerular Filtration Rate 
Proteinuria, raised creatinine and Glomerular Filtration Rate (GFR) 
were described in Chapter 3. The association between these 
variables and hypertension has also been described in chapter 5. 
Their relation to mortality is presented in Chapter 8. The results 
presented here reflect the associations of proteinuria, raised 
creatinine and GFR with other diabetic endpoints; poor vision, 
blindness, angina, myocardial infarction, cerebrovascular accident 
and foot ulceration. The results are presented for the non diabetic 
population and for the diabetic population. 
The 2002 guidelines from the National Kidney Foundation(153) have 
highlighted two levels of GFR; 60 and 15 ml/min per 1.73 m2. In the 
UK renal function is graded into five stages. GFR below 60 ml/min 
per 1.73 m2 corresponds to stage 3 (moderate) disease and less 
than 15 ml/min per 1.73 m2 corresponds to stage 5 (established 
renal failure). These two levels of GFR (60 and 15) were also 
assessed in relation to diabetic end points. 
6.3.2 Analysis 
The diabetic populations with and without proteinuria and raised 
creatinine were described. This used the factors which have been 
used consistently throughout this thesis. Univariate analysis was 
performed and any significant associations were recorded. 
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Forward fitting logistic regression models were created incorporating 
potential confounding factors, identified in the univariate analysis. 
Every attempt was made to keep the models as parsimonious as 
possible. 
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6.4 Results 
6.4.1 The description of the diabetic populations with and 
without proteinuria and raised creatinine 
The populations were described in terms of age group and sex. 
There were no significant associations seen when proteinuria was 
considered. Raised creatinine was associated with both increasing 
age (p<0.01, test for trend) and sex (p<0.001) in the diabetic 
population. The results are shown in table 6.1. 
In table 6.2 the associations between the two diabetic populations 
are given. The variables used were Carstairs index, MMSE, Alcohol, 
smoking BMI and WHR. There were no significant associations 
recorded in either of the populations for any of the variables tested. 
When logistic regression models were created for use in the 
remainder of this chapter only age and sex were found to be 
significant. Only these two variables were used in the models for 
both the diabetic populations; proteinuria vs no proteinuria and 
raised creatinine vs no raised creatinine. 
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6.4.2 The association between microvascular complications and 
proteinuria and raised creatinine 
The examination of microvascular end points (poor vision and 
blindness) found no associations in the non diabetic population. 
Neither proteinuria or raised creatinine were associated with either 
end point, although raised creatinine and poor vision was 
approaching significance (p=0.07). The results can be seen in table 
6.3 When considering only the diabetic population, no significant 
associations were observed using either end point, see table 6.4. 
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6.4.3 The association between macrovascular complications 
and proteinuria and raised creatinine 
The non diabetic population demonstrated an association between 
proteinuria and cerebrovascular accidents, adjusted odds ratio 1.28 
(1.03-1.59), p<0.02. In the non diabetic population, proteinuria was 
not associated with angina, myocardial infarction or foot ulceration. 
The non diabetic population showed consistent associations 
between raised creatinine and angina, myocardial infarction and 
cerebrovascular accidents, p=<0.01 for each. There were no 
associations seen between renal impairment and foot ulceration in 
the non diabetic population. The results are shown in table 6.5. 
When the diabetic population was considered, there were no 
associations seen between proteinuria and any of the macrovascular 
complications. In this population, renal impairment did not show 
significant associations between angina, myocardial infarction or foot 
ulceration. The only significant association was between renal failure 
and cerebrovascular accidents, adjusted odds ratio 1.68 (1.20-2.35), 
p<0.01. The results are shown in table 6.6. 
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6.4.4 The association between Glomerular Filtration Rate (GFR) 
and diabetic endpoints 
When considering GFR it is important to remember that decreasing 
GFR reflects worsening renal function. The results for GFR and 
diabetic end points showed a continued association between 
worsening renal function and diabetic end points, particularly 
macrovascular end points. Statistical significance was achieved in 
the relationship between both GFR and myocardial infarction and 
GFR and cerebrovascular disease, among the non diabetic and the 
diabetic populations. It was also approaching significance (p=0.09) 
for angina in the non diabetic population. The odds ratios for the 
association between increasing GFR and myocardial infarction and 
cerebrovascular disease were 0.98 (0.97-0.98), p<0.001 and 0.98 
(0.98-0.99), p<0.01 for the non diabetic population and 0.98 (0.97- 
0.99), p<0.01 and 0.97 (0.96-0.98), p<0.001 for the diabetic 
population. 
There were 6809 (48.92%) out of the 13918 non diabetic people with 
GFR less than 60 ml/min per 1.73 m2 and 585/1177 (49.45%) 
diabetic people with GFR less than 60 ml/min per 1.73 r2, (p=0.32). 
The were only 22 (0.14%) of people in the whole trial with GFR less 
than 15 ml/min per 1.73 m2 . Due to the small numbers statistical 
results were not reliable and this cut off point was not considered 
further. When GFR was grouped into those with GFR above and 
below 60 ml/min per 1.73 m2 strong associations were seen for the 
non diabetic population. Visual impairment, blindness, angina, 
myocardial infarction and cerebrovascular disease all demonstrated 
significant odds ratios in non diabetic people with GFR less than 60 
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ml/min per 1.73 m2, see table 6.7. In the diabetic population only 
myocardial infarction and cerebrovascular disease were associated 
with GFR less than 60 ml/min per 1.73 m2; odds ratio 1.39 (1.02- 
1.90, p=0.04) and 1.62 (1.12-2.35, p=0.01) respectively. The results 
are shown in table 6.8. 
Please note that all the results for GFR were "unadjusted". Age and 
sex are used in the calculation of GFR and it was therefore not 
appropriate to adjusted for them again. The results are shown in 
tables 6.7 and 6.8. 
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6.5 Discussion 
The lack of available epidemiological evidence regarding kidney 
function and diabetes was surprising even by the standards of the 
diabetic elder. There was only one paper of note published by 
Wasen et. al(263) that characterised this population in detail and the 
results from this chapter should therefore add to the available 
evidence. The reasons for the lack of evidence may be explained by 
the fact the diabetic renal disease is becoming a disease of the older 
person whereas previously it was a disease of the younger person. 
As this population continues to grow, through the continued aging of 
the population as a whole, increasing diabetes prevalence and 
improvements in diabetic care, it is likely the published evidence 
base will continue to expand. 
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6.5.1 The characteristics of the diabetic populations with proteinurla and 
raised creatinine 
Only male sex and increasing age were shown to affect the relationship 
been diabetes and raised creatinine. These two factors are established 
risk factors for diabetic renal disease(47). The lack of other associations 
seen in both populations was interesting. Not even smoking which has 
been previously associated with diabetic renal disease showed any 
association(47). It is possible that this was due to a survivor affect with all 
susceptible smokers dying before the age of 75 years. Other associations 
may also have become apparent with larger populations. Despite the 
absence of positive results the description of these populations forms an 
interesting cross sectional assessment of these two older diabetic 
populations. 
6.5.2 Protelnuria, raised creatinine and microvascular end points 
Interestingly there was no association observed between diabetic 
eye disease and proteinuria or raised creatinine. Neither proteinuria 
or raised creatinine showed any significant associations, although 
significance was being approached for raised creatinine and poor 
vision in the non diabetic group. This was in sharp contrast to the 
published evidence suggesting that that diabetic eye and renal 
disease are closely linked(251). The associations previously 
observed were between diabetic retinopathy and renal disease. As 
has been noted elsewhere in this thesis, retinopathy and visual 
impairment are not the same thing. It was highly likely that many of 
the diabetic population had retinopathy which had not manifested as 
worsening vision. Therefore direct comparisons with previous 
epidemiological evidence concerning diabetic eye disease were not 
possible. Another explanation for the lack of associations observed 
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was that visual impairment and blindness were both under 
represented in the trial population as a whole. The physical handicap 
of reduced vision may have prevented many people from actively 
participating in the original trial. Visual handicap may also have 
prevented some people from reading their letters of invitation into 
the trial and hence they did not participate in the MRC trial. 
6.5.3 Proteinuria, raised creatinine and macrovascular end points 
The non diabetic population with proteinuria were more likely to have 
suffered from a cerebrovascular accident than non diabetic people 
without proteinuria. Proteinuria did not appear to predict other large 
vessel disease in the non diabetic population. In the non diabetic 
population the well established associations between large vessel 
disease and raised creatinine were observed. Angina, myocardial 
infarction and cerebrovascular accidents all demonstrated a raised 
adjusted odds ratio. When the diabetic population was considered 
the only association shown from the MRC trial was between raised 
creatinine and cerebrovascular accidents. No other associations 
were seen in the diabetic population in conjunction with renal 
disease, either proteinuria or raised creatinine. 
It was interesting to observe that the only association seen In the 
diabetic population was between cerebrovascular disease and 
raised creatinine, not cardiovascular disease and renal Impairment. 
All cardiovascular outcomes have previously been consistently and 
strongly associated with diabetic renal disease(50; 240). 
Cerebrovascular disease is associated with renal Impairment In 
diabetic people but possibly to a lesser extent(45; 256). Why the 
cardiovascular associations seen in the MRC trial were less strongly 
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associated with diabetes than in previous studies is not clear. The 
possibility of bias must therefore be considered. One possible 
explanation for the results seen is premature cardiovascular death. 
The early death of diabetic people from cardiovascular disease may 
have prevented these people from surviving into older age; the 
healthy survivor effect. This implies that these people who have 
survived are less susceptible to macrovascular end points and may 
reflect a distinct group of patients, able to survive into older age with 
diabetes. Could the lack of associations seen have been attributable 
to improved cardiovascular risk factor management? In clinical 
practice there is a strong emphasis on cardiovascular risk prevention 
in renal patients. The MRC trial results were adjusted for the number 
of hypertensive medications used and smoking did not affect the 
results of the logistic regression models. However, other factors, 
which were not assessed as part of the MRC trial, such as adverse 
lipid profiles, may have been more commonplace in the people with 
renal disease. This explanation seemed unlikely because the 
associations between cardiovascular disease and renal disease 
were still observed in the non diabetic population. One would expect 
all renal patients to have cardiovascular risk factors managed 
aggressively, regardless of their diabetic status. The healthy 
participator effect, common to all clinical trials, is also likely to reduce 
the incidence of major cardiovascular disease in both populations 
and may have had the affect of reducing any effects seen. 
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6.5.4 GFR and diabetic end points 
In the non diabetic populations the occurrence of both myocardial 
infarction and cerebrovascular accidents were associated with 
worsening renal function, as measured by worsening GFR. The 
results for angina also approached significance (p=0.09). For the 
diabetic population, both myocardial infarction and cerebrovascular 
accidents were associated with worsening GFR. The results were 
even stronger when GFR was grouped into people above and below 
60 ml/min per 1.73 m2. This figure represents a clinically useful 
measure and corresponds to stage 3 renal disease. Strong 
associations were seen in the non diabetic population for all diabetic 
end points with the exception of foot ulceration. This included visual 
impairment. The associations were weaker in the diabetic population 
but still present for myocardial infarction and cerebrovascular 
accidents. The results generated previously in this thesis question 
the validity of GFR in older diabetic populations (see section 3.9). In 
chapter 3 of this thesis the results failed to demonstrate a difference 
in GFR between the diabetic and the non diabetic populations, 
despite a higher mean creatinine in the diabetic group. The results 
from this chapter suggest that worsening GFR was a strong 
predictor of cardiovascular and cerebrovascular disease in diabetic 
older people. 
The low absolute number (22,0.14%) of people with GFR less than 
15 ml/min per 1.73 m2 presumably reflects the poor health of these 
people and the inability to enrol in a clinical trial. This group is not 
discussed again in this thesis. 
214 
Chapter 6 Proteinuria, renal impairment and diabetes in the older 
person 
6.5.5 Diabetic renal disease and peripheral vascular disease 
Peripheral vascular disease (represented in the MRC trial by the use 
of foot ulceration) did not show any associations with diabetic renal 
disease. There is no biological evidence base for an association 
between diabetic renal disease and peripheral vascular disease, 
other than. shared risk factors for the development of either 
condition. The results generated from the MRC trial were in keeping 
with the results of the-UKPDS 59, which did not find that proteinuria 
or renal impairment was associated with peripheral vascular 
disease(132). However, as discussed at length in chapter 1, the 
results of all the UKPDS are hard to extrapolate to the older person 
because the age of the participants recruited was much younger. 
Another factor limiting comparison between the two trials is the 
methods used to identify peripheral vascular disease. The UKPDS 
59 identified peripheral vascular disease if two of three of the 
following criteria were identified in either leg; 1. ankle-arm blood 
pressure index <0.8,2. neither dorsalis pedis or posterior tibial 
pulses were palpable or 3. intermittent claudication was reported. 
The MRC study collected self reported data on the presence of foot 
or leg ulcers and used this as a proxy measure for peripheral 
vascular disease. 
6.5.6 Hypertension, hypertensive medications and diabetic renal disease 
Hypertension, either systolic or diastolic had little or no affect on any 
of the odds ratios generated and was not included in the final 
adjusted odds ratios. Therefore, the only blood pressure variable 
included in the final model used for the analysis was the number of 
blood pressure medications being taken. This variable fitted into the 
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models well and was included throughout. As highlighted in Chapter 
5 the number of blood pressure medications being taken correlated 
closely with both systolic and diastolic blood pressure. 
The use and number of blood pressure medications and ACE-Is 
were correlated. There were over 56% of people taking an ACE-I if 
they were taking three or more medications for hypertension 
(chapter 5, section 5.4.3); in effect ACE-Is and the number of blood 
pressure medications represented a similar measure. Both fitted into 
each statistical model assessing outcomes. However, they added no 
more together, than alone. Keeping the statistical model as 
parsimonious as possible led to the use of only the number of blood 
pressure medications in the final model. Any additional benefits of 
ACE-I and/or ARBs in diabetic renal function over and above that of 
simply lowering the blood pressure could therefore not be addressed 
and therefore remain unknown in this population. It is also worth 
mentioning that since the MRC trial ended in 1999, the use of ACE-I 
and ARBs has increased dramatically as the evidence base for 
benefits of their use has increased. At the time that the MRC trial 
was conducted there were 167 out of a diabetic population of 1177 
(14.2%) who were taking an ACE-I. There were only 12 participants 
in the original trial identified as taking an ARB, which had only 
recently been launched as a drug class. The numbers of older 
people taking both ACE-Is and ARBs is likely to be much higher 
today. Therefore any results which may have been generated 
regarding ACE-Is and ARBs would probably have been out of date 
and not reflect current clinical practice. 
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6.5.7 Inherent weaknesses 
The results generated from this chapter are most striking for the lack 
of associations seen between renal impairment and diabetic end 
points. While the lack of available evidence in the older person 
should be noted, based on younger populations, one would have 
expected to find more positive associations. 
Chapter 5 also showed a lack of association between hypertension 
and diabetic end points. The two main factors discussed in chapter 5 
are also relevant to this chapter; a lack of identification of all diabetic 
end points and the cross sectional nature of the data. 
Using the questionnaire it is possible that several diabetic end points 
were under represented. Diabetic eye disease may have been under 
represented because it is difficult for visually impaired people to 
participate in trials and macrovascular complications may not always 
have been recorded due to failure to be identified from the 
questionnaire, although the questions used have been well validated 
in the past(159). 
The cross sectional nature of the data can limit the power of a study 
to identify all possible associations. This may be particularly likely in 
the setting of a secondary analysis. The point is highlighted by the 
finding that when GFR was analysed, a linear variable, positive 
associations were identified between renal impairment and diabetic 
end points. This reflects the increased power which is obtained from 
using a linear variable rather than the binary variables obtained from 
the majority of the data which is obtained in cross sectional studies. 
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6.6 Conclusions and recommendations 
The results presented here add further information regarding the 
characterisation of renal impairment in the older diabetic person. The 
information which is currently available is extremely limited. This 
chapter showed that renal impairment appears to have associations 
with macrovascular disease, particularly cerebrovascular disease, in 
the older diabetic person. In general the associations demonstrated 
in this chapter were weaker than previous studies. The majority of 
the associations demonstrated here were between GFR and diabetic 
end points. 
In general, the overall absence of associations seen in this chapter 
was surprising. Why should associations, between renal damage 
and diabetic end points, which are well established in younger 
people not be apparent with increasing age? It appears unlikely that 
they should. Therefore one has to suspect that the results generated 
from the MRC trial were biased. The most likely reason for this bias 
was the cross sectional nature of the study. The MRC trial was not 
designed to detect diabetic complications and was not powered to 
do so. It must therefore be suggested that further more appropriately 
designed studies are undertaken. The cross sectional nature of the 
study and the potential affect that that has had on the results 
generated in this chapter is expanded in chapter 9. In order to avoid 
repetition it was not discussed in detail here because it also affects 
some of the results from other chapters of this thesis. 
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Clearly there is room for further description of renal impairment 
among the older diabetic population to continue to characterise the 
condition. 
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Chapter 7 The relationship between admission to 
hospital and diabetes in the older person. 
7.1 Summary of objectives 
To assess the: 
Association between diabetes and hospital admission in an elderly 
population. 
7.2 Background 
7.2.1 Introduction 
If diabetes contributes to morbidity and mortality then health care 
use amongst people with diabetes is likely to be increased. This was 
previously observed in an older population in an assessment of the 
Medicare program utilisation(54). In the Medicare study, diabetes 
was established as an independent predictor of health care 
utilisation in 5138 community dwelling persons aged 71 years or 
older. The increased use of health care can manifest in several 
ways; an increased number of total admissions, an increased 
number of repeated admissions or an increased number of total 
days in hospital. 
Social deprivation has been established as an Independent risk 
factor for hospital admission for most chronic medical conditions, 
including diabetes, in all age groups(264; 265). However information 
regarding other factors associated with admission to hospital in older 
age groups is sparse. 
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This thesis provided an opportunity to assess the total number of 
admissions to hospital, assess the number of repeat admissions, the 
length of stay of participants and some of the risk factors for 
admission to hospital in an older diabetic population. 
7.2.2 Admission rates in diabetic populations 
Analysis of the Veterans Administration diabetic cohort (n=33481) 
showed that since 1994 admission to hospital had increased in 
people aged over 75 years. They recorded total hospital discharges, 
in veterans with diabetes, on a yearly basis between 1994 and 1998, 
in all other age groups hospital admissions (recorded as discharges) 
were decreasing(266). The Veterans were nearly all men, 
predominantly white and had a mean age of 61.1 years. 
7.2.3 Length of hospital stay 
In 2005, a large hospital based audit, from Liverpool, showed that 
the average length of stay in hospital was increased for people with 
diabetes. The 113 patients, with predominantly type 2 diabetes and 
mean age 73 years, were in hospital for 19 days. This compared to 
10 days for patients without diabetes(267). This figure is higher than 
Tayside, Scotland which used the DARTS database(268). In this 
study the average number of days which diabetic people spent in 
hospital was seven days. The Diabetes and Audit and Research in 
Tayside Scotland (DARTS) group studied 366849 people, of which 
6871 had type 2 diabetes, with an average age of 67.6 years. The 
DARTS database is a well validated diabetes information system 
with 95% sensitivity for the identification of people with diabetes. A 
large retrospective cohort study of veterans in the US with type 2 
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diabetes demonstrated comparable results to the DARTS study. In 
the American study, the average length of stay was eight days(269). 
7.2.4 Repeated hospital admission 
A six year cohort study in the US showed that diabetes predisposed 
to repeated admission to hospital. Boult and colleagues studied the 
Medicare program and assessed 5876 people aged over 70 
years(55). The authors found that eight factors emerged as risk 
factors for repeated admission; older age, male sex, poor self-rated 
general health, availability of an informal caregiver, having ever had 
coronary artery disease, a hospital admission within the previous 
year, more than six doctor visits, or diabetes. Jiang and colleagues 
showed that 55.2% of elderly people, with diabetes, have multiple 
stays in hospital as a percentage of total stays(270). This was in a 
large cohort of people (n=378226) aged over 65 years taken from 
the Healthcare Cost and Utilisation project database, representing 
five states in the U. S. 
7.2.5 Factors associated with hospital admission in diabetic 
populations 
Studies have established that access to health care is inversely 
proportional to admission rate in persons aged 18 to 64 years but 
not disease prevalence, physician admitting style or an individuals 
propensity to seek health care(271). Social deprivation has also 
been linked to increased hospital admission in diabetic populations. 
Positive correlations have been suggested between hospital 
admission and both being in receipt of disability living allowance and 
being a member of an unskilled socioeconomic group, for all 
diagnoses (R=0.64, p<0.0001 for disability allowance and R=0.51, 
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P<0.0001 for unskilled socioeconomic group (R=correlation 
coefficient)) (264). A separate study, from 120 general practices in 
South London, confirmed these findings(265). The authors showed 
that deprivation, measured by the Jarman Index, was related to 
emergency admission to hospital (R=0.46, p<0.001). The study by 
Jiang, mentioned above, also showed that 29.9% of elderly people 
with diabetes and multiple admissions came from low income 
areas(270). When compared to the highest income areas, the odds 
ratio for admission was 1.03 (1.01-1.05 95% Cl) p<0.01. 
Socioeconomic status was also found to be related to hospital 
admission in a study from Canada(272). A population based cohort 
of 605825 people with diabetes was analysed between the period 
1992 and 1999. Socioeconomic data was calculated using 
neighbourhood level data derived from the 1996 Canadian Census. 
They found that individuals in the lowest quintile of income were 
more likely to be admitted to hospital when they attended the 
Emergency Department. In people of all ages the odds ratio for 
admission, lowest quintile vs highest quintile, was 1.20 (95% Cl 
1.14-1.26). A study of acute hospital admission in the Paisley and 
Renfrew area of Scotland found an association between increased 
BMI (BMI>30Kg/M2) and hospital admission in people with abnormal 
glucose, odds ratio 3.19 (2.09-4.86 95% Cl)(273). It should be noted 
that this study only included 103 people with abnormal glucose, who 
were aged between 45 and 64 years, from a total population of 
15406. 
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7.3 Methods 
7.3.1 Classification and identification of hospital admission 
rates, number of admissions and the average length of stay 
Admission to hospital was collected for each trial participant for the 
two years immediately after they had completed the brief 
assessment. Nurses based within each participating general practice 
carried out six monthly notes searches on admission to hospital, 
based on the hospital discharge letter. The information recorded 
included date of admission, date of discharge and diagnosis. A 
patient was still classified as having been admitted to hospital even if 
they died during that admission. It should be noted that diagnosis 
was not considered further because this data was not considered to 
be accurate. There were some inaccuracies with the coding software 
used at the London School of Hygiene and Tropical Medicine to 
record the diagnosis, which made the recorded diagnosis unreliable. 
The software problems did not occur with the other information 
recorded regarding admission to hospital i. e. date of admission. 
Explanatory factors tested in the analysis were the same as for the 
analysis used in previous chapters of this thesis; sex, smoking 
history, excess alcohol intake, BMI, WHR, previous history of 
myocardial infarction or cerebrovascular accident, MMSE<=23 and 
quintiles of Carstairs index. Section 7.2.4, above, describes 
previously identified risk factors for repeated admission to hospital. 
Where comparable information was available from the MRC trial, the 
associations with hospital admission was assessed. These were the 
presence of an informal care giver and self rated health. 
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The questions regarding the presence of a care giver and self rated 
health were (see appendix 2); 
" "Do you have a relative, neighbour or friend whom you can 
call on for help when required? " Yes or No. 
" "Compared with other people of your own age would you say 
your health is generally: excellent, very good, good, fair or 
poor? " 
The responses to the last question were regrouped into poor or 
otherwise. The justification for doing so was to simplify the outcome 
and increase the statistical power by making the outcome binary. 
7.3.2 Analysis 
Admissions for the non diabetic and the diabetic populations were 
described in terms of age and sex, allowing for the clustered studied 
design. The total number of days spent in hospital were calculated. 
Next the average number of admissions per diabetic subject was 
compared to the average number of admissions for the non diabetic 
subject. Repeated admission to hospital was then summarised for 
both populations. Next the average length of hospital stay was 
compared in days between the two groups. Poisson regression, 
comparing the rates of any admission between all diabetic 
individuals and non diabetic individuals, was then undertaken 
stratifying by five year age groups which calculated the rate of any 
admission for both populations. Every admission, single or multiple, 
was included. The Poisson model was tested at the 5% significance 
level using likelihood-ratio testing after any addition to the model of 
potential confounding factors or interaction terms. 
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Rate ratios were calculated for admission to hospital for the diabetic 
participants using Poisson regression. This allowed for the affect of 
associations to be tested, such as the affect of Carstairs index, the 
presence of a care giver or BMI. Each of these associations were 
adjusted for age group and sex. 
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7.4 Results 
7.4.1 Description of the admissions to hospital for the MRC trial 
There were a total of 80896 days spent in hospital for the entire 
population. The mean length of admission was 12.6 days. The range 
was from 0-427 days. The data was positively skewed 
(skewness=7.02), reflecting large numbers of people who weren't 
admitted to hospital at all (11170,24.0%) and the small number of 
people who suffered a very long admission (72 (0.5%) people spent 
over 120 days in hospital). People admitted to hospital were more 
likely to be older (p<0.001) and male (p<0.001). 
7.4.2 Rate of admission to hospital for the non diabetic and 
diabetic participants 
Overall the rate of admission to hospital was higher for people with 
diabetes than people without diabetes. The rates also remained 
consistently higher for each age group when comparing the two 
populations. Similarly the rate of admission plateaus for both groups 
in the very elderly. Men showed higher rates of admission for both 
populations. Men and women with diabetes had higher rates of 
admission than those without diabetes. The rate ratios were 
consistently higher when the diabetic participants were compared to 
the diabetic participants, p<0.01 for each. The results are shown 
below in table 7.1. 
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7.4.3 Average length of days spent in hospital per admissions 
to hospital for the non diabetic and diabetic participants 
The non diabetic participants spent a total of 72564 days in hospital 
and the diabetic participants spent 8332 days in hospital. The 
average length of stay was 12.4 days and 13.9 days for the non 
diabetic and the diabetic participants respectively. The difference 
between the two was significant (p<0.001). 
7.4.4 The number of hospital admissions for the non diabetic 
and diabetic participants 
In the non diabetic population there were 3567 out of a population of 
13918 (25.6%) people who had at least one admission to hospital. 
The majority (2331/13918,16.7%) had just one admission. The 
range was between one and thirteen admissions. The average 
number of admissions per person was 1.58. Within the diabetic 
population 358/1177 (30.4%) people had one or more admission 
with 228/1177 (19.4%) having only one admission. The range was 
one to ten admissions. The average number of admissions per 
diabetic person was 1.64. In each case the results were significantly 
different (p<0.001, for each). The non diabetic population had a total 
of 5624 separate admissions to hospital and the diabetic population 
558 separate admissions. In the non diabetic population multiple 
stays were 58.6% (as a percentage of total the stays) which was 
lower than the diabetic population whose multiple stays (as a 
percentage of total stays) was 67.2%. The results are shown in table 
7.2. 
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Participants without diabetes 
n=13918 % 
Participants with diabetes 
n=1177 
Number of (repeated) admissions 
0 10351 (74.42) 819 (69.60) 
1 2331 (16.92) 223 (18.95) 
2 775 (5.56) 85 (7.22) 
3 254 (1.82) 28 (2.38) 
4 117 (0.84) 12 (1.02) 
5 50 (0.36) 4 (0.34) 
6 28 (0.04) 3 (0.25) 
7 8 (0.02) 1 (0.08) 
8 2 (0.01) 1 (0.08) 
9 0 0 
10 1 (0.01) 1 (0.08) 
11 0 0 
12 0 0 
13 1 0.01 0 
Total number of separate admissions 5624 558 
7.4.5 The factors which affected admission to hospital in older 
people with diabetes 
Social deprivation (as measured by the Carstairs index) showed an 
association with increased admission in people from the lowest 
social economic group, (rate ratio, test for trend, p<0.01). Diabetic 
participants with MMSE <=23 (implying a high degree of cognitive 
impairment) did not show any change in the likelihood of being 
admitted to hospital. Equally alcohol had no affect on admission to 
hospital for either men or women. Smoking was associated with a 
trend toward admission to hospital when never, ex and current 
smokers were compared (test for trend, p<0.01). BMI did not show 
any relationship with admission to hospital. The absence of available 
help (someone to call in an emergency) was not associated with an 
increased rate ratio for admission to hospital. Poor self rated health 
and admission to hospital also showed no association. The results 
are shown in table 7.3. 
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Number Rate* Rate ratio 
(1000/year, 95 %Cl) (95% Cl) 
P value 
Carstairs 1st (most deprived 74 190.49 (151.68-239.24) 1.75 (1.64-1.86) 0.01 
by quintile 2nd 131 235.01 (198.68-278.91) 1.34 (1.24-1.44) test for 
3rd 114 226.23 (188.29-271.82) 1.19 (1.14-1.30) trend 
4th 100 255.97 (210.41-311.40) 1.23 (1.12-1.32) 
5th (least deprived 70 334.61 (264.73-422.93) 1 (-) 
MMSE <=23** 106 281.13 (232.40-340.08) 1 (-) 
>23 426 231.90 (210.89-255.00) 0.87 (0.63-1.27) 0.42 
Alcohol 0-21 units (men) 269 270.84 (240.17-305.42) 1 (-) 
>21 units (men) 5 312 (130.16-751.31) 1.62 (0.76-4.39) 0.18 
0-14 units (women) 256 220.61 (195.18-249.36) (-) (-) 
>14units (women) 2 ^ (-) (-) 
Smoking Never 163 196.27 (168.34-228.84) 1 (-) 
Ex-smoker 305 253.67 (226.74-283.80) 1.29 (1.18-1.40) <0.01 
Current 63 359.21 (280.61-459.82) 1.83 (1.45-2.18) trend 
BMI <18.5 Kg/m2 10 386.55 (207.98-718.42) 1 (-) 
18.5-25 178 286.27 (247.16-331.57) 0.74 (0.25-2.36) 0.09 
25-30 184 221.30 (191.53-255.70) 0.57 (0.22-1.86) test for 
>30 104 190.99 (157.59-231.46) 0.49 (0.19-1.54) trend 
WHR <0.90 (men) 72 343.97 (273.03-433.35) 1 (-) 
>0.90 (men) 183 250.61 (216.81-289.68) 0.72 (0.51-1.23 0.22 
<0.85 (women) 103 212.46 (175.15-257.72) 1 (-) 
>0.85 (women) 142 224.73 (190.64-264.90) 1.06 (0.90-1.25) 0.55 
Help Availiable Yes 474 236.71 (216.33-259.01) 1 (-) 
No 14 391.42 (231.82-660.90) 1.65 (0.96-2.34) 0.06 
Self Rated Health Better than poor 515 239.81 (219.97-261.45) 1 (-) 
Poor 14 30430 (180.22-513.81) 1.27 (0.51-3.36) 0.99 
Table 7.3 Rates and rate ratios for any admission to hospital 
in the diabetic population 
*adjusted for age and sex, **indicates cognitive impairment, "less than 3 events 
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7.5 Discussion 
The results showed that people with diabetes had a higher rate of 
admission to hospital than people without diabetes. This was true 
for the diabetic population as a whole and when the diabetic 
population was assessed in terms of age group and sex. Each 
rate ratio was higher in the diabetic group, p<0.01 for each. 
Unsurprisingly, the absolute rates of admission increase with age. 
However, in both the non diabetic and the diabetic groups, the 
rates of admission to hospital plateau in those aged over 85 
years. This could represent an unwillingness of these people to 
be admitted to hospital, possibly preferring to remain at home for 
treatment (or death) or a reluctance of healthcare providers to 
refer or admit these people to hospital. 
The people with diabetes spent one and a half days longer in 
hospital than those without diabetes (13.9 days versus 12.4 
days). The figure is less than the Liverpool study, where a 
younger population with diabetes (mean age 71 years) spent an 
average of 19 days in hospital per hospital admission(267). The 
DARTS group and the Veterans administration both showed a 
lower average length of hospital stay, seven and eight days 
respectively(268; 269). There were some differences between the 
DARTS and the Veterans studies when they are compared to the 
MRC trial. The mean age in both studies was a lot lower than the 
MRC trial and the Veterans study contained very few women, 
factors which may account for the differences. 
People with diabetes were more likely to suffer one or more 
admissions to hospital than people without diabetes (30.4% 
versus 25.6%). They also had a higher average number of 
admissions to hospital per person (1.64 in people with diabetes 
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versus 1.58 in people without diabetes). These higher figures 
may reflect the increased burden of disease in the older diabetic 
person. The Healthcare Cost and Utilisation project 
database(270) previously found that 55.2% of diabetic people 
aged over 65 years had multiple stays in hospital which is lower 
than our older cohort for whom 67.2% had multiple hospital stays 
(as a percentage of total hospital stays). 
When considering the factors which affected admission to 
hospital for the diabetic cohort only high Carstairs index and 
smoking demonstrated significantly raised rate ratios. The 
findings for the MRC trial for the Carstairs index were similar to 
previous studies which linked emergency admission to hospital to 
decreased social status(264; 265; 270; 272). Current and ex 
smokers had an increased rate ratio for hospital admission, 
(p<0.01, test for trend), which presumably reflects the well 
established associations between smoking and disease. 
Available help has been previously shown to predispose to 
admission to hospital(55). The same study(55) found that poor 
self rated health increased admission to hospital, but neither of 
these two factors demonstrated an increased rate ratio for 
admission to hospital in the MRC trial. Increased BMI did not 
appear to increase hospital admissions. This result was different 
from the small Scottish study of younger people which found an 
association between admission to hospital and being obese 
(BMI>30 Kg/M2)(273). Heavy drinkers, of either sex, or people 
with cognitive impairment, showed no differences for admission to 
hospital. 
The diabetic population was analysed as a whole when the 
individual factors which affect hospital admission where 
considered, rather than separately by age group or sex. This 
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ensured that numbers within each group studied remained large. 
By doing this statistical power remained high and the results more 
meaningful, albeit it a far broader group. This group (over 75 
years and of either sex) is large and formed the first 
representative sample of the factors which affected admission to 
hospital in the older diabetic person. 
There are of course other factors which influence hospital 
admission in the older diabetic person. These include both 
physical and social measures. For example, a three year 
prospective study in America found the Geriatric Depression 
score was an important independent risk factor for hospital 
admission(274). However, not every factor predictive of 
admission, including the Geriatric Depression score, was 
available in the MRC study. In the analysis of this study a large 
number of indices were used and their inclusion has been 
justified where possible. 
The results of this chapter appear to confirm that diabetes 
contributes to hospital admission in every area; the rate of 
admission, the length of stay, total admissions and repeated 
admissions to hospital. It has also established some factors which 
increase the chances of hospital admission; low socio-economic 
status and smoking. The main criticism is the potential lack of 
power, particularly at the extremes of age. However, this study 
population is far older than those previously reported and 
provides new information regarding hospital admission in the 
elderly diabetic person. 
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Chapter 8 The relationship between diabetes and 
mortality in the older person 
8.1 Summary of objectives 
To compare the rate of death (all cause and cause specific; 
circulatory and renal) among older people with and without diabetes. 
To assess the association between proteinuria, raised creatinine, 
glomerular filtration rate and mortality in the older diabetic subject. 
8.2 Background 
8.2.1 Introduction 
Although it is likely that diabetes affects mortality in the older person, 
the evidence is sparse. Evidence first emerged of a detrimental 
affect of diabetes on life expectancy in the older person from two 
large studies from the Mayo clinic, now both over 30 years 
old(275; 276). Using long term clinic data they followed diabetic 
people of all ages from 1939 onwards. In general both reports 
suggested that diabetes increased mortality in the older person, 
although some of the age and sex specific results differed between 
the two authors. The population demographics were different to 
modern populations and contained very few older people. In 
addition, mortality papers written before 1980, when the WHO 
markedly changed the diagnostic criteria of diabetes, were likely to 
classify people with impaired glucose tolerance (IGT), as having 
diabetes. The Bedford survey, a well known cohort study, showed 
that individuals with IGT, have raised mortality compared to the 
general population but lower mortality than people who have 
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diabetes(277). Therefore the results of any mortality figures which 
were published before 1980, are likely to have been diluted by 
people with IGT and underestimate the true figure. Due to the age of 
the studies from the Mayo clinic (and therefore the different 
diagnostic criteria used today) and altered population demographics 
the findings reported in these papers may not be applicable today. 
Since 1980, a number of studies have assessed mortality in diabetic 
older people and these are reviewed below. The affect of diabetes at 
the extremes of old age has not previously been assessed in the 
U. K, in a large population. The affect of diabetes on mortality in 
people aged over 90 years has not previously been published. In the 
older person the majority (but not all) of the mortality studies have 
concentrated on all cause mortality, although in younger populations 
all cause, cardiovascular and renal mortality are all raised. Whether 
cardiovascular and renal mortality are increased in the older person 
is less clear. Renal impairment (proteinuria, raised creatinine and 
decreasing GFR) is also an independent risk factor for all cause and 
cardiovascular mortality. The affect of renal impairment on mortality 
(of any cause) in the older diabetic person has rarely been 
assessed. 
The associations between death (all cause, circulatory and renal) 
and diabetes and the affect of renal impairment and mortality in 
elderly people with diabetes were studied in this thesis to establish 
their affect. 
8.2.2 All cause mortality in the older diabetic person 
A comprehensive literature review, by Sinclair and colleagues(56), 
found that there was likely to be an association between diabetes 
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and increased death rates in the older person. They reviewed 
papers relating to mortality from 1980 onwards and selected the 
most valid and useful. In total they included 20 papers in the review. 
The differences between the studies, including the different ages of 
the participants; different ethnic populations; the statistical methods 
used; the type of diabetes; different methods used to identify people 
with diabetes; and the length of follow up, were considered by the 
authors to preclude a meta analysis. The age of participants in the 
studies ranged from 55 years to greater than 85 years, although only 
two studies reported mortality figures for people aged over 
80(278; 279). The first of these from Finland, by Stengard and 
colleagues(278) included 82 men with diabetes (no women) and did 
not show a statistically significant increased rate of death in men 
aged 75 to 84 years (mortality ratio 1.8,95% confidence interval 0.8- 
4.1) when compared to the non diabetic population. There was 
criticism of this study for the methods used to recruit diabetic 
participants. They identified trial participants using oral glucose 
tolerance tests (OGTT). Some of the OGTTs were performed after 
an inadequate period of fasting and some were conducted in the 
afternoon. This had the affect of overestimating the number of 
people defined as having diabetes and biased the results. The 
second study, by Croxson and colleagues(279), based in the UK (in 
a single town, Melton Mowbray) was the only study to provide 
hazard ratios of death for patients over the age of 85. The results of 
this study suggested that there was no increase in mortality in this 
age group, however, these results were based on only 6 participants 
aged over 85 years (hazard ratio 1.3 95% confidence interval 0.4- 
4.9). Unlike the Stengard study, a strength of this study was the 
appropriate use of OGTTs to identify trial subjects, therefore 
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correctly identifying as many older diabetic people as possible. Of 
the remaining 18 articles reviewed, four provided mortality estimates 
for Caucasian populations aged over 75 years(280-283). Panzram 
and Zabel-Langhenning used a central diabetic registration 
database in Erfurt, Germany. They identified 50 women and 112 
men aged between 75 and 79 years. They followed these people for 
10 years and compared excess mortality to the general population. 
They found a mortality ratio of 1.04 for women and 0.96 for 
men(281). It was possible that the long period of follow up 
accounted for the lack of differences seen in this trial; if a cohort of 
people is followed up for long enough eventually the results will be 
the same, 100% death. Waugh et a/ studied type 1 and type 2 
diabetic subjects in Dundee, Scotland and identified 201 subjects 
aged over 75 years. The authors calculated the relative risk of death 
to be 1.3 (95% Cl, 0.9-1.9)(280). They also noted that a large 
number of the type 2 patients, especially the elderly, were under the 
care of their GP. This highlighted both the potential underestimation 
of the affect of diabetes on mortality in their results and difficulties of 
clinic based mortality studies in identifying all possible diabetic 
participants. There are also established differences in the care 
provided by hospital based and community based care, which forms 
another source of bias in hospital clinic based studies(284). The third 
study, this time from Aberdeen, Scotland, identified 1276 people with 
diabetes aged over 75, recruited from local GPs(282). They reported 
standardised mortality ratios (SMRs). They showed the SMR for 
men with diabetes was 0.81 (0.74-0.89) and 0.92 (0.84-1.01) for 
women. These results were liable to selection bias. The referral 
rates to the clinic were markedly different between General 
Practices, with some referral rates 96% and some referral rates not 
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quoted. The extremely high referral rates and (potentially) low 
referral rates from different GPs implied that the diabetic clinic 
population may not have been representative of older diabetic 
people living in the community. The fourth study discussed in the 
review by Sinclair et al, which provided a mortality figure for a 
Caucasian population aged over 75 years was conducted by Walters 
and colleagues(283). They reported a SMR of 1.26 (1.08-1.45) for all 
cause mortality in a combined group of men and women aged over 
75 years. They assessed a total population of 849 diabetic people, 
all aged over 45 years, but did not state how many were aged over 
75 years. 
The review by Sinclair and colleagues(56) provided an overview of 
articles published up to 1994. Since then there have been several 
large scale studies which addressed diabetic mortality in the older 
diabetic person. One of the most comparable to the MRC study was 
a study from Canada(161), which showed an increased risk of death 
amongst older diabetic people. Diabetes was identified using a self 
reported questionnaire. It included 9008 individuals aged 65 years 
and over. The risk of death was presented as an overall rate and not 
by age group or gender; relative risk 1.9, (95% Cl 1.6-2.2). The 
Verona Diabetes Study showed that Standardised Mortality Ratios 
(SMR) were higher in people of all ages including those aged over 
75 years. The SMRs for men and women aged over 75 years were 
1.13 (1.00-1.28) and 1.32 (1.20-1.44) respectively. They 
demonstrated that SMRs declined with increasing age. For example, 
in the 45-54 year age group, the SMRs were 2.33 (1.38-3.69) for 
men and 3.43 (1.43-6.77) for women(285). The study also 
demonstrated that people with the most variation in fasting glucose 
239 
Chapter 8 Mortality and diabetes in the older person 
results, measured using the coefficient of variation, also had a 
higher mortality. Another Italian study, by Bruno and colleagues, 
also showed decreasing SMRs as people with diabetes got 
older(58). They followed a cohort of 1967 people with type 2 
diabetes. The average age of the group was 64.0+/-10.6 years and 
included people over the age of 80, although the paper did not state 
how many. For diabetic people aged 60-69 years, the SMR was 1.86 
(1.52-2.25), for 70-79 years it was 1.37 (1.18-1.58) and for 80 plus 
years it was 1.12 (0.98-1.27). In 1997, a Danish study assessed the 
relative risk of death in 1323 Danes with diabetes, aged between 40 
and 85 plus years(286). They showed relative risks of death to be 
0.98 and 1.02 for men, aged 75-79 years (n=24) and 80-84 years 
(n=19). For women the relative risks were 1.24 and 1.19 for the 
same age groups (n=26 and n=25). The authors were unable to 
calculate relative risks for any participants aged over 85 years, due 
to "technical reasons" which they did not clarify. The small numbers 
of very elderly people should be noted and this was a clinic based 
study, thus possibly liable to selection bias (as discussed above). 
Roper and colleagues published overall death rates for men and 
women with diabetes aged over 80 years in the South Tees area of 
North East England(60). They showed that the death rate (per 1000 
person years) for men aged over 80 years with diabetes was 155.56 
(143.67-167.45) for the 131 men studied and 134.55 (127.70- 
141.41) for the 250 women studied. Compared to the non diabetic 
population the relative risks of death were 1.25 (1.09-1.43) and 1.09 
(0.92-1.29) for men and women respectively. Once again the relative 
risk of death in this older age group was lower, for both men and 
women, than younger age groups. The South Tees study used a 
central diabetes register to identify diabetic people and consequently 
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may have underestimated the true number of diabetic people in the 
community. A strength of the study was that nearly all the deaths 
were detected because all participants were registered for death at 
the Office for National Statistics. A large cohort study of 148519 
older people with diabetes was analysed from the American 
Medicare system(57). The study compared the relative risk of death 
in Medicare beneficiaries with diabetes compared to non diabetic 
beneficiaries, in a predominantly (84.9%) white population. They 
found the relative risk of death to remain elevated, but once again 
declined with increasing age; 65-69 years, relative risk 2.59 (95% Cl, 
2.37-2.82), 70-74 years, 2.27 (2.19-2.35), 75-79 years, 2.11 (2.05- 
2.17), 80-84 years, 1.85 (1.80-1.90) and 85 plus years 1.46 (1.43- 
1.49). The primary limitation of this study was the use of claims data 
which does not identify all diabetic people. Identification of diabetic 
people from the Medicare system has previously been estimated to 
have a sensitivity of 63.4% and specificity of 98.8%. The use of 
claims data does not have the ability to identify undiagnosed 
diabetes within their population. Using the same cohort of 
participants, women with diabetes had a higher relative risk of death 
compared to men with diabetes even after adjustment for age, 1.34 
(95% Cl, 1.31-1.38)(287). Another large study, again using Medicare 
data, but with a different cohort of participants, assessed mortality 
rates for all cause mortality in people with diabetes(288). For the 
year 2001, they showed the mortality rate per year per 1000 
Medicare beneficiaries to be 75.1 for people aged 75-79 years, 
112.5 for ages 80-84 years and 202.2 for people aged over 85 
years. The same limitations applied to this study as the previous 
one; namely the inability of claims data to identify all the people with 
diabetes from their population. A recent study published using the 
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DARTS database based in Tayside, Scotland(289)produced 
interesting up to date figures for mortality in the older diabetic 
person(290). They identified people who were diagnosed with 
diabetes at older age. They identified 3594 people with type 2 
diabetes and 7188 age and sex matched comparators and assessed 
all cause and cardiovascular mortality over an average follow up 
period of 4.6 years. They identified the cause of death from death 
certificates (a noted limitation). In men, who were aged over 65 
when they were diagnosed with diabetes, the relative risk of death 
was not increased regardless of the age of diagnosis. In women 
relative risk of death was increased for each age group of diagnosis. 
Women diagnosed at 65-74,75-84 and over 85 years had relative 
risks of 1.47 (95% Cl, 1.21-1.78), 1.15 (0.97-1.38) and 1.36 (1.06- 
1.73) respectively. 
In summary, it appears that mortality rates in the older person, while 
remaining raised, decline with increasing age. In addition there is no 
overall consensus of the affect of gender and mortality in the older 
diabetic person. This summary is based on estimates primarily in 
"younger" older people, there are very few papers published in 
people aged over 85 years and none in people aged solely over 90 
years. 
8.2.3 Circulatory mortality 
The predominant cause for excess mortality in younger people with 
diabetes is cardiovascular disease and this has been shown in many 
studies(44; 60; 162; 291; 292). For example, data from the First 
National Health and Nutrition Examination Survey (NHANES I) 
reported that "heart disease" was recorded on 69.5% of death 
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certificates in people with diabetes(162). The importance of 
cardiovascular disease as a cause of death was further 
demonstrated in type 2 diabetic people from all over the world using 
the WHO multinational study of vascular disease in diabetes, (WHO 
MSVDD)(44). This study was conducted in 14 different centres and 
reported results from 10 centres. It assessed many diabetic vascular 
outcomes reporting separate results for type 1 and type 2 diabetic 
people aged between 35 and 54 years at recruitment. Morrish and 
colleagues showed that for the study population cardiovascular 
disease accounted for 52% of the deaths in the people with type 2 
diabetes(292). The Verona diabetes study also stated that 
cardiovascular death remained raised in diabetic participants aged 
over 75 years but that the contribution of cardiovascular mortality 
was less in this age group when compared to the younger 
participants in their study(59). The authors suggested that 
cardiovascular mortality may have already caused the death of 
susceptible younger diabetic people and hence the decreasing affect 
of cardiovascular mortality was due to a survivor effect. They did not 
provide exact figures for different age groups for comparison. The 
South Tees group (whose paper was discussed above) provided 
cardiovascular cause specific mortality for older men and 
women(60). For males aged 60-79, the cardiovascular death rates 
(per 1000 person years) were 34.46 (31.47-37.46), relative risk 1.96 
(1.72-2.23) and 80.50 (74.47-86.53), relative risk 1.39 (1.10-1.76) for 
men aged over 80 years. For the women aged 60-79 years the rates 
of death (per 1000 person years) were 34.25 (30.80-37.71), relative 
risk 3.24 (2.81-3.74) and for women aged over 80 years, 72.83 
(67.62-78.04), relative risk 1.47 (1.22-1.77). The results by Tan and 
colleagues from the Diabetes and Audit and Research in Tayside 
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Scotland (DARTS) database failed to show a conclusive difference 
in cardiovascular mortality in their cohort of people who were 
diagnosed with diabetes at a later age(290). They showed that 
absolute numbers of cardiovascular deaths where higher in people 
with diabetes 49.4% vs 45.2%, but the adjusted relative risk of 
cardiovascular death was 1.01 (0.93-1.10). 
Circulatory disease has been established as a major cause of death 
in people with diabetes. It has also been suggested, that in a similar 
manner to all cause mortality, mortality rates remain raised but 
decrease with advancing age. A potential explanation for the 
decreasing affect is the survivor effect, with susceptible individuals 
succumbing to circulatory death before they reach old age. 
8.2.4 Renal mortality 
The WHO MSVDD showed that renal disease accounted for 8% of 
deaths in men and 14% for women in their worldwide population with 
type 2 diabetes(292). This was not, however, an elderly population. 
The oldest person in this population was aged 54 years at 
recruitment, and the cohort followed for an average of 8.4 years(44). 
There was no other evidence available describing the affect of 
diabetes on renal mortality in the older diabetic person. 
In addition to their contribution to end stage renal disease (ESRD), 
poor renal function and proteinuria have both been established as 
independent risk factors for both all cause(60) and cardiovascular 
mortality(65). In younger populations with type 2 diabetes and ESRD 
the five year survival is worse than non diabetic ESRD patients. Five 
year survival has been reported to be as low as 29%(293). The first 
study which identified the link between microalbuminuria, clinical 
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proteinuria and death was conducted by Morgensen in 1984(294). 
Since then studies have increased in size and range, the results of 
which can be illustrated by a recent large Italian study (n=3892, 
mean age 69.7 years). This study, based in Turin, recruited type 2 
diabetic people and confirmed that renal impairment (micro and 
macroalbuminuria and impaired renal function) all contributed to 
increased hazard ratios for both all cause and cardiovascular death. 
While the trial did include people aged over 75 years no hazard 
ratios were presented specifically for these age groups(295). In the 
U. K. a five year retrospective study of type 2 diabetes in Manchester 
showed that proteinuria was associated with all cause and 
cardiovascular death. In patients with an average age of 58.2 years 
mortality was directly related to increasing proteinuria. For each log 
unit increase in proteinuria a 36% excess risk of mortality was 
observed. The hazard ratio for cardiovascular disease in patients 
with nephropathy (proteinuria or raised creatinine) was 5.56 (1.62- 
19.06) p=0.006(65). Globally, Fuller et al(291), used the WHO 
MSVDD study to demonstrate that proteinuria was an independent 
risk factor for cardiovascular death. The study demonstrated that in 
type 2 diabetes the relative risk of cardiovascular death continued to 
increase for both men and women with diabetes as proteinuria 
increased from no proteinuria, to light proteinuria and to heavy 
proteinuria. The South Tees study was the only study published 
which assessed the affect of altered renal function and death in the 
older diabetic person. They showed that creatinine above 150 pmol/I 
markedly increased the death rate in type 2 diabetic people aged 
over 80 years compared to diabetic people with creatinine less than 
150 pmol/I of the same age, relative rate 1.92 (1.60-2.31). The 30 
people with raised creatinine had an all cause death rate (per 1000 
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person years) of 260.90 (95% Cl, 202.35-319.46), relative rate 1.92 
(1.60-2.31)(60). 
Worsening GFR, before the onset of ESRD, has been linked to 
death and cardiovascular disease(296). This large survey used the 
Kaiser Permanente Renal Registry to identify people with renal 
insufficiency, but not ESRD. They demonstrated that both the risk of 
death and cardiovascular disease increased with decreasing GFR. 
There is very little evidence available for renal death, diabetes and 
the older person but it is likely that diabetes increases the renal 
death rate in older people. Proteinuria, renal impairment and 
worsening GFR have been established as independent predictors of 
death in older diabetic people. However, this thesis provided a larger 
population on which to test those findings. 
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8.3 Methods 
8.3.1 Identification of participants In the MRC trial who died 
All participants were registered with the Office for National Statistics 
(ONS) who provided information on date and coded cause of death 
(including any cause mentioned on the death certificate and the 
underlying cause of death). The ONS used the International 
Classification of Diseases, 9th revision (ICD-9) for deaths reported 
up to September 2002 (86% of the deaths analysed for this thesis) 
and the 10th revision (ICD-10) after that date. Analyses were based 
on deaths for all cause mortality, circulatory mortality and renal 
mortality. The cause of death used in the MRC trial was the cause of 
death identified by the ONS, as the underlying cause of death on the 
death certificate. Underlying causes coded as circulatory used codes 
390-459 in ICD9 and 11-199 in ICD10, and for renal disease used 
codes 580-589 in ICD 9 and codes N00-N19 in ICD10. Changes in 
coding between ICD9 and ICD10 did not affect the broad 
classifications used in this thesis. 
A previous estimate from English and Welsh death certificates 
suggested that diabetes was recorded (either immediate cause of 
death or any mention of diabetes) in 67% of people who have 
diabetes(297) These findings were found to have worsened over 
recent years. The analysis of the death certificates of participants in 
the UKPDS was published (on-line) in 2005. There were 981 deaths 
in their solely diabetic population and diabetes (any record) was 
found on only 419 (42%) of the death certificates(298). In the MRC 
trial diabetes was recorded on some certificates, however this was 
likely to underestimate the true figure by at least 30%, but the recent 
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UKPDS paper suggested a lot more. Therefore diabetes as a cause 
of death was not considered further. 
Practices and patients were recruited during four years (1995 to end 
1998), mortality analyses were based on the first five years of follow- 
up for every eligible patient from baseline to ensure that all 
individuals had potentially the same length of follow-up. Information 
regarding death was complete up to the end of October 2003. All 
trial participants who were analysed in this thesis either died within 
five years or completed five years of follow up. 
8.3.2 Analysis 
There were 51787 (98.8%) participants out of 52401 who entered 
the original trial, regardless of their responder status, who were 
registered for mortality flagging. Death records were not complete 
because some of the records were deemed unreliable and some of 
the trial participants had emigrated. 
In order to make comparisons between the responders and non 
responders, death rates, hazard ratios and Kaplan-Meier survival 
plots were generated. Death, age and sex were the only variables 
which were available for the non responders and therefore these 
results were presented after adjustment of age group and sex. It was 
not possible to assess the affect of other factors on non responding 
participants. 
Rates of death were calculated for participants with and without 
diabetes. These were calculated per 1000 persons per year. All 
cause mortality, mortality within each age group and by sex are 
given for all cause, circulatory and renal mortality. All cause and 
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circulatory death rates within age group and by sex were also 
calculated for diabetic people with and without proteinuria and raised 
creatinine. Circulatory mortality did not include heart failure, which is 
coded differently in the ICD classification. 
Cox proportional hazards models were constructed allowing for 
clustering by practice. All the possible potential explanatory factors 
discussed in this thesis were incorporated in the model. These were 
age group, sex, smoking status, BMI, WHR, previous history of 
myocardial infarction, previous history of cerebrovascular disease, 
proteinuria, raised creatinine, systolic blood pressure >130 mmHg, 
diastolic blood pressure >80 mmHg, any one to call for help, poor 
self rated health, quintile of Carstairs index, MMSE<=23 and high 
alcohol intake. After the addition of each variable to the model visual 
inspection of the proportional hazard ratio was undertaken to ensure 
that it was maintained. The proportional hazards ratio was also 
tested. Any changes in the hazard ratio were observed. In order to 
maintain the most parsimonious model possible variables were only 
left in the final model if the hazard ratio for death, changed by five 
percent and the proportional hazard testing was not significant, 
p>0.05, (significance indicates a departure from proportionality). 
Kaplin-Meier survival graphs were created for all cause mortality for 
the five year period of follow up. For all cause mortality they are 
presented for trial non responders compared with responders, 
diabetic participants versus non diabetic participants, diabetic 
participants with and without proteinuria and diabetic participants 
with and without raised creatinine. Survival graphs are also 
presented for diabetic and non diabetic subjects for circulatory and 
renal mortality. Circulatory mortality survival graphs are also 
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presented for diabetic subjects with and without proteinuria and 
raised creatinine. All the Kaplan-Meier survival graphs were adjusted 
for any variables included in the final Cox model. 
Chapters 3 and 6 of this thesis raised interesting questions about 
GFR calculated using the MDRD modified equation. Chapter 3 
suggested that despite higher mean creatinine in diabetic people 
than non diabetic people, mean GFR was not different between 
people with and without diabetes. Chapter 6 showed worsening GFR 
was a good predictor of macrovascular disease in people with 
diabetes. In order to further test the validity of GFR in the older 
person a hazard ratio for death for decreased GFR was calculated. 
GFR was assessed for each unit change in GFR and for GFR above 
and below 60 ml/min per 1.73 m2. This was performed in the non 
and the diabetic populations for all cause death, circulatory and 
renal death. 
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8.4 Results 
8.4.1 The relationship between questionnaire response and 
mortality 
There were 21140 people randomised to the universal arm of the 
MRC trial, of whom 15095 (71.4%) responded to the detailed 
assessment. There were 2842 (47.0%) deaths out of a total of 6315 
non responders and 5072 (33.6%) deaths in the 15095 people who 
responded. The rate of death per 1000 persons per year was 119.4 
(95%Cl, 109.7-130.3) in the non responding group and 80.3 (76.3- 
84.5) in those who responded. The unadjusted hazard ratio for death 
in the non responding group compared to the responding group was 
1.49 (1.38-1.62), p<0.001. There was no evidence of departure from 
the proportional hazards assumption, p=0.26. The Kaplan-Meier 
survival plot is shown below in figure 8.1. Apart from death, the MRC 
trial only contained information regarding age and sex for the non 
responding participants. After adjustment for age and sex the hazard 
ratio for death comparing the non responding group versus the 
responding group was 1.44 (1.33-1.56), p<0.001. 
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Figure 8.1. Kaplan-Meier survival estimates by responder status 
8.4.2 Total numbers of deaths and death rates for diabetic 
participants in the MRC trial 
The overall numbers and rate of death for the whole cohort were 
given above in section 8.4.1. For the responding participants; in the 
75-79 years age group there were 1612 (22.89%) deaths out of a 
total population of 7042 in the five year follow up period. In the 80-84 
year group 1640 (34.47%) deaths out of 4758 people, in the 85-89 
years group 1236 (50.63%) deaths out of 2441 people and in the 90 
plus age group there were 584 (68.38%) deaths out of 854 people. 
In the diabetic population there were 517 deaths (43.93%) out of a 
total diabetic population of 1177. For the diabetic population the total 
numbers of deaths were; 200 (34.19%) deaths from the 585 diabetic 
people aged 75-79 years, 161 deaths (44.23%) of the 364 people 
aged 80-84 years with diabetes, 110 deaths (65.87%) of the 167 
people with diabetes aged 85-89 years and 46 deaths (74.41 %) of 
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the 61 people aged over 90 years with diabetes. The rates of death 
for all cause mortality are given for age and sex in table 8.1. 
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In the whole population there were 2720 (53.6%) deaths for which 
circulatory disease was listed as the underlying cause of death, out 
of a total of 5072 deaths. There were 285 (55.1 %) deaths in the 
diabetic participants whose underlying cause of death was listed as 
circulatory disease out of a total of 517 deaths. The overall rate and 
rates by sex and age group are shown for circulatory mortality in 
table 8.2. 
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Renal disease was listed as the underlying cause of death in 109 
(2.1%) of all 5072 deaths. This figure was 17 (2.9%) in the diabetic 
population, which had 517 deaths. The overall rate and rates by sex 
and age group are shown for renal mortality in table 8.3. Please note 
that some of the age and sex specific groups contained less than 
three deaths which made statistical analysis unreliable due to the 
small numbers. 
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Chapter 8 Mortality and diabetes in the older person 
Rates are also presented for all cause mortality for diabetic 
participants with and diabetic participants without proteinuria and 
raised creatinine. The rates are presented in terms of the overall rate 
and by age group and gender. The results are shown in tables 8.4 
and 8.5. 
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Chapter 8 Mortality and diabetes in the older person 
Finally rates are presented for all circulatory mortality for diabetic 
participants with and without proteinuria and raised creatinine. The 
rates are presented in terms of the overall rate and by age group 
and gender. The results are shown in tables 8.6-7. 
Rates of renal mortality in relation to proteinuria and raised 
creatinine were not calculated for specific age groups and gender. 
This was because of the low number of diabetic people who suffered 
from renal mortality made the majority of the rates meaningless, due 
to the low numbers within each group, when specific age group and 
sex analysis was attempted. However, overall rates and hazard 
ratios for men and women of all ages were calculated (the results of 
which are shown in section 8.4.9). 
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Chapter 8 Mortality and diabetes in the older person 
8.4.3 Hazard ratios for all cause mortality for people with 
diabetes compared to those without diabetes 
The final adjusted hazard ratio for death due to diabetes for men and 
women aged over 75 years was 1.50 (95% Cl, 1.38-1.65). The crude 
unadjusted hazard ratio for death from diabetes was 1.48 (95% Cl, 
1.35-1.61). The Cox proportional hazard model (and hazard ratio) is 
shown for every variable tested in table 8.8. When every possible 
variable was included in the model the adjusted hazard ratio was 
1.42 (95%Cl, 1.27-1.59). However, this was not a parsimonious 
model and does not conform to the predetermined modelling 
strategy; significance within the model and large alteration of the 
hazard ratio. The table shows that systolic blood pressure over 130 
mmHg, diastolic blood pressure over 80 mmHg, having no one to 
call for help, difficulty making ends meet, living alone and high 
alcohol intake (men or women), waist hip ratio above 0.9 (men only) 
were not significant in the model containing every variable. They 
were excluded from the model and not used further. 
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Hazard Ratio, (95% Cl) P value 
Crude HR diabetes 1.48 (1.35-1.61) H 
Adjusted HR diabetes 1.42 (1.27-1.59) <0.001 
Variable* 
Age group 75-79 1 (-) 
(years) 80-84 1.56 (1.44-1.70) <0.001 
85-89 2.46 (2.21-2.76) <0.001 
90 plus 4.60 (3.98-5.33) <0.001 
Sex Male 1 (-) 
Female 0.74 (0.69-0.80) <0.001 
Smoking Never 1 (-) 
Ex-smokers 1.20 (1.11-1.30) <0.001 
Current 1.67 (1.46-1.91) <0.001 
BMI <18.5 Kg/m2 1 (-) 
18.5-25 0.57 (0.47-0.69) <0.001 
25-30 0.44 (0.36-0.52) <0.001 
>30 0.48 (0.39-0.58) <0.001 
WHR Men (<0.90) 0.90 (0.80-1.01) 0.08 
Women (<0.85) 1.25 (1.16-1.36) <0.001 
Previous MI 1.51 (1.36-1.66) <0.001 
Previous CVA 1.40 (1.21-1.62) <0.001 
Proteinuria 1.35 (1.20-1.53) <0.001 
Raised Creatinine 1.53 (1.38-1.69) <0.001 
Systolic blood pressure >130 mmHg 0.97 (0.88-1.07) 0.51 
Diastolic blood pressure >80 mmHg 1.01 (0.94-1.09) 0.75 
Anyone to call for help 1.10 (0.87-1.39) 0.43 
Poor self rated health 1.98 (1.47-2.67) <0,001 
Difficulty making ends meet 0.96 (0.79-1.17) 0.72 
Living alone 1.03 (0.96-1.11) 0.36 
More than one fall in the last 6 months 1.27 (1.15-1.39) <0.001 
Taking more than 5 medications 1.49 (1.37-1.61) <0.001 
Carstairs index 1st (highest) 1 (-) 
2nd 1.13 (1.00-1.27) 0.04 
3rd 1.15 (0.99-1.34) 0.07 
4th 1.17 (1.02-1.33) 0.02 
5th (lowest) 1.26 (1.10-1.44) <0.01 
MMSE <=23** 1.42 (1.27-1.59) <0.001 
High alcohol Men 1.07 (0.88-1.32) 0.48 
Women 0.78 (0.54-1.13) 0.18 
rahIP s_8 Hazard ratio for diabetes us ina all variables 
*All variables mutually adjusted **indicates cognitive impairment 
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The other criteria for inclusion in the final model were the affect each 
variable had on the adjusted hazard ratio for diabetes. These are 
shown in table 8.9 after the subsequent inclusion of each additional 
variable. Age and sex both altered the crude hazard ratio by 
approximately five percent. Age and sex are both factors that one 
would have expected to include in an adjusted hazard ratio. The 
other variables are therefore presented after they have been 
adjusted for age and sex. The table shows that in each instance 
none of the variables alters the hazard ratio by more than five 
percent. Therefore the final parsimonious model contains only age 
and sex. The final adjusted hazard ratio for death from diabetes was 
therefore 1.50 (95% Cl, 1.38-1.65). 
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Hazard Ratio, (95% CI P value 
Crude HR diabetes 1.48 (1.35-1.61) 
Variable Adjusted HR diabetes 
Age group 1.55 (1.42-1.96) <0.001 
Sex* 1.50 (1.38-1.65) <0.001 
Smoking" 1.53 (1.39-1.67) <0.001 
BMI" 1.53 (1.38-1.67) <0.001 
WHR (women)* 1.43 (1.. 24-1.65) <0.001 
More then one fall 1.48 (1.34-1.56) <0.001 
in the last six months" 
Greater than 5 mdeciations" 1.43 (1.30-1.56) <0.001 
Previous MI" 1.51 (1.36-1.66) <0.001 
Previous CVA" 1.47 (1.34-1.61) <0.001 
Proteinuria" 1.49 (1.35-1.65) <0.001 
Raised Creatinine" 1.46 (1.34-1.60) <0.001 
Poor self rated health" 1.53 (1.39-1.67) <0.001 
Carstairs index" 1.49 (1.36-1.64) <0.001 
MMSE" 1.48 1.35-1.62 <0.001 
Table 8.9 Hazard ratio for diabetes after adjustment for individual variables 
*Adjusted for age, AAdjusted for age and sex 
The Kaplan-Meier survival graph for all cause mortality for people 
with and without diabetes is given in figure 8.2. 
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Figure 8.2. Kaplan-Meier survival estimates for all cause mortality 
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8.4.4 Age and sex specific hazard ratios for all cause mortality 
in people with diabetes 
Hazard ratios were calculated for each age group (75-79 years, 80- 
84 years, 85-89 years and 90 plus years) for men and women. The 
results are shown in table 8.10. 
Hazard ratio (95% Cl) P ealue 
Men 75-79 years 1.55 (1.27-1.89) <0.001 
80-84 years 1.47 (1.16-1.86) 0.002 
85-89 years 1.62 (1.25-2.11) <0.001 
90 plus 1 19 (0.66-2.15) 0.56 
Women 75-79 years 1.70 (1.33-2.17) <0.001 
" 80-84 years 1.42 (1.14-1.78) 0.002 
85-89 years 1.52 (1.17-1.97) 0.002 
90 plus 1.27 (0.91-1.78) 0.17 
Table 8.10 Age and sex specific hazard ratlos for diabetes 
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8.4.5 Hazard ratios for all cause mortality for people with 
diabetes and renal impairment 
The unadjusted all cause mortality ratio for diabetic people who had 
proteinuria compared with diabetic people without proteinuria was 
1.51 (95% Cl 1.21-1.87). After adjustment for age and sex this was 
1.54 (95% Cl 1.28-1.84), p<0.001. Survival in diabetic people with 
and without proteinuria, adjusted for age and sex, is shown in the IF, 
Kaplan-Meier survival graph (figure 8.3). 
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Figure 8.3. Kaplan-Meier survival estimates for diabetic people with and without protenuia 
The unadjusted all cause mortality ratio for diabetic people who had 
raised creatinine was 1.78 (95% Cl 1.42-2.24). After adjustment for 
age and sex this was 1.53 (95% Cl 1.19-1.98), p=0.001. The 
addition of further variables were not significant in the Cox 
proportional model and hence not included. Survival in diabetic 
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people with and without raised creatinine, adjusted for age and sex, 
is shown in the Kaplan-Meier survival graph (figure 8.4). 
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Figure 8.4. Kaplan-Meier survival estimates for diabetic people with and without rasied creatnine 
8.4.6 Hazard ratios for circulatory mortality in people with 
diabetes 
The unadjusted hazard ratio for circulatory mortality in people with 
diabetes compared with non diabetic people was 1.57 (95% Cl, 
1.39-1.77). When all possible factors were tested in the Cox 
proportional hazards model raised systolic, raised diastolic, anyone 
to call for help and alcohol were not significant and were excluded 
from future use. When the remaining variables were assessed, to 
ascertain their affect on the hazard ratio, five were found to alter the 
hazard ratio by over five percent. These were age group, sex, 
previous myocardial infarction previous cerebrovascular accident 
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and raised creatinine (all, p<0.001). The final parsimonious model 
included all of these factors. None of the other variables altered the 
hazard ratio for circulatory death to an extent which warranted their 
inclusion in the model. Therefore after adjustment for age group, 
sex, previous myocardial infarction, previous cerebrovascular 
accident and raised creatinine the hazard ratio for circulatory death 
in people with diabetes compared to people without diabetes was 
1.40 (95% Cl, 1.22-1.60). No other variables were significant in the 
final model. The adjusted Kaplan-Meier survival plot is shown in 
figure 8.5 for circulatory mortality. Note the change of scale on the y- 
axis. 
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Figure 8.5. Kaplan-Meier survival estimates for circulatory mortality 
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8.4.7 Hazard ratios for circulatory mortality In people with 
diabetes and renal impairment 
In diabetic participants with proteinuria the unadjusted hazard ratio 
was 1.46 (95% Cl, 1.12-1.91) compared to diabetic people without 
proteinuria. The adjusted hazard ratio was 1.41 (1.10-1.81). The 
variables which remained significant in the final model were age 
group (p<0.001) previous myocardial infarction (p<0.001) and 
previous cerebrovascular accident (p=0.007). Sex was not 
significant (p=0.84). No other variables were significant in the final 
model. In diabetic participants with raised creatinine the unadjusted 
hazard ratio for circulatory death was 1.79 (95% Cl, 1.24-2.59) 
compared to diabetic people without raised creatinine. The adjusted 
hazard ratio comparing was 1.54 (1.02-2.36) p=0.039. The factors 
which remained significant within the model were age group 
(p<0.001), previous myocardial infarction (p<0.001) and previous 
cerebrovascular accident (p=0.032). Sex was not significant 
(p=0.781). No other variables were significant in the final model. The 
adjusted Kaplan-Meier survival graphs for circulatory mortality and 
diabetic people with proteinuria and raised creatinine are shown in 
figures 8.6 and 8.7. 
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Figure 8.6. Kaplan-Meier survival estimates for circulatory mortality in diabetic participants 
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Figure 8.7. Kaplan-Meier survival estimates for crculatory mortality in diabetic participants 
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8.4.8 Hazard ratios for renal mortality in people with diabetes 
The unadjusted hazard ratio for renal mortality in trial participants 
with diabetes compared to trial participants without diabetes was 
2.45 (95% Cl, 1.53-3.94). After adjustment the hazard ratio was 1.98 
(1.14-3.44) (p=0.015) comparing the two groups (people with and 
without diabetes). Age group (p<0.001), raised creatinine (p<0.001) 
and proteinuria (p=0.003) were all significant in the final model. Sex 
was not significant within the model (p=0.334). No other variables 
were significant in the final model. The adjusted Kaplan-Meier 
survival graph is shown in figure 8.8, note the change of scale on the 
y-axis. 
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Figure 8.8. Kaplan-Meier survival estimates for renal mortality in diabetic participants 
8.4.9 Hazard ratios and rates of death for renal mortality for 
people with diabetes and renal impairment 
The unadjusted hazard ratios for renal mortality in diabetic people 
with and without proteinuria and raised creatinine were 4.01 (1.41- 
12.05) and 3.42 (1.12-10.26) respectively. After adjustment for age 
group and sex they were 2.90 (0.75-11.12) and 3.31 (0.91-12.38) 
respectively. However, both of these results should be treated with 
caution as visual inspection of the proportional hazards ratio showed 
that neither ratio was maintained. 
The rate of renal mortality (per 1000 person years) for people with 
diabetes of both genders and all ages with proteinuria compared to 
those without proteinuria was 8.9 (4.0-22.6) (676 years of follow up) 
vs 2.2 (1.1-5.0) (3593 person years of follow up). The rate of renal 
mortality (per 1000 person years) for people with diabetes of both 
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genders and all ages with raised creatinine compared to those 
without raised creatinine was 6.1 (2.7-16.4) (821 years of follow up) 
vs 1.8 (0.9-4.6) (3245 person years of follow up). 
8.4.10 Hazard ratios for GFR for all cause, circulatory and renal 
mortality 
The hazard ratio for each unit increase in GFR and all cause 
mortality was 0.98 (0.98-0.99, p<0.001) for the non diabetic 
population and 0.99 (0.98-0.99, p<0.01) for the diabetic population. 
The hazard ratios for all cause mortality were unadjusted. No 
variable was found to alter the hazard ratio significantly. Age and 
sex have been used in the calculation of GFR using the MDRD 
equation and were therefore not included in the Cox proportional 
model. 
The hazard ratio for circulatory disease and each unit increase in 
GFR was 0.98 (0.98-0.98, p<0.001) in the non diabetic population 
and 0.98 (0.97-0.99, p<0.01) in the diabetic population. For renal 
death the hazard ratio for each unit increase in GFR was 0.95 (0.92- 
0.98, p<0.01) for the non diabetic population and 0.94 (0.88-0.97, 
p=0.04) for the diabetic population. All the final Cox models 
remained unadjusted because no variables were found to improve 
the final models and were therefore not used. 
The hazard ratio for GFR below 60 ml/min per 1.73 m2 and all cause 
mortality was 1.32 (1.01-1.44, p<0.001) for the non diabetic 
population and 1.21 (0.99-1.48, p=0.06) for the diabetic population. 
The hazard ratios for all cause mortality were unadjusted. The 
hazard ratio for circulatory disease and GFR below 60 ml/min per 
1.73 m2 was 1.54 (1.36-1.75, p<0.001) in the non diabetic population 
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and 1.45 (1.08-1.96, p=0.01) in the diabetic population. For renal 
death the hazard ratio for GFR below 60 ml/min per 1.73 m2 was 
1.86 (1.08-. 322, p=0.03) for the non diabetic population and 2.25 
(0.67-7.61, p=0.19) for the diabetic population. The hazard ratios 
were again unadjusted. 
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8.5 Discussion 
8.5.1 Introduction 
The results presented in this thesis represent the most 
comprehensive estimate of mortality rates and cause of death in 
the older diabetic person undertaken in the UK. The results for 
the very oldest age groups (over 90 years) appear to be the first 
estimates of the risk and rate of death to be described. 
8.5.2 Non responding participants 
The increased numbers of deaths and the raised hazard ratios for 
death of the non responding participants compared to the 
responding participants were consistent with the results one 
would have expected. Each result showed that non responders 
were more likely to die than responders. Non responders had a 
higher proportion of deaths, 47.0% vs 33.6%, a higher rate of 
death (per 1000 person years), 119.4 (109.7-130.3) vs 80.3 
(76.3-84.5) and an increased hazard ratio for death 1.49 (1.38- 
1.62) vs 1.0. 
It is extremely difficult to ensure complete participation of eligible 
people in any cohort study. People who do agree to participate 
are likely to be different from those who do not participate(299). 
Participants may vary in several ways. They may have different 
levels of attitudes towards health, personal motivation, risk factor 
status and be in poorer health(300). The MRC trial did not contain 
information regarding exposure status for any of the non 
responders (other than age and sex). It contained data relating to 
death; outcome data. Therefore, in the MRC study, non response 
could only be related to outcome. In epidemiological studies when 
only outcome data is available for every participant involved in the 
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study, regardless of responder status, the death rates generated 
for the responding participants will be an underestimate. This is 
due to the overall poorer health of those who did not respond. 
However, beyond simply reporting the increased death rates for 
all ages and genders and highlighting the possible reasons for 
this, no further information regarding these people existed in the 
MRC trial. Further information was unavailable as it was deemed 
unethical to obtain additional information in people without their 
consent. Therefore non responders could not be described 
further. 
8.5.3 Hazard ratios and rates of death for diabetes and all 
cause mortality 
8.5.3.1 The Hazard ratio and the statistical model used 
In the final model, the hazard ratio for death in people aged over 
75 years with diabetes compared to those without diabetes was 
1.50 (1.38-1.65), p<0.001. The figure was only adjusted for age 
and sex. The hazard ratio for the saturated model, which included 
all potential variables in the Cox proportional hazard model, was 
1.42 (1.27-1.59). The reasons that I chose one model over the 
other and only adjusted for age group and sex warrant 
discussion. Firstly, the predetermined modelling strategy stated 
that factors would only be included in the final model if they were 
significant within that model and altered the hazard ratio by at 
least five percent; only age and sex met these criteria. While the 
hazard ratio for the saturated model differed from the overall 
hazard ratio by five percent no single variable other than age and 
sex altered it significantly and hence were not included. Secondly, 
variables were decided a priori. Therefore every variable, used 
during the course the thesis, was tested in the Cox proportional 
hazard model. Finally the use of the most parsimonious model as 
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possible has many advantages; primarily simplicity and 
reproducibility. My final model was extremely parsimonious. 
8.5.3.2 The hazard ratio and death rates for different age groups and 
gender 
The results of the MRC trial showed that diabetes continued to 
be a contributory factor for death until the extremes of old age, in 
both men and women. The adjusted hazard ratios for death in 
people with diabetes were consistently elevated until above the 
age of 90 years. Prior to 90 years of age the hazard ratios did not 
show any increasing or decreasing trends and were all 
approximately 1.50. Gender did not produce different results. For 
both men and women the hazard ratios for death were above one 
and did not differ to any large extent between the sexes. Above 
the age of 90 years the hazard ratio remained above one but the 
95% confidence interval encompassed one for both men and 
women. However, the absolute rate of death was higher for men 
and the low number of deaths (14) and wide confidence intervals 
for men with diabetes aged over 90 years should be highlighted. 
It was therefore likely that a lack of statistical power was 
responsible for failure to clearly demonstrate a difference in the 
rate of death or hazard ratio for the oldest groups of men and 
women with diabetes. 
8.5.3.3 How did the results from the MRC trial compare with other trial 
results? 
The problems drawing comparisons with other studies 
The MRC trial generated hazard ratios and rates of death for four 
age groups above 75 years and for both sexes. Therefore the 
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results could not be compared exactly to all the studies which 
were discussed in the introduction to this chapter, as many of 
them did not provide results for the same groupings. For 
example, the most comparable study to the MRC study was the 
large self reported questionnaire conducted in Canada(161). The 
results produced from the Canadian study were only presented 
for a combined group of men and women aged over 65 years, 
without providing subgroup analysis. In addition, the trial results 
discussed in the introduction provided a variety of "estimates" of 
death; relative rate of death, death rates, hazard ratios, relative 
risks or Standardised Mortality Ratios and therefore direct 
statistical comparison was difficult. In spite of these limitations, I 
have made attempts to compare my results with those from 
previous trials. I have done so my comparing my results in terms 
of age group and by gender as closely as possible to previous 
studies. 
Age group 
My results for the hazard ratios of death from all cause mortality 
were different to the other studies reported. The hazard ratios 
generated from the MRC trial for people aged 80-84 years and 
85-89 years were higher than previous estimates. Previous trials 
showed that the effect estimates for death comparing people with 
and people without diabetes, while remaining elevated, tended to 
become nearer one with increasing age(57; 58; 60; 279; 285). Each 
study showed that the affect of diabetes tended to decrease, 
while remaining elevated, with each increase in age group. None 
of these studies specifically reported hazard ratios for people 
aged over 90 years. The five most comparable studies included 
the Melton study lead by Croxson(279), the Italian study by Bruno 
et al(58), the US Medicare study(57), the Verona diabetes 
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study(285) and the South Tees study(60). The Melton study i 
showed that the hazard ratio for death from diabetes decreased 
from 6.96 (2.99-16.21) for ages 75-79 years, to 2.48 (0.78-7.86) 
for ages 80-84 years and 1.34 (0.37-4.93) for people aged over 
85 years. The author noted that the confidence intervals were 
wide due to sample size and low numbers of deaths(301). The 
Italian study calculated SMRs for a combined group of men and 
women with diabetes. The SMRs declined from 1.86 (1.52-2.25) 
for people aged 60-69 years to 1.12 (0.98-1.27) for people aged 
over 80. The Medicare study showed that the relative risk of 
death from diabetes declined from 2.11 (2.05-2.17) for people 
aged 75-79 years, 1.85 (1.80-1.90) for those aged 80-84 years 
and 1.46 (1.43-1.49) for those aged over 85 years. In the Verona 
diabetes study SMRs declined markedly with increasing age 
group. In the oldest age group (75 plus years) the SMR was 1.13 
(1.00-1.28) for men and 1.32 (1.20-1.44) for women. While the 
South Tees study did not use exactly the same age groupings as 
other studies, the results again showed decreasing relative risks 
of death with increasing age group. For people aged 60-79 years 
the relative risk of death was 1.96 (1.74-2.21) for men and 1.41 
(1.28-1.56) for women. In the oldest age group (80 plus years) 
the relative risks were 1.25 (1.09-1.43) for men and 1.09 (0.92- 
1.29) for women. 
There were two previous studies which published actual rates of 
death(60; 288). The first study was conducted by McBean which 
calculated death rates in people with diabetes, for the single year 
2001, using the Medicare system (288). Their results showed a 
death rate (per 1000 persons per year) of 75.1 for people aged 
75-79 years, 112.5 for ages 80.84 years and 202.2 for ages over 
85 years. The results obtained from the MRC trial were similar; for 
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the same age groups the results were 81.8,116.0 and 201.9, 
respectively. The rate for those aged over 90 was 268.2, in the 
MRC trial. Both studies were undertaken at approximately the 
same time, among predominantly white populations. Comparison 
of the two studies showed that the rates of death for people with 
diabetes in the UK were not different to those in North America, 
although direct comparison of rates between the studies may 
have been inappropriate. The Medicare study was based on 
claims data, the sensitivity of which has been estimated to be 
63.4%. This is a lot lower than that obtained for the MRC trial, 
estimated as 88.5% (see section 3.6.8). Consequently the 
American study may have represented the true rates in North 
America for Medicare claimants, while the MRC trial was a more 
accurate representation of the true rate of death for people living 
in the community with diabetes in the U. K. The Medicare study 
was undertaken to assess changes in death rate and incidence 
since 1994, with 2001 being the last year recorded. Therefore it 
did not include comparisons with non diabetic groups and it was 
not possible to assess whether the affect of diabetes on mortality 
declined with increasing age from this study. The second study 
which published rates was the South Tees group. They South 
Tees group published the rates of death from which the relative 
rates of death were calculated for men and women(60). The rate 
of death for the men aged over 80 years was 155.56 (95% Cl, 
143.67-167.45) and 134.55 (127.70-141.41) for women. The 
results from the MRC trial were 144.0 (114.8-182.0), 244.4 
(186.8-321.8) and 327.5 (200.0-538.4) for men aged 80-84 years, 
85-89 years and 90 plus years respectively The rates of death for 
same age groups of women were 98.1 (78.8-122.7), 117.2 
(140.3-223.7) and 248.5 (187.4-332.1). Both sets of results would 
appear to be similar, with the South Tees results reflecting an 
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average figure of the MRC trial results if all the different age 
groups had been combined. 
Gender 
The hazard ratios for mortality comparing people with and people 
without diabetes for both men and women were both raised until 
past the age of 90 years. They were all approximately 1.50 and 
did not differ between the sexes. This contrasted with many of the 
previous studies which have shown inconsistent affects of 
sex(285-287; 301; 302). In the Melton study, after 4.5 years of 
follow up men aged over 75 years had a survival of under 40% 
compared to over 50% for women. The large Medicare study 
showed that compared to men with diabetes aged over 65 years 
women had a higher relative risk of death; 1.34 (1.31-1.38). The 
Danish study showed that relative risks of death were higher for 
women of 75-79 years and 80-84 years; 1.24 vs 0.98 and 1.19 vs 
1.02 for the two groups. The Verona diabetes study found SMRs 
for men aged over 75 years to be 1.13 (1.00-1.28) which were 
lower than women 1.32 (1.20-1.44). The South Tees data which 
was described above, showed that in addition to decreasing 
hazard ratios as diabetic people got older, men had consistently 
higher hazard ratios than women. 
8.5.3.4 Why did the MRC trial produce different results than previous 
studies? 
Due to the size of MRC trial and the large numbers of elderly 
diabetic people involved it was likely that the results generated for 
age reflect the true affect of diabetes in the older person. 
Previous estimates were derived from studies that may not have 
been big enough to detect true differences. And this lack of 
statistical strength, seen in the other studies, should be 
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highlighted as a limitation in the MRC trial in the very oldest age 
groups. 
Do the similar hazard ratios for all cause mortality generated for 
men and women represent true results? Why should men and 
women suffer different biological outcomes from a disease which 
affects men and women equally. Some of the previous studies 
which found a higher affect of diabetes in women attributed the 
results to a survivor affect(285-287). The men were more likely to 
die from diabetes before they reached older age than women. 
Once men had become elders the affect the diabetes decreased 
and tended to contribute to death equally for men and women. 
Were some of the previous differences between sexes 
attributable to the age of diagnosis of diabetes? The paper by 
Tan et al(290) suggested that women but not men diagnosed with 
diabetes at older age had an increased chance of death. The 
MRC trial did not provide the age of diagnosis of diabetes and 
hence this theory could not be tested using the MRC trial and 
must remain a possibility. 
8.5.3.5 Other potential biases of the MRC trial 
The number of deaths increased massively in all people aged 
over 90 years, with more than 20% of people aged over 90 years 
dying each year. The yearly rate of death for people aged over 90 
years without diabetes was 214.5 per 1000 people and 268.2 per 
1000 people with diabetes. However, in absolute terms only 6% 
more people aged over 90 years with diabetes died than people 
aged over 90 years without diabetes over the five year follow up 
period. It was possible, that due to the extremely high mortality 
rate from all causes at this age, diabetes had little or no affect. 
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Could the decreased affect of diabetes in those aged over 90 
years have been due to the survivor effect? In a cohort of people 
with diabetes surviving to older age, diabetes may have already 
killed susceptible people. This explanation did though seem 
unlikely. Why should simply living to over 90, rather than ones 
mid to late eighties, lead to a survivor effect. Could this be a true 
effect? Is diabetes is a less dangerous condition at the extremes 
of old age? It again seems implausible that a biological disease 
should suddenly have less effect at this age, although diabetic 
older people may not live long enough to develop the 
complications of diabetes, especially if they were diagnosed with 
diabetes at an older age. 
While it is possible that any results are biased by a multitude of 
factors, why would the MRC trial results be different to those 
previously generated from other studies? As discussed elsewhere 
in this thesis (specifically chapter 9) the number of people 
detected with diabetes in the MRC trial was likely to have been an 
underestimate with consequential dilution of any affects seen. 
Similarly many of the previous studies will have also 
underestimated the true local diabetic population, either through 
the use of clinic based populations(280; 286) or through the use of 
claims data(287). Therefore insufficient case ascertainment is an 
unlikely explanation for the differences seen between the MRC 
trial and previous studies. 
Insufficient case ascertainment is also a potential (if unlikely) bias 
for all the subsequent results discussed in this chapter i. e. 
circulatory and renal death and the affect of altered renal function 
on death. However, the bias has been noted here and to avoid 
repetition it was not discussed further in this chapter. 
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It is also unlikely that (all cause) death was incorrectly registered. 
Over 99% of trial participants were registered for mortality and 
death was not distinguished on the basis of diabetes status. 
Therefore the results for the all cause mortality should not differ 
by death registration between the trial participants with diabetes 
and trial participants without diabetes. In fact, the extremely high 
rate of death registration, by the ONS, was a strength of the MRC 
trial. 
8.5.4 Hazard ratios and rates of death for diabetes and 
circulatory mortality 
The adjusted hazard ratio for death from circulatory disease in 
people with diabetes was 1.40 (1.22-1.60). The final Cox model 
used to generate this figure included previous myocardial 
infarction, previous cerebrovascular accident and raised 
creatinine, in addition to age group and sex. A history of previous 
vascular disease (cardiac or cerebral) represents existing disease 
and it was not surprising that they significantly altered the 
outcome. An extensive history of cardiac disease could also have 
increased the chances of cardiac death being recorded on the 
death certificate. Another potential confounding effect. Raised 
creatinine has also been established as a predictor of circulatory 
disease in diabetic populations(65; 295) and its effect in the Cox 
model supported that. 
The results for rates of death from circulatory death were raised 
in the diabetic groups of all ages and sex compared to the non 
diabetic group. It was worth noting the results for the male 
participants with and without diabetes. While the overall rates 
were different between the two groups 60.7 (50.6-73.6) vs 47.9 
(43.9-52.3) the results for individual age groups were very similar 
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for all groups aged over 80 years. The largest difference occurred 
between the 75-79 year age groups. This lent support to the 
hypothesis of a survivor effect amongst male diabetic people, at 
least for circulatory disease. i. e. diabetic males only succumb to 
circulatory disease at a higher rate than non diabetic males 
before the age of 80. 
The WHO MSVDD showed in a younger diabetic population that 
cardiovascular mortality accounted for 52% of deaths(292). The 
results from the older diabetic population in the MRC trial were 
remarkably similar (51%). This results suggested that there was 
no change in the overall affect of diabetes on circulatory death 
between the younger population in the WHO MSVDD and the 
older diabetic population used in the MRC trial. Direct 
comparisons with the Verona diabetes study were difficult 
because that published report provided few specific results for the 
older person(59). It concluded that diabetes contributed to 
cardiovascular disease but to a decreasing extent in people aged 
over 75 years compared to younger age groups. The MRC trial 
could not make exactly the same comparisons. However, the 
raised hazard ratio for death from circulatory causes in the older 
diabetic person implied that diabetes did contribute to circulatory 
death. The South Tees data also produced outcome measures 
for cardiovascular death in the older diabetic person. In males 
aged 60-79, the cardiovascular death rates (per 1000 person 
years) were 34.46 (31.47-37.46), and 80.50 (74.47-86.53) for 
men aged over 80 years. For the women aged 60-79 years the 
rates of death were 34.25 (30.80-37.71) and for women aged 
over 80 years 72.83 (67.62-78.04). The use of different age 
structures made direct comparisons difficult but in a similar 
manner to all cause mortality their results would seem to be a 
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composite of the results obtained from the MRC trial. The paper 
from the DARTS database which concentrated on the affect of 
the age of diagnosis of diabetes did not show any increase in 
cardiovascular disease(290). Age of diagnosis was not 
determined from the MRC trial and therefore direct comparisons 
were not possible. 
It should also be noted that circulatory disease was identified as 
the underlying cause of death from the death certificate. This 
grouping included all forms of cardiac and vascular disease. The 
vast majority would have been due to cardiac ischaemia or stroke 
but not all. For example, heart failure is another mode of death 
which frequently, but not exclusively, results from ischaemic heart 
disease. What implications does that have when interpreting the 
results generated? Firstly, it makes direct comparisons with other 
trials less reliable if those trials assessed specifically 
cardiovascular death, although it is likely that circulatory death 
and cardiovascular death represent very similar measures. 
Secondly, could the use of circulatory death biased the results 
when compared to cardiovascular death. This would seem a 
small but real possibility. If people with diabetes suffered from a 
disproportionately high or low amount of one particular form of 
circulatory death compared to the non diabetic people the results 
could have been biased. For example, did diabetic people have a 
much larger incidence of stroke death (coded as a circulatory 
death) compared to the non diabetic population? Unfortunately is 
was not possible to determine this from the data which was 
available. Finally, from a scientific perspective, it was a pity not to 
be able to differentiate between exact cardiac disease and 
cerebrovascular disease more accurately. The potential 
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inaccuracy of the recording of cardiovascular death in this study 
must be considered as a limitation. 
The reporting of cause of death was a potential source of bias in 
diabetic people with circulatory (and renal) death. Unlike all cause 
mortality, it was possible that circulatory and renal mortality were 
recorded differently between trial participants with and without 
diabetes. It is established that diabetes contributes to vascular 
and renal disease. Therefore the possibility of recording the 
cause of death and contributory causes of death differently 
between people with and people without diabetes must exist. This 
statement can also be supported from studies of death 
certificates which showed, that in addition to extremely low levels 
of reporting diabetes itself, reporting of circulatory disease was 
higher on death certificates of people with diabetes(298). While 
the similar results have not been published for renal death, 
different levels of reporting of renal disease on the death 
certificates of diabetic and non diabetic people must also exist as 
a potential bias. 
8.5.5 Hazard ratios and rates of death for diabetes and renal 
mortality 
In a younger diabetic population, the WHO MSVDD demonstrated 
renal disease in 8% of male deaths and 14% of female 
deaths(292). The MRC trial showed death rates for the whole 
diabetic cohort to be 2.9%. The percentage of deaths in male 
diabetic participants was 2.1% and 3.8% in female diabetic 
participants. While the MRC trial showed a higher percentage in 
women, overall the percentage of deaths was far lower than the 
WHO MSVDD. These results may have reflected the true figure 
of death attributable to renal disease in an elderly population. 
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However, the extremely lower numbers of overall cases recorded 
(17) and the large discrepancy between the previous figures and 
those generated by the MRC trial suggest that the figures from 
the MRC trial under represented the true figure. The most 
obvious reason for the low number of renal deaths recorded was 
that renal disease was not accurately recorded on the death 
certificate. 
However the rates of death from renal disease in the older 
diabetic person represent the largest estimate currently available. 
The results showed that for men and women combined renal 
mortality increased with age group. The other groupings were not 
really large enough for meaningful conclusions to be drawn from 
them. In addition, the adjusted hazard ratio for renal mortality in 
people with and without diabetes was raised 1.98 (1.14-3.44). 
This result clearly demonstrated that diabetes affects renal 
mortality in the older diabetic person. 
8.5.6 Hazard ratios and rates of death for people with 
diabetes and proteinuria, raised creatinine and Glomerular 
Filtration Rate 
8.5.6.1 Proteinuria and all cause mortality 
The adjusted hazard ratio for all cause mortality was raised for 
diabetic people with proteinuria compared to those without; 1.54 
(1.28-1.84), p<0.001. The rates of death were also consistently 
higher in diabetic people of all age groups and gender. 
Interestingly the rates of death for men and women were similar 
for all people aged over 75 years and for individual age groups. 
Neither was sex significant in the adjusted hazard model. These 
results implied that among people with diabetes and proteinuria 
sex did not add predictive information about the likelihood of 
292 
Chapter 8 Mortality and diabetes in the older person 
death. There were 105 deaths and 676 years of follow up which 
allowed meaningful results to be generated and thus decreasing 
the likelihood that chance was responsible for this result. 
The Manchester study by Jude et a/(65) showed that increasing 
proteinuria was associated with all cause mortality in younger 
diabetic groups. Similar results in the older diabetic person were 
supported by our findings. The large Italian study by Bo and 
colleagues(295) assessed several aspects of renal function and 
death in diabetic people of all ages. The study included some 
people aged over 75 years and showed that the hazard ratio for 
death in people with microalbuminuria was 2.08 (1.69-2.56). In 
this study microalbuminuria was defined as an albumin excretion 
rate of 20-199pg/min. The MRC study detected the presence of 
protein in the urine without quantifying the exact amount which 
made direct comparisons difficult. Regardless, the MRC study 
only included older people and confirmed that proteinuria 
continues to predict all cause mortality into older age. 
8.5.6.2 Proteinuria and circulatory mortality 
The adjusted hazard ratio for death from circulatory disease in 
diabetic people with and without proteinuria was 1.41 (1.10-1.81), 
p<0.001. The rates of death were also raised in diabetic people 
with proteinuria. However, unlike all cause mortality, women 
tended to have higher rates of death. Unfortunately the small 
number of circulatory deaths in the diabetic proteinuric group 
made the results of the death rates unreliable. 
The raised hazard ratio did imply that proteinuria predicts 
circulatory death in the older diabetic person, an idea first 
confirmed on a worldwide basis, in younger diabetic people by 
Fuller et a/ in the WHO MSVDD(303). The Italian study discussed 
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above(295) did not assess circulatory death per se but did show 
that the hazard ratio for coronary artery disease was raised (5.45 
(3.27-9.08)) in diabetic people with microalbuminuria of a mixed 
age range. 
8.5.6.3 Raised creatinine and all cause mortality 
Diabetic people with raised creatinine had an adjusted all cause 
hazard ratio for death compared to diabetic people without raised 
creatinine of 1.53 (1.19-1.98), p<0.001. The rates of death were 
consistently higher in diabetic people with raised creatinine 
compared to those with normal creatinine. Within the diabetic 
group with raised creatinine the rates of death increased with 
increasing age group and were very similar between the sexes. 
Once again, the Italian study provided a good comparison group. 
In their trial participants with raised creatinine (defined as above 
114.5 pmol/I for men and above 106.1 pmol/I for women, 
compared to above 120 pmol/I for men and women in the MRC 
trial) had a hazard ratio for all cause mortality of 3.48 (2.67-4.46). 
Another good comparison can be drawn from the South Tees 
study(60). In the 30 participants aged over 80 years with 
creatinine greater than 150 pmol/I they demonstrated a death rate 
of 260.90 (202.35-319.46). This would once again appear to be a 
composite of the combined aged groups aged above 80 years in 
the MRC trial. 
8.5.6.4 Raised creatinine and circulatory mortality 
The next group of results which needed consideration were 
between diabetic people with and without raised creatinine and 
circulatory mortality. The adjusted hazard ratio was 1.54 (1.02- 
2.36), p=0.039. The rates of death were higher for diabetic people 
with raised creatinine compared to those without raised 
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creatinine. In the group with raised creatinine the rates increased 
with age group. Women also appeared to have a higher death 
rate. It was likely that the potential sex difference may have been 
spurious. The male age group of 80-84 years appeared to be a 
very low rate hence resulting in overall bias. 
The Manchester group(65) assessed cardiovascular mortality and 
found it to be raised in younger diabetic people with renal 
impairment. They used a composite measure of "nephropathy" to 
do this. This grouping included both albuminuria and raised 
creatinine. Thus the comparisons between this study and the 
MRC trial were limited. Again the Italian study provided one of the 
best comparisons available(295). They showed that the hazard 
ratio for coronary artery disease in their diabetic participants with 
raised creatinine was 5.87 (3.08-11.2) compared to diabetic 
participants without raised creatinine. 
8.5.6.5 Renal mortality, proteinuria and raised creatinine 
Renal mortality and proteinuria in people with diabetes was 
increased. Comparing renal mortality in diabetic people with 
proteinuria to those diabetic people without proteinuria the 
mortality rate (per 1000 person years) was 8.9 (4.0-22.6) vs 2.2 
(1.1-5.0). Renal mortality in diabetic people with and without 
raised creatinine was also raised. The rate of death (per 1000 
person years) was 6.1 (2.7-16.4) vs 1.8 (0.9-4.6). While lack of 
statistical power hampered both sets of results, unsurprisingly, it 
seemed likely that renal impairment contributed to a renal cause 
of death. 
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8.5.6.6 Glomerular Filtration Rate, all cause, circulatory and renal 
mortality 
Worsening renal function, measured using the modified MDRD 
equation was shown to be a good predictor of death in both the 
diabetic and the non diabetic populations. This was true for all 
cause mortality, circulatory mortality and renal mortality. The 
associations were strongest in the non diabetic population but 
persisted in the diabetic population. These results form the first 
estimation of the ability of the GFR calculated using the MDRD 
equation to predict death in an exclusively older population. The 
results generated in this thesis support those of Go and 
colleagues(296) who showed that worsening GFR was 
associated with an increased risk of death and cardiovascular 
death in a large population with a mean age of 52.2 years. When 
GFR above and below 60 ml/min per 1.73 m2 was assessed poor 
renal function was reflected in an increased hazard ratio for all 
cause, circulatory and renal death. In the diabetic population all 
the hazard ratios were above one but the only significant result 
was for circulatory death (1.45,95%Ci 1.08-1.96, p=0.01). These 
results imply that especially in non diabetic populations GFR 
below 60 ml/min per 1.73 m2 is associated with death. 
8.6. Conclusions 
The hazard ratios obtained from this thesis represent a large and 
accurate estimate of the affect of diabetes on mortality in the 
older person. The results are different to previous estimates and 
suggested that diabetes increased mortality risk until at least the 
age of 90. It was also likely that the absence of significant results 
seen in diabetic people aged over 90 years was due to a lack of 
statistical power. In contrast to pervious studies the detrimental 
affect did not show evidence of declining but remained 
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consistently raised. The results for gender showed that mortality 
rates for men and women were equally affected by the disease. 
Diabetes affected all cause, circulatory and renal mortality. These 
findings were similar to results obtained from younger populations 
and those obtained from the South Tees study. As well as 
confirming the South Tees findings the results provided a more 
accurate picture of diabetes in a broader range of older age 
groups and gender in the U. K. 
Proteinuria, raised creatinine and decreasing GFR were also 
shown to be independent risk factors for all cause and circulatory 
mortality. 
The MRC trial results confirmed that diabetes remains an 
important cause of mortality in older people. Diabetes did not 
become more benign and therefore should be considered as an 
important health problem, on both an individual level and a 
population level in the older person. It requires health planning 
and adequate provision for the needs of the older diabetic person. 
Now the importance of diabetes has been established as an 
important issue the next logical step would be to establish 
randomised controlled trials to establish appropriate and 
beneficial care of the older person with diabetes. 
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Chapter 9. Discussion 
9.1 Introduction 
This chapter provides an overall summary of the results of this 
thesis, a general discussion of the thesis and future 
recommendations. 
General discussion of methodological and epidemiological points, 
relevant to the whole thesis are given in this section in order to avoid 
repetition within each of the previous chapters. For example, how did 
the original trial design or the selection of diabetic participants, affect 
the results generated? As discussion of some points relevant to 
specific chapters has already been provided, not all of this material 
is discussed again here in detail. 
9.2 Summary of results 
9.2.1 The prevalence of diabetes 
Due to the age of the participants in the MRC trial, only participants 
with type 2 diabetes were identified. The methods used to identify 
diabetic people were a combination of self reporting, identification of 
high random glucose, identification of diabetic medication and 
searching of selected GP records. In total, 1177 diabetic people 
were found. The total population in the MRC trial was 15095. The 
overall prevalence of diabetes was therefore calculated to be 7.80% 
(7.11-8.47). Included in this figure are 130 people who were 
classified as having diabetes based solely on a high random 
glucose. These people constitute the estimation of undiagnosed 
diabetes, which was found to be 0.86% (0.96-1.02). 
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The age specific prevalence rates were 8.31 % (7.56-8.49) for people 
aged 75-79 years, 7.65% (6.89-8.49) for 80-84 years, 6.84% (5.60- 
8.33) for 85-89 years and 7.14% (5.61-9.05) for people aged 90 plus 
years. These results are similar to previous prevalence estimates; 
namely that the prevalence of diabetes increases with age and then 
tends to plateau at the extremes of old age. The prevalence of 
diabetes was higher in men, 9.42% (8.44-10.50) than in women, 
6.79% (6.10-7.56). The prevalence estimates generated by the MRC 
trial represent the largest community based survey conducted in 
diabetic people of this age. 
By comparing the questionnaire responses with the available GP 
records, sensitivity and specificity estimates for self reported 
clinically diagnosed diabetes were calculated to be 88.5% and 
99.9% respectively. These results imply that over 10% of people had 
a diagnosis of diabetes but did not know it, while very few people 
wrongly reported having diabetes. 
9.2.2 The prevalence of the complications of diabetes 
Diabetic people had a higher prevalence of both visual impairment 
and blindness (Snellen acuity <3/60) compared to the non diabetic 
population. The prevalence of visual impairment, defined as vision 
less than Snellen acuity <6/18 in the best eye, in the diabetic 
population was 13.26%. In the non diabetic population the 
prevalence of visual impairment was 9.80%. The population 
attributable risk fractions (PAF) attributable to diabetes assuming 
complete causality, and low vision and blindness, were 3.46% and 
1.02% respectively. Direct comparisons to previous studies were 
limited because previous studies had focused on diabetic 
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retinopathy, rather than visual impairment. However, these results 
clearly show that diabetes contributes to the causes of eye disease. 
The diabetic population demonstrated an increased prevalence of 
proteinuria and raised creatinine compared to the non diabetic 
population. The prevalence rates were 15.97% and 22.65% 
respectively. In the non diabetic population the prevalence rates 
were 10.15% and 13.27% respectively. The PAF for proteinuria 
attributable to diabetes was 6.99% and for raised creatinine 5.35%. 
The results from the MRC trial represent by far the largest 
community based estimates published. Surprisingly, raised 
creatinine levels were not reflected in decreased GFR 
measurements, calculated using the MDRD equation. This point is 
expanded later in this chapter. 
Angina was more common in people with diabetes compared to 
people without diabetes. The prevalence was found to be 12.10% 
and the PAF for angina attributable to diabetes was 3.31% The 
prevalence was 10.41% in the non diabetic group. A history of 
myocardial infarction was present in 16.14% of the diabetic 
population, which was higher than the non diabetic population 
(10.62%). The PAF attributable to diabetes for myocardial infarction 
was 4.82%. Cerebrovascular accidents were also more likely to 
occur in people with diabetes compared to people without diabetes. 
The prevalence of cerebrovascular accidents was 13.94% in the 
diabetic population compared to 8.93% in the non diabetic 
population. The PAF attributable to diabetes in people who have 
suffered from a cerebrovascular accident was 2.56%. Foot 
ulcerations were also more likely to occur in diabetic people. The 
prevalence of foot ulceration was 4.14% compared to 2.80% in the 
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non diabetic population. The PAF attributable to diabetes was 
1.09%. 
9.2.3 The management and understanding of diabetes in the 
older person 
Over 96% of the people who were aware of their diabetes, were 
under the care of at least one medical professional. Similarly, over 
97% of the population reported managing their condition using at 
least one form of recognised treatment; diet, medication, insulin or a 
combination of these. These are extremely high and encouraging 
figures. 
The MRC trial assessed the use of home glucose testing, either 
urine or blood monitoring. Over 75% of the diabetic population did 
some form of testing. In the 75% of people who did test, 58% tested 
at least once per week. Roughly two thirds (63.5%) of older diabetic 
people were taking medication which was capable of inducing 
hypoglycaemia. Nearly one quarter of them (23.4%) reported 
experiencing a hypoglycaemic attack. Nearly half (48.7%) gave an 
incorrect response when asked about the correct management of 
their condition in time of illness and over 30% gave incorrect 
responses to questions about hypoglycaemia and "sick day" 
management. 
There appeared to be high levels of utilisation of specialities allied to 
diabetes. There were 77.7% of older diabetic people who had seen 
an eye specialist within the last year and 79.9% had had their feet 
examined within the last year. Less people had seen a dietician 
within the last year (31.1%). Less emphasis is placed on annual 
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dietician review, than annual eye and foot review, so this result was 
consistent with expectations. 
There was a high degree of cognitive impairment, measured using 
the Mini Mental State Examination (MMSE), within the diabetic 
population, (22.5%). This compared to 15.8% in the non diabetic 
population. There was 22.2% of people who were taking 
hypoglycaemic medication who had cognitive impairment 
(MMSE=<23). There were 19.1% of people who had a MMSE=<23 
who reported testing their blood at home. 
9.2.4 Hypertension and the older diabetic person 
The systolic blood pressure readings were similar in the people with 
and the people without diabetes. The average systolic blood 
pressure for people with diabetes was 149.3 mmHg compared to 
148.6 mmHg in the non diabetic population. There were over 80% of 
people, with and without diabetes, who had systolic blood pressure 
above 130 mmHg. 
Diastolic blood pressure was lower in people with diabetes 
compared to people without diabetes, 73.2 mmHg vs 74.7 mmHg. 
There was evidence to suggest that this may have been due to 
increased treatment in people with diabetes. 
There were no strong and consistent associations between 
hypertension and diabetic complications found in this trial. These 
results, or lack of them, may have been a reflection of the cross 
sectional trial design. This point is explored further in this chapter, 
see section 9.3.2. 
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9.2.5 Renal impairment and the older diabetic person 
Less strong associations between, proteinuria and raised creatinine, 
and diabetic endpoints were observed than may have been 
expected from the reviewed literature. The only association of note 
was observed between raised creatinine and cerebrovascular 
accidents in the diabetic population. Interestingly worsening GFR 
showed a strong association with increased macrovascular end 
points, although this relationship was not seen with microvascular 
end points. When GFR above and below 60 ml/min per 1.73 m2 was 
assessed worsening GFR was associated with diabetic end points. 
This was particularly strong in the non diabetic group. In the non 
diabetic population poor vision, angina, myocardial infarction and 
cerebrovascular accidents were all shown to be associated with a 
GFR below 60 ml/min per 1.73 m2. In the diabetic population the 
only associations demonstrated were between lower GFR and 
myocardial infarction and cerebrovascular disease. 
The observational nature of the study and secondary analysis of the 
dataset, were potential explanations for the absence of significant 
results recorded. 
9.2.6 Admission to hospital and the older diabetic person 
Diabetes contributed to an increased rate of admission to hospital 
when compared to non diabetic people of similar age and sex. Rate 
ratio, 1.31 (95% Cl, 1.23-1.39) comparing admissions in the diabetic 
population against the non diabetic population. Men with diabetes 
had a higher rate of admission to hospital than women with diabetes. 
Diabetic people also had a higher average number of admissions 
per person. The average number of admissions per person was 1.58 
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in the non diabetic population. The average number of admissions 
per diabetic person was 1.64, (p<0.001). Diabetic people spent 
longer in hospital per admission. The average length of stay was 
12.4 days and 13.9 days for the non diabetic and the diabetic 
participants respectively (p<0.001). 
Social deprivation, as measured by the Carstairs index, was 
associated with an increased odds ratio of being admitted to 
hospital. Current or ex-smokers, were also found to be associated 
with an increased odds ratio of hospital admission. Both of these 
factors have previously been identified as contributing to increased 
admission in diabetic populations. 
9.2.7 Mortality and the older diabetic person 
Diabetes was associated with all cause mortality in men and women, 
up to and including those aged over 85 years. The adjusted hazard 
ratio for death due to diabetes for men and women aged over 75 
years was 1.50 (95% Cl, 1.38-1.65). The hazard ratio remained 
approximately 1.50 for each age group up to 89 years. These results 
are in contrast to previous published results which suggest that 
diabetes becomes less hazardous with increasing age. It appeared 
that diabetes also contributed to death in people aged over 90 years, 
although the result was not significant. In the over 90 year age group 
a lack of statistical power may have been responsible for the lack of 
significant results. 
Similarly, circulatory death rates were raised in people with diabetes. 
Overall the rate of death from renal causes was higher in people with 
diabetes than people without diabetes. Low numbers of deaths from 
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renal causes prevented further subgroup analysis to be accurately 
performed. 
Proteinuria and raised creatinine were associated with death (all 
cause, circulatory and renal) in older diabetic people. These results 
are in contrast to chapter 6, when only limited associations were 
found between diabetic end points and either of these exposure 
variables. The positive associations recorded reflect the statistical 
strengths of the MRC study; it was designed to analyse mortality 
outcome data not detect cross sectional observations in secondary 
analyses. Worsening GFR resulted in an increased hazard ratio for 
all cause, circulatory and renal death. 
9.3 The methodology of the MRC trial and the implications 
for this thesis 
9.3.1 The primary aim of the MRC trial 
The primary aims of the MRC trial were to measure the affects of 
different approaches to assessment and management of older 
people(66; 80). It was described fully in section 2.1.1. It was 
envisaged at the trial outset that there would be a large amount of 
additional data produced in the process of conducting the trial. This 
information was always likely to be of use to health researchers. This 
PhD thesis uses part of the additional data generated. It is important 
to state that this thesis is, therefore, a secondary analysis of the 
MRC trial. A primary concern of secondary analyses is "data 
dredging". This is the practice of simply analysing as many results, 
and permutations of results, as possible, in order to identify 
statistically significant results. This often occurs in studies where the 
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primary hypotheses of the study has not been adequately answered. 
I would argue that this has not been the case in the writing of this 
thesis. This thesis involved the analysis of data relating the health 
care of the diabetic elder, testing predetermined hypotheses 
identified in the course of the development of this PhD. It is simply 
that the source of the data used in this thesis came from another 
trial. The results of this thesis are unconnected to the results of the 
original trial. 
9.3.2 The design of the MRC trial 
The MRC trial collected cross sectional data at the time of the 
detailed screening assessment. It is this information that was used 
for the a large amount of this thesis. Cross sectional data formed the 
basis of the identification and description of the diabetic population. 
It was used in determining the associations between diabetes, 
hypertension and renal impairment. As has been alluded to earlier in 
this thesis, this sort of observational analysis of diabetes and its 
complications is not ideal. It simply does not have the power or 
subtlety to detect differences between the populations. A cohort 
study would have been far more suitable. It would have had the 
ability to follow diabetic people with and without hypertension or 
renal impairment and identify any differences in the outcome of 
diabetic end points. The observational nature of some of the results 
may well have contributed to the lack of associations seen between 
diabetes, hypertension, renal impairment and many of the diabetic 
end points. 
The MRC trial used a self reported questionnaire for many variables. 
This has epidemiological implications(304). Any responses will be 
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subject to reporting bias. Reporting bias occurs when a trial 
participant reports an exposure incorrectly. This commonly occurs 
when a person inaccurately reports an exposure due their own 
attitudes, beliefs and perceptions. For example, self reporting as a 
non smoker to avoid being stigmatised (perceived or otherwise) as a 
smoker. Fortunately, we had a one method of cross checking the 
self reporting of diabetes, by the use of the EMIS data. The high 
sensitivity and specificity estimates which were calculated in this 
thesis, using the EMIS data show that, while not perfect, the self 
reporting of diabetes was reasonable. This supports the validity of 
the results generated in this thesis. Despite this, it was not possible 
to validate all the variables using EMIS data. Some of the self 
reported variables used in the MRC trial have previously been 
validated and shown to be accurate(159). However, not all of the 
different variables self reporting accuracy has been established. 
Therefore self reporting bias should be noted as a limitation of this 
thesis. 
9.3.3 The responding participants of the MRC trial 
The overall response rate for people invited to participate in the 
universal arm of the trial was 70.5%. This is high for a large study in 
this age group. It is virtually impossible to obtain 100% enrolment in 
a clinical trial of this kind and scale. People invited to attend may 
move home or die, before they are formally enrolled. Many people 
simply do not want to be involved in clinical trials. People may be too 
ill to participate. Many people are unable to find the time or the 
inclination to take part no matter how many times they are 
approached or reminded. The result is a group a trial "participants" 
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who constitute the non responders, of which there had already been 
some discussion. 
Chapter 8 showed that these non responding individuals have a 
higher mortality than responding individuals. The possible reasons 
for this were discussed in full in chapter 8. One of the reasons that 
non responders have a higher mortality than responders is the 
higher prevalence of all diseases in this population. It is therefore 
likely that the prevalence of diabetes, detected and undetected is 
higher, in the non responding population. This is another reason that 
the prevalence estimates in this thesis are likely to be an 
underestimation of the true figure in the community. 
9.3.4 Statistical methods used in the MRC trial 
The presence of missing data raises questions about any statistical 
inferences generated(305). The primary issue is whether the missing 
data constitutes different data compared to the data which is not 
missing. For the purposes of this thesis decisions were taken a priori 
regarding the management of missing data. Two methods were 
used. The first method was to ignore small amounts of missing data. 
The size of the MRC trial enabled small amounts of missing data not 
be considered because they simply would not have been large 
enough to meaningfully alter the results. For example, 100 missing 
entries constituted 0.66% of all entries when the total participating 
trial population of 15095 was considered. Therefore in the case of 
this analysis, if a variable had less than 100 missing data entries, 
these missing data entries were ignored. The second method of 
considering missing data was employed for any variable which had 
over 100 missing data entries. People with the missing data were 
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treated as a separate strata and compared with the reference 
populations. For example, did diabetic people with proteinuria have 
more missing data, than non diabetic people with proteinuria. The 
point being to detect differences in trial subjects with missing data 
compared to trial subjects without missing data. In the MRC trial 
people with missing data were not found to be different from those 
without missing data for any area which was assessed. Thus, while 
undetected bias may still exist between those with and those without 
missing data, the statistical methods used in this thesis to detect any 
differences did not find any. 
Section 2.2.1 describes cluster randomisation and why it was used 
in the MRC trial. The analysis used in this thesis successfully 
accounted for cluster sampling. Therefore the results generated from 
the thesis are not biased due to the inadequate consideration of 
clustering. 
9.3.5 EMIS data 
EMIS data was only available for about one third of the people 
included in the analysis. This information improved the quality of the 
results in this thesis. It was used to help find cases and provide 
sensitivity and specificity results. In all, 42 people were found to 
have diabetes from the EMIS data who otherwise would not have 
been identified. One can hypothesise that up to another 100 people 
would have been identified with diabetes if the remaining two thirds 
of the trial population had EMIS data available. However, this data 
was simply not available for the majority of the trial participants. 
Many GPs did not use the system and a small proportion of GP 
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practices refused access to the information, which is their right. 
Nonetheless, the EMIS data was still extremely helpful. 
9.3.6 The benefits of the MRC trial 
The MRC trial was primarily designed and funded to investigate the 
affect of health care screening and subsequent management 
options, of detected disease, in older people. It achieved those 
aims(80). In order to do so, it collected vast amounts of information 
concerning many areas of the health and socio-economic status of 
the older person. Part of the legacy of the MRC trial has been the 
database of information it created. It continues to provide the basis 
for multiple publications, MSc projects and PhD 
theses(81; 82; 120; 121; 306-310). 
The MRC trial also dedicates a full page of the universal screening 
questionnaire to diabetes. The questions were selected by Professor 
N. Chaturvedi, a renowned diabetic epidemiologist. The questions 
reflect careful and insightful design, within the confines of this type of 
epidemiological study. While it does not contain every question that 
could have been useful to the study of diabetes, it is still an excellent 
source of diabetic data. 
The MRC trial was funded by, amongst others, the MRC. It was 
conducted using General Practices as the primary clustering unit, It 
utilised the MRC General Practice Research Framework (MRC 
GPRF) which is a collaboration of research orientated practices who 
help conduct different clinical trials for the MRC. Within the context 
of the MRC GPRF, the MRC trial of assessment and management of 
older people in the community, highlights the strength and 
organisational depth of this wonderful resource. 
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9.3.7 The role of chance 
All analytical studies are prone to certain possible alternative 
explanations for the results obtained. The roles of bias and 
confounding have been highlighted and discussed throughout this 
thesis. It is therefore important to mention the role of chance. It is, of 
course, possible that all the statistically significant results obtained in 
this thesis occurred by chance. However, significance testing and 
the generation of p values are performed to indicate the perceived 
mathematical strength of a result and thus estimate the likelihood 
that it simply occurred by chance. In accordance with standard 
statistical practice, p values above 0.05 were treated as non 
significant. Nonetheless, ap value of 0.05 implies that one in twenty 
of them will be wrong. However, most of the major findings in this 
thesis had p values far smaller than 0.05, indicating a far lower 
chance of an erroneous result being presented. Thus, it is highly 
unlikely that the results given here occurred by chance but it is, and 
always will be, a possibility. 
9.4 The limitations of the MRC trial and the implications for 
this thesis 
9.4.1 Glucose measurements 
One of the main drawbacks of the MRC trial from the view point of 
this thesis was the lack of satisfactory glucose measurements. This 
was disappointing from two major perspectives. The first was case 
ascertainment. Fasting glucose measurements would have allowed 
for an accurate and epidemiologically valid, diagnosis of diabetes to 
be made. While fasting glucose measurements tend to identify 
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younger obese people with diabetes, they almost certainly would 
have identified more older people with diabetes as 
well(18; 103; 311; 312). The letter of invitation to participants for take 
part in the MRC trial did not request participants to be fasted. 
Therefore it was not surprising how few fasting blood tests were 
completed. The MRC trial conducted over 15000 blood tests and it 
would have been unrealistic to have expected people to attend in a 
fasting state at different times of the day. From an ideal 
epidemiological standpoint, an OGTT should have been conducted 
which would have allowed the most accurate detection of diagnosed 
and undiagnosed diabetes possible. Unfortunately, as well as being 
unpleasant for any individual to undergo, it is simply not practical to 
perform 15000 OGTTs, in people of any age let alone the older 
person. Therefore incomplete diabetic case ascertainment must be 
noted as a limitation of every aspect of this thesis. 
The second major disappointment concerning the lack of glucose 
measurement, was the absence of a long term measure of glucose 
control, such as HbAlc. This information would have provided an 
insight into the degree of diabetic control within our diabetic 
population. It would also have enabled levels of glycaemic control to 
have been correlated with diabetic end points to assess potential 
associations. Like other aspects of this thesis, some of this 
information would have been cross sectional and thus limited. It may 
therefore have suffered from a lack of power. Nonetheless, it would 
have been interesting to have assessed glycaemic control, 
especially in relation to mortality. The MRC trial did not measure 
HbAI c because when the trial was designed this blood test was only 
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starting to become common place and was expensive. I am sure that 
if the trial was repeated today HbA1 c would be included. 
9.4.2 Lipid measurements 
In 1994, the 4S study confirmed the benefits of treatment of 
abnormal lipid levels using statin medications(313). The study 
contained relatively small numbers of participants, although some of 
them were aged over 60 years. Since that time many studies have 
continued to expand the clinical evidence base. One of the largest 
and most recent was the Heart Protection Study, which included 
people up to the age of 80 years(314). Specific benefits were seen 
in the diabetic participants within the Heart Protection Study(315). 
While the evidence for the benefits of lowering cholesterol in older 
people is less than younger people, it is increasing. Many authors 
now support statin use in fit older people up to their 9th decade and 
beyond(316). 
With the benefit of hindsight, lipid measurements would have been 
beneficial. They would almost certainly have been included as part 
of MRC trial if it had been performed today{Bulpitt, 2005 347 rd}. 
The reasons it was not done are because its importance was not as 
well recognised as it is today among this age group and the cost, of 
what was then an expensive test. 
9.4.3 Drug data 
The analysis of the affect of the different blood pressure lowering 
medications, especially ACE-Is, would have been extremely 
interesting. For example, did the people with diabetes who were 
taking an ACE-I survive longer than the diabetic people who weren't 
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taking an ACE-I? Unfortunately this proved difficult. Analyses were 
attempted, the results of which were not presented due to a lack of 
viable results. The reasons for the lack of results was several fold. 
Firstly, there was a relatively low number (167,14.2%) of diabetic 
people taking an ACE-I, which weakened the statistical analysis. 
Secondly, most of these people were also taking other blood 
pressure lowering drugs, which confounded the results. Thirdly, and 
finally, it was not possible to distinguish how much blood pressure 
had been lowered, if at all, from taking medication. 
In order to avoid these issues it is necessary to conduct randomised 
controlled trials. These would allow for more appropriate study of the 
medications used to treat blood pressure in the older diabetic 
person. They would randomly and in an unbiased manner select 
who was given medication, unlike our trial population. Repeated 
blood pressure measurements could be conducted detecting the 
amount of effect each medication was having on blood pressure. In 
these scenarios, both the affect of lowering blood pressure and the 
beneficial effects of medications themselves can be assessed. 
It was not possible to conduct any useful analysis of ARB drugs. 
When the MRC trial was conducted in the second half of the 1990s 
ARBs were uncommon drugs. They had only just become 
commercially available. Their clinical evidence base was not well 
established. Up to 15% of people develop a cough while taking an 
ACE-I, a common reason for discontinuing these medications. One 
of their primary indications when ARBs were launched was as an 
alternative to ACE-is in these situations. The rarity of their use was 
confirmed from the MRC trial, only 12 people were recorded as 
taking this medication. This low figure rendered any statistical 
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analysis redundant. It is also very likely that more older people are 
taking ARBs today than when trial recruitment ended in 1999, which 
would also have made any results defunct. 
9.5 Recommendations for future research highlighted from 
the MRC trial 
9.5.1 Publication of the results of this thesis and the NSF 
The National Service Frameworks have highlighted areas of 
knowledge, areas of concern and made attempts to standardise 
medical care(4; 36; 37). It is therefore hoped that this thesis will 
further add to the available knowledge base and therefore the 
National Service Frameworks, ultimately leading to improved care of 
the older diabetic person. 
It is anticipated that the following fives area will provide the basis for 
future publications; 
The prevalence estimates of diabetes, both diagnosed and 
undiagnosed and all of the diabetic endpoints characterised in this 
thesis. Chapter 3 emphasised the paucity of even basic information 
in the older diabetic person and this thesis helps to further 
characterise the older diabetic person. 
The high prevalence of cognitive impairment and the poor 
understanding of daily diabetic management are likely to be some of 
the most practical and clinically useful information generated from 
this thesis. Cognitive impairment is rarely considered in the diabetic 
clinic or General Practitioners surgery when prescribing 
hypoglycaemic medication or insulin. The high prevalence of 
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cognitive impairment identified in this thesis may raise the 
awareness of this problem. 
Hypertension and renal disease in the older diabetic person were 
further characterised by this thesis. Many of the results were 
controversial and unexpected. These unexpected results were 
probably due to the nature of the data and therefore erroneous. 
While negative results deserve publication, erroneous ones do not. 
In which case the results which deserve highlighting are the high 
prevalence of hypertension and the GFR data, which were more 
scientifically solid. 
Hospital admission data in the diabetic older person should be of 
use to health planners. While some interesting factors were 
unavailable, this thesis demonstrated that diabetes contributed to an 
increased number of hospital admissions and an increased number 
of days spent in hospital for each admission. 
The mortality estimates were also revealing and were supportive to 
previous findings but more expansive. The results showing that 
diabetes remains a serious condition into the extremes of old age. 
These figures were generated from one of the largest populations of 
older diabetic people ever assembled and studied the effect of 
diabetes into much older age groups than has previously been 
attempted. They confirm the detrimental effect of diabetes into the 
extremes of old age. 
9.5.2 Specific issues generated from this thesis 
MDRD equation 
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Since 1999, the MDRD equation has become the equation of choice 
for calculating GFR(152; 154). The original study, by Levey, included 
people aged 50.6 years, standard deviation 12.7 years(152). Two 
subsequent studies have validated the use of the equation in 
diabetic populations(155; 156). The first study using a diabetic 
population included 1286 people with exclusively type 1 
diabetes(156). The second study in diabetic people included 160 
people aged 62.2 years, standard deviation 13.7 years, range 19-83 
years(155). 
In the MRC trial the results of the mean GFR, generated using the 
MDRD, did not demonstrate any meaningful difference for older 
people with and without diabetes. This result is surprising because 
the trial participants with diabetes had higher mean creatinine levels. 
The MDRD equation is calculated using logarithmic manipulation of 
the variables of creatinine and age (it also contains fixed correction 
factors for gender and people of black origin). It is possible that this 
logarithmic manipulation becomes unreliable with increased age. 
The MRC trial did not precisely measure GFR and therefore it is not 
justified to reject the MDRD equation on the basis of this result. 
Conversely, this thesis generated some results supporting the use of 
GFR, calculated using the MDRD equation. This thesis 
demonstrated that worsening GFR, either per unit change and below 
60 ml/min per 1.73 m2 predicted some diabetic end points and 
death; good reasons for promoting the use of GFR calculated using 
the MDRD equation. However, it would appear sensible to 
recommend that formal GFR measurements are conducted in the 
older person, with and without diabetes, and the MDRD equation 
properly validated in older populations. 
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Routine MMSE evaluation 
The MRC trial demonstrated high levels of cognitive impairment in 
the diabetic population. Over one in five older people with diabetes 
who were taking hypoglycaemic medication had cognitive 
impairment. This figure is not only high but it is extremely 
concerning. It argues for the routine use of regular cognitive function 
testing in older diabetic people. In the absence of appropriate 
supervision of daily diabetic care, i. e. a cognitively intact primary 
carer, alternative treatment regimes should be considered. 
Systolic BP>130 mmHg 
In the MRC trial, over 80% of older people with diabetes had a 
systolic blood pressure above 130 mmHg. The ADA currently 
recommends treatment for systolic blood pressure above this level in 
people with diabetes(196). This recommendation applies to older 
people. This recommendation is the most aggressive currently used. 
During this thesis this lower "aggressive" figure was used as a 
hypothesis for the threshold of treatment benefit. The implications of 
treating 80% of diabetic people aged over 75 years are huge and 
could not be justified from the results generated in this thesis. In 
contrast, there are European guidelines specifically designed for the 
older diabetic person(39). The European guidelines suggest systolic 
blood pressure should not exceed 140 mmHg in fit older diabetic 
people and 150 mmHg in frail older diabetic people. It appears that 
the European guidelines are currently the most appropriate in this 
age group. 
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9.5.3 General recommendations relating to epidemiology in the 
older diabetic person 
For nearly every aspect of this thesis there is a smaller amount of 
epidemiological information available compared to younger diabetic 
populations. Much of the evidence for diabetic management is 
based on extrapolation of results from younger populations. This is 
highlighted by the UKPDS, one of the premier type 2 diabetes trials. 
It enrolled people with a median age of 53 years and no people older 
than 65 years(14). 
One of the reasons for a smaller evidence base for the older diabetic 
person is historical. Diabetes used to be a disease of younger 
people. However, for reasons that have been discussed, it is 
increasingly becoming a disease of older people. Therefore, the 
amount of known epidemiology is increasing and will continue to do 
so. Whether older people are beginning to be recruited into clinical 
trials is less clear. There is some evidence to suggest that they 
might be. For example, the Heart Protection Study included people 
up to the age of 80 years(314). Nonetheless, this still does not 
provide clinical evidence for people aged over 80 years. Age should 
not usually be a factor in deciding on inclusion in to a trial. If a trial is 
randomised, by definition, age should not be a factor. 
The possibility that diabetes behaves differently at the extremes of 
age is another area of current research. There are several 
hypothesis, highlighted in the previous chapters, to suggest that 
diabetes may become less harmful with age. These include excess 
mortality at younger ages in susceptible individuals and a lack of 
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time for the development of diabetic complications. Trials are 
underway which assess these issues.. 
It must be a recommendation of this thesis that an increased amount 
of research in to diabetes in the elderly is performed. One of the 
most easily accessible routes would be the inclusion of older people 
in clinical trials. 
9.6 Conclusions 
" The MRC study represents one of the largest and most varied 
community based resources for the study of diabetes available 
worldwide. 
" Prevalence of diabetes and its complications are common in 
older people. 
" Of major concern is the apparently high degree of cognitive 
impairment in the older diabetic person. 
" Older diabetic people utilise all diabetic healthcare providers 
and services and are prescribed a wide range of diabetic 
medications. 
" The prevalence of systolic hypertension was extremely high in 
the older diabetic population, this has major implications if all 
these people are to receive treatment. Hypertension and renal 
impairment were not strongly associated with diabetic 
endpoints, which were commonly seen in younger 
populations. This may have been the result of the 
inappropriate design of this study to assess these issues. 
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" Diabetes -was clearly associated with increased admission to 
hospital and longer stays in hospital following admission. 
" Diabetes was associated with mortality in both sexes at least 
up to the age of 90 years. 
" Diabetes in the older person needs to be recognised as a 
major issue and enrolment in clinical trials should not be 
limited by age. 
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Appendix 1. 
The Design of the MRC Trial of the Assessment and 
Management of Older People in the Community 
The design of the MRC trial is given overleaf. It includes description 
of the targeted arms and the universal arms of the trial. It also shows 
multidisciplinary geriatric care (GM) and primary care based 
treatment (PC). The quality of life assessment is also highlighted at 
the bottom of the page. Reproduced courtesy of Professor Astrid 
Fletcher. 
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Appendix 2. 
The detailed questionnaire 
The following pages contain an exact reproduction of the detailed 
questionnaire. The page numbers here represent the page 
numbers which have been highlighted throughout the text in 
relation to this appendix. 
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DETAILED ASSESSMENT 
............................................................................................ 
Patient Name Label 
- 
............................................................................................ 
Barcode Label 
Date of birth Sex: Male Q Female Q 
0123 
456789 Marital status 
Day 
0123456789 10 11 12 Single 
Month Married 0123456789 Separated/divorced 
Widowed 
Year Living with a partner 
PLEASE TICK APPROPRIATE BOX: - 
Q Interview completed with subject 
Q Totally proxy interview (Reasons for proxy) 
Q Partly proxy interview (Reasons for proxy) 
Q Subject unable to complete interview (NV proxy) 
Q Subject not found (Reason not found) 
Q Subject refused interview 
Q Subject died 
Q Subject moved to long stay care 
_Q 
Subject admitted to. hospital 
Q Subject moved away (New address) 
(New GP/FHSA) 
Nurse number 
Date of interview 
0 1.2 3458789 
10 
1 
0123 
456789 
Day 
0123456789 10 11 12 
Month 
0123458789 
Year 
Visit start time (use 24 hour clock) 
012 
3456789 
Hours 
012345 
8789 
Minutes 
Survey : 103 
Nurse name 
Place of interview 
Surgery (7 
Residential home 
Own home F7 
Other (Specify) [] 
Interview start time (use 24 hour clock) 
012 
3456780 
Hours 
012345 
8789 
Minutes 
Serial : 7325 
Scanning by Formic Ltd, London, (+44) 071 9241730 
Page 1' 
ýý 
After 3 minutes rest, take the patient's sitting blood pressure. Repeat sitting blood pressure after 
3 minutes rest, and then take standing blood pressure after 3 minutes rest. 
Record to the nearest 2mmHg. 
Sitting 
First Second 
Systolic 
Diastolic 
Zero error 
mm 
Average corrected sitting reading Standing 
True Systolic 
True Diastolic III 
'In 
[IL] 
Hi Calculations 
Action: 
Repeat in 1 week if average sitting systolic is >=180mmHg, or average sitting diastolic is >=100mmii: 
To repeat for either, standing systolic must be >=140mmHg. 
Repeat blood pressure: 
Sitting 
First Second 
Systolic 
Diastolic 
Zero error 
mm 
Average corrected sitting reading Standing 
True Systolic 
7 
True Diastolic 
:1 
Calculations 
Immediate Action: 
(Any age) If average repeat sitting systolic >=220mmHg or sitting diastolic >=115mmHg, inform GP I 
within 4 hours. 
Action: 
Refer to team if subject is less than 80 years old and average repeat sitting systolic >=180mmHg or 
sitting diastolic >=100mmHg. To refer for either, standing systolic pressure must be >=140mmHg. 
Surve : 103 Serial 7325 
Scanning by Formic Ltd, London, (+44) 071 9241730 
Page :2 
am 
t 
ýý 
0123456789 
2(a) 
, Pulse rate '0° 10 
=' 
Immediate Action: 
If pulse <40 or >130, inform GP within 4 hours. 
Action: 
Refer to team if pulse 40-49 or 110-129. 
2(b) Continuously irregular pulse? Yes Q No Q 
m 
Action: 
If yes, do ECG if surgery has facilities. Refer to team if ECG reports atrial fibrillation, atrial flutter 
runs of ventricular extrasystoles. If surgery has no ECG facility, refer to team. 
3 Measure patient's standing height to the nearest 0.1 cm. o, 2345e7ao , oo 
,o 
o., cm 
4 Measure patient's weight without coat and shoes 
to the nearest 0.1 kilogram. 
5(a) Measure patient's demi span to nearest 0.1cm. 
123456789 
L_I loo 
,o 
o., 
Kg 
0123.56189 
IIIIIIIIII 100 
10 
1 
al 
cm 
5(b) Repeat demi span measurement to nearest 0.1 cm. 01234567ao 
, oo 
10 
n cm 
6(a) Measure patient's mid-arm circumference to nearest 0.1cm. 01234567 10 
I III o., cm 
6(b) Repeat mid-arm circumference measurement to nearest 0.1 cm. o12345e7eo 10 
cm o. ý 
Survey : 103 Serial : 7325 
- 4ý 
` 
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m 
m 
'(a) Measure patient's waist circumference to nearest 0.1 cm. 
o., 
cm 
'(b) Repeat waist circumference measurement to nearest 0.1cm. 
I(a) Measure patient's hip circumference to nearest 0.1cm. 
fi(b) Repeat hip circumference measurement to nearest 0.1cm. 
Please indicate if there were any special circumstances that might 
have affected any of the above anthropometric measurements. 
0 1 '2 3 4 5 8 7 8 9 
100 
10 
1 
0123456789 
100 
10 
z= 0.1 cm 
0123456789 
100 
10 
1 
0.1 
" 
012345 
T6 
789 
III TI IIIID 100 
10 
1 
cm 0.1 
Yes Q No Q 
Please record these special circumstances in the space below, (see training notes). 
Surve 103 Serial : 7325 
Page :4 
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ft 
m 
"1 am now going to ask you some questions about your recent health, that is, over the past month. " 
9(a) Have you ever had any pain or discomfort in your chest? Yes 
No +- go to (i) 
9(b) Do you get this pain or discomfort when you walk uphill Yes 
or hurry? No ---go to (i) 
9(c) Do you get it when you walk at an ordinary pace on the Yes 
level? No 
9(d) When you get any pain or discomfort in your Stop 
chest, what do you do? Slow down Continue at the same pace i-go to (i) 
9(e) Does it go away when you stand still? Yes 
8 
No +--go to (i) 
9(f) How soon? 10 minutes or less R More than 10 minutes +--go to (i) 
9(g) " 
ere do you get this pain or discomfort? Sternum 
(Tick all places mentioned) Left chest 
Left arm 
Other 
If "other", specify 
9(h) . Are you receiving treatment 
for this? Yes 
No 
Action: If No, refer to team 
9(i) Have you ever had a severe pain across the front of Yes 
your chest lasting for half an hour or more No 
10(a) Are you wearing a hearing aid now? Yes t-go to (c) No 
10(b) Do you have a hearing aid at home for your own use? Yes No 
8 
i--go to (e) 
10(c) Do you use the hearing aid regularly? Yes 
No R 
10(d) Does it help? A lot QA little Q Not at all Q 
Only ask (e) if "No" to (a) and (b). Otherwise go to Q11. 
10(e) Have you ever tried one? Yes No 
Q 
"-go to 11 
10(f) Did it help? A lot 
Q. A little E] Not at all Q 
Survey : 103 Serial : 7325 Page :5 
®-I 
Scanning by Formic Ltd, London, (+44) 071 924 1730 a 
m m 
"J am now going to do some checks on your hearing by whispering some letters and numbers. 
Please keep looking forward': 
Stand behind subject at a distance of 6 inches. Take a deep breath in, breathe right out and then whir, 
at one item per second: "3, A, 2". Ask the subject to repeat this. The test is passed if the sequence is 
repeated correctly. If they respond incorrectly or not at all, the test is repeated once more using "I, F, 
Passed first time Q 
Action: 
If patient fails, examine the ears. 
Examination of the ears 
Nothing abnormal Q 
Wax Q 
Other (specify) Q 
Passed second time El Failed El 
Action: 
If wax not present and hearing has not been investigated in the last year, refer for audiometry. If 'tiac 
present, arrange for drops and syringing. Repeat whispered voice test 1 week after syringing. 
Repeat whispered voice test. 
0123 
Date 456789 
Day 
0123456789 10 11 12 
Month 
0123456789 
Year 
Passed first time Q Passed second time Q Failed El 
Action: 
If patient still fails and hearing has not been investigated in the last year, refer for audiometry. 
'As people grow older it is quite normal to find they sometimes have trouble with their bladder or 
bowels. I'd like to ask you some questions about it. " 
12(a) Ask all: Do you ever wet yourself if you are not able Yes 
to get to the toilet as soon as you need to, or when asleep, No 
or if you cough or sneeze? Catheter 
12(b) If yes, how often does this happen? More than once a day 
Once a day 
Three or more times a week 
Once or twice a week 
Less than once a week 
+-go to 13 
-go to (d) 
E* 
12(c) If yes, is it just a few drops or more than that? Just a few drops 
More than that 
Action: If *incontinent of urine (more than a few drops) once a week or more, do MSU. If infected 
MSU refer to team; if not infected refer to continence advisor/community nurse. 
12(d) If catheter, do you have any problems with this? Yes 8 
No 
Action: If yes, refer to continence advisor/community nurse 
Surve 103 Serial : 7325 Page :6 
Scanning by Formic Ltd, London, (+44) 071924 1730 
13(a) Ask all: Do you ever soil or mess yourse 
13(b) If yes, how often do you have 
soiling accidents? 
a Yes 
NoR 4-go to 14 
More than once or twice a day 
Once or twice a day 
Three or more times a week 
Once or twice a week 
Once or twice a month 
Less than once a month 
Action: If 3 or more times a week, refer to team. If once or twice a week, refer to continence advisor/ 
community nurse. 
14 Men only, women go to Q15. 
14(a) In the last month have you usually had to get up Yes 
to pass water during the night? No 
E 
«-go to (d) 
14(b) o123456789 Twice a night or less - go to (d) 
If yes, how often per night? + times: More than twice - go to (c) 
14(c) If more than twice, have you seen your doctor Yes El 
about this problem in the last month? No 
Action: If No, refer to team. 
14(d) In the last month have you had difficulty in No difficulty ---go to 16 
passing your water? 
A loSome t of 
difficult + -go to 16 
y 
14(e) If a lot of difficulty, have you seen your doctor about this problem Yes 
in the last month? No 
Action: a lot of difficulty passing water and not seen doctor in the last month, refer to team. 
Women only. Men go to 16. o1234s6789 
10 
15a How old were you when you had your first menstrual period? IIII T7T 11 years 
15b o12345e1eo 
Io 
How old were you when you had your last menstrual period? ' years 
15c Did your periods stop naturally, because of surgery, Naturally 
or for some other reason? Other (specify) 
15d Have you ever been pregnant 
(including miscarriages and stillbirths)? 
15e How many children, including stillbirths, have you had? 
Yes 
No 
R 
+-go to 16 
o® a4see9 
10 
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16 Ask all patients: 
16(a) In the last month have you been more constipated 
than usual? 
16(b) If yes, have you seen your doctor about this in the 
last month? 
16(c) If no, is it a problem for you? 
Action: If it is a problem, refer to team 
17(a) In the last month have you had repeated attacks 
of diarrhoea? 
17(b) If yes, have you seen your doctor about this in the 
last month? 
17(c) If no, is it a problem for you? 
Action: If it is a problem, refer to team 
18 In the last month have you had alternating attacks 
of diarrhoea and constipation? 
19(a) In the last month have you had blood in your motions? 
19(b) If yes, have you seen your doctor about this in the 
last month? 
20(a) 
Yes 
No 
J+--goto17 
Yes +--go to 17 
No 
Yes 
No 
Yes B 
No +-go to 18 
Yes 4--go to 18 
No 
Yes 
No 
Yes 
No 
Yes 8 
No E-go to 20 °- 
Yes 
No 
Action: If No, send stool specimen to laboratory for analysis. If it is positive for blood, refer to team. 
In the last month have your motions been black? Yes 
Noe E-go to2l. 
20(b) Are you taking iron tablets? 
20(c) If no, have you seen your doctor about this in the last month? 
Yes B +--go to 21 
No 
Yes 
No 
R 
Action: If No, send stool specimen to laboratory for analysis. If it is positive for blood refer to team 1 
21 Can you chew satisfactorily? 
Action: If No, refer to dentist. 
22(a) Do you have a problem with swallowing? 
22(b) If yes, have you seen your doctor about this? 
Action: If No, refer to team. 
23(a) In the last month have you vomited blood or 
vomit that looks like coffee grounds? 
23(b) If yes, have you seen your doctor about this in the last month? 
Action: If No, refer to team. 
Yes 8 
No 
Yes 
No +-go to 23 
Yes 
No 
Yes B 
No +-go to 24 
Yes 8 
No 
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24(a) Have you coughed up blood? 
24(b) If yes, have you seen your doctor about this in the last month? 
Action: If No, refer to team. 
25(a) Do you usuall bring up any phlegm from your 
chest first thing in the morning in the winter? 
25(b) Do you usually bring up any phlegm from your 
chest during the day - or at night - in the winter? 
If Yes to 25(a) or 25(b), ask 25(c). If not, go to 25(d). 
25(c) Do you bring up phlegm like this on most days 
for as much as three months each year? 
25(d) In the past three years, have you had a period of increased 
. cough and phlegm 
lasting for three weeks or more? 
25(e) Does your chest sound wheezy or whistling on most 
days (or nights)? 
25(f) Do you get short of breath walking with people of 
your own age on level ground? 
25(g) Are you short of breath on talking? 
If yes to Q25(g), have you seen your doctor about this in the 25(h) last month? 
Action: If No, refer to team. 
26(a) Do you have swelling of your legs up to 
your knees on getting up in the morning? 
Yes 
No 
8 
+-go to 25 
Yes 8 
No 
Yes 8 
No 
Yes 8 
No 
Yes 8 
No 
Yes +-one period 
Yes --2 or more periods 
No 
Yes e 
No 
Yes 8 
No 
Yes 8 
No "-go to 26 
Yes 
No 
Yes E 
No ---go to 27 
26(b) If yes, have you seen your doctor about Yes 
this in the last month? No 
Action: If No, refer to team. 
27 In the last six months, how many falls have None 
you had at home? 1 
2 
3 
4 
More than 4 
Action: More than 4, refer to team 
28 Over the last six months have you noticed Yes 8 
unexplained weight loss of more than half a stone? No 
Action- If Yes, refer to team. 
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29 Compared with other people of your own age would you say Excellent 
that your health is generally: excellent, good, fair or poor? Very good 
Good 
Fair 
Poor 
30 Compared to other people of your age, would you Very physically active 
describe yourself as: Fairly physically active 
Not very physically active 
Not at all physically active 
31 Here are some activities which people sometimes find difficult. For each one ask, "Do you do the 
following by yourself or could you do the following by yourself if you had to? And if unable to do it 
alone, do you receive enough help? " 
No Some Unable to do it Unable to do it 
difficulty difficulty alone but help is alone and not enough 
usually available help is available 
31a Cut your own toe nails ...... 
Q 
.... .. 
Q.. 
.. .... 
QQ* 
31b Dress yourself including 
zips or buttons .................. 
Q 
.... .. 
Q Q Q 
.... .... .. 
* 
31c Cook a hot meal ................ 
QQ QQ* 
31d Do light housework or QQ simple repairs ................... 
QQ 
.... .... .. 
Me Go up and down stairs and 
steps (if necessary using a 
frame, tripod or stick) ....... 
Q 
.... .. 
Q Q 
.... .... .. 
Q 
31f Wash all over (including 
bathing or showering) ....... 
QQ.. 
.. .... 
Q 
.... .... .. 
Q 
31g Walk 50 yards down the 
road (if necessary using a 
frame, tripod or stick) ....... 
Q 
.... .. 
Q.. 
. 
Q 
. .... 
Q 
.... .... .. 
31h Do shopping ................... 
Q 
.... .. 
Q QQ 
Action: Any * refer to the appropriate service. 
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Introduction: 
I am now going to ask you some questions which involve memory, reading and writing type 
exercises. 
Nurse Instruction: 
Remember not to prompt the patient. Ask the questions exactly as they are written. 
32 Orientation (Ask the following questions) correct Incorrect 
32a What is the date today? Date Q Q 
Code whether date, month and year are correct). Y Q Q 32b ear 
32c Month Q Q 
32d What day of the week is it today? Day Q Q 
32e What is the season Seasons: Season Q Q Jan/Feb = Winter 
March = Winter or Spring 
Apr/May = Spring 
June = Spring or Summer 
July/Aug = Summer 
Sept = Summer or Autumn 
October = Autumn 
ov/Dec = Autumn or Winter 
32f What is the name of this place? Where is it located? 
For home visits ask, "What is the full address of this place? " Place Q Q 
32g What floor of this-building are we on? Floor Q Q 
32h What is the name of this city/town/village? Town Q Q 
32i What county are we in? County 
Q Q 
32j What country are we in? Country Q Q 
33 Immediate Recall 
Instruction to Patient: 
'7 am now going to say three words. After I have 
finished saying all three, I want you to repeat them. 
Remember what they are because 1 am going to ask First Repetition 
you to name them in a few minutes. Correct Incorrect 
Name these three objects taking I second to say each: 
Apple QQ 
"Apple" "Table" "Penny" 
Table Q [-: ] 
Rate the first attempt. If any errors or omissions are 
til ll h P QQ e names un t made on the first attempt, repeat a enny 
patient learns all three up to a maximum of 5 repeats. 
34 Attention and Calculation 
34a "Now I would like you to take 7 away from 100". 
Correct Incorrect 
"Now take 7 away from the number you get". 
"Now keep taking 7 away until I tell you to stop". Subtraction 1 
2 
Rate as correct each time the difference is 7, even if 3 
a previous answer was incorrect. Do not repeat the 4 
number you were given. 5 
1: 1 ED 
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34b If 34a is not done, ask 34b. 
NB Only count score for 34b if 34a not done. 
Ask the subject to spell the word "world" backwards 
The score is the number of letters in correct position. 
For example, "dlrow" is 5, "dlorw" is 3. 
35 Recall 
Correct Incorrect 
d 
1 
r 
0 
w 
Correct Incorrect 
"What were the three words I asked you to repeat Apple Q Q 
a little while ago? " (33). 
Table Q Q 
Penny Q [Q 
36 Language 
"Now 1 am going to ask you to do some things so please listen , 
carefully. Some may seem very simple, but please bear with us. " 
If, for physical or educational reasons, the patient is not able to 
complete this section, leave all coding boxes blank and make a note 
of the reasons for omission. Then go to the end of this section 
(Deriving total score). 
36a Naming 4 
Correct Incorrect 
Show the subject a wrist watch and ask, "What is this called? " Watch Q Q 
Show a pencil and ask, "What is this called? " Pencil 
Q Q 
Answer is only correct if object is accurately named. 
36b Repetition Correct Incorrect 
1 am now going to say something and I would like you to Repetition 
Q Q 
repeat it after me": "No ifs, ands, or buts". 
Only one presentation is allowed, so it is essential that you read 
the phrase clearly and slowly, enunciating all the s's. 
36c 3-Stage command Correct Incorrect 
"I am now going to give you a piece of paper. Takes paper ED Q 
When I do, take the paper in your RIGHT hand, in right han d 
fold the paper in half with BOTH hands and put 
the paper down on your LAP". Folds paper 
' 
Q Q 
s midline, in half Hand the paper to the patient 
If the full sequence is not completed, repeat the whole Puts paper E] 1: 1 instruction. on lap 
36d Readin 
Hold up the card which reads "Close your eyes", so the Correct Incorrect 
subject can see it clearly. Say, "Please read what is here 
l " Q Q oses eyes :C and do what it says 
Score as correct only if patient actually closes eyes. 
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Writing 
36e Give the subject a blank piece of paper and say, 
"Write a complete sentence on the piece of paper". 
Spelling and grammar are not important. The sentence 
must have a subject and a verb. 
Copying 
36f 
, 
"Here is a drawing. Please copy the drawing on the paper". 
Give intersecting pentagons card. 
Answer is correct if the two five-sided figures intersect to form 
a four-sided figure and if all the angles in the five-sided figures 
are preserved. 
Writes 
sentence 
Draws 
pentagons 
ým 
Correct Incorrect 
QQ 
Correct Incorrect 
E-1 a 
Deriving total score 
Yes No 
Language section (Q36) completed: QQ 
012345e789 
10 
Total score: 1 
a. For patients who did not complete the language section on physical/educational grounds, tick "No" for 
"language section completed". 
Give one point for every correct answer and fill in the number grid. 
NB Only include scores for Q28b (world spelled backwards) if Q28a (subtraction) not 
conducted. 
Action: If the total score is less than 12, refer to the Community Psychiatric Nurse or Memory 
b. For all other patients, tick "Yes" for "language section completed". Sum the total of correct answers 
and fill in the number grid. 
NB Only include scores for Q28b (world spelled backwards) if Q28a (subtraction) not 
conducted. 
Act_ ion: If the total score is less than 17, refer to the Community Psychiatric Nurse or Memory 
Comments on MMSE (032-36): 
Survey : 103 Serial 7325 
0 Scanning by Formic Ltd, London, (+44) 071 9241730 
Page : 13 
a 
R 
37 Hasa doctor ever told you that you had any of the following? If yes, was that 
in the last year? 
Yes, within Yes but before 
No last year last year 
Pneumonia 
...................................... 
Q 
..... 
Q 
..... 
Q 
Emphysema 
.................................... 
Q Q 
..... 
Q 
Asthma 
.......................................... 
Q 
..... 
Q 
..... 
Q 
Arthritis/Rheumatism ...................... 
Q 
..... 
Q 
..... 
Q 
Eczema 
.......................................... 
Q 
..... 
Q 
..... 
Q 
Stomach ulcer/other digestive ulcer . 
Q 
..... 
Q 
..... 
Q 
Haemorrhoids or piles .................... 
Q 
..... 
Q 
..... 
Q 
High blood pressure ....................... 
Q 
..... 
Q 
..... 
Q 
Heart attack ................................... 
Q 
..... 
Q 
..... 
Q 
Stroke ............................................ 
Q 
..... 
Q 
..... 
Q 
Leg ulcer ........................................ 
Q 
..... 
Q 
..... 
Q 
Varicose veins ................................ 
Q 
..... 
Q 
..... 
Q 
Gout .............................................. 
Q 
..... 
Q 
..... 
Q 
Depression needing treatment .......... 
Q 
..... 
Q 
..... 
Q 
Thyroid trouble Q 
Cataract ......................................... Q ..... 
Q 
..... 
Q 
Glaucoma 
....................................... 
Q 
..... 
Fractured spine .............................. 
Q 
..... 
Q 
..... 
Q 
Fractured hip .................................. 
Q 
..... 
Q Q 
Parkinson's disease ......................... 
Q 
..... 
Q 
..... 
Q 
Cancer (if yes, ask where) ............... 
Q Q Q*-- Site 
Infection in bladder or kidneys ........ 
Q 
..... 
Q 
..... 
Q 
Men only 
Trouble with your prostate gland .... 
Q 
..... 
QQ 
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38a Have you ever been told by a doctor that you have sugar diabetes? 
38b- When were you first told you had diabetes? (give year) 
38c What treatment are you on for your diabetes? 
(Tick all that apply) 
38d, Do you test your blood for sugar? 
If yes, ask "how often do you do this? " 
38e Do you test your urine for sugar? 
If yes, ask "how often do you do this? " 
38f Who do you normally see about your diabetes? 
(Can be more than one person) 
38g In the last year, have you had your feet examined? 
38h In the last year, have you had your eyes examined? 
Yes No D/K 
QQQ 
Yes No D/K 
QQQ 
Yes No D/K 
38i In the last year, have you discussed your diet with a dietician? E: 1 F-1 F-1 
Nurse instruction: 
Questions (j) and (m) should be asked only to patients on tablets or insulin. 
Yes No ö 38j Have you ever had a low blood sugar (a "Hypo 
Ask all patients on tablets or insulin Q38k to m. 
38k If you have a low blood sugar, should you increase Yes No D/K 
your diabetes treatment? 
381 If you have a low blood sugar, should you take a es No D/K 
sugary drink or snack? f7 f7 F-1 
38m If you have the Wu, should you stop taking your diabetes Yes No D/K 
tablets/insulin? 1: 1 7 F-I 
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;ý 
Yes No 
QQ go to 39 
0,2 3456789 
19 10 
Diet alone 
Tablets 
Insulin injections 
No treatment 
Yes No 
QQ 
About once a day 
About once a week 
About once a month 
Less than once a month 
Yes No 
a F-1 
About once a day 
About once a week 
About once a month 
Less than once a month 
Family doctor/GP 
Hospital doctor 
Practice/District nurse 
No one 
39a I would like to ask you some questions about your housing. 
Who do you live with? Alone 
Spouse 
Son/Daughter 
Other relative 
Friend 
Other (specify) 
39b What kind of accommodation do you live in? Council rental 
Private rental 
Housing Association 
Home owner 
Sheltered accommodation ) 
Local Authority residential home ) 
Private residential home ) go to 40 
Local Authority nursing home ) 
Private nursing home ) 
If living in own or rented accommodation, ask: 
Yes No 
39c In the last year have you had difficulty keeping your home warm? *Q Q 
Yes No 
39d Do you have central heating? Q Q 
All Some None 
39e If yes, in which rooms? Living rooms 
Bedrooms 
Q QQ 
Yes No 
39f Do you have an indoor toilet? Q * Q 
39g Do you have a relative, neighbour or friend Yes No - 
whom you can call on for help when required? Q Q* 
Yes No 
39h Is there anyone available if you need help at night? Q Q 
Action: If 3 or more *, refer to Social Services. 
40a When you need to talk about private matters or when 
you are worried or stressed, who can you really count 
on or feel at ease with? (May give more than one answer). 
No one 
Spouse 
Friend 
Neighbour 
Relative 
Home Help/other paid help 
Warden 
40b During the last year have you Death or separation from a loved one 
experienced? Serious illness in a loved one 
(May give more than one answer) Moving your residence 
40c Do you ever have difficulty in making ends meet, I mean, 
is it difficult to find the money to pay your bills? 
40d Do you have difficulty in managing your own finances, I mean 
things like paying for bills, working out change etc? 
Action: If 2 or more *, refer to Social Services. 
*Yes 
Yes 
Yes 
*El 
Ej, 
No 
No 
No 
r-l 
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41 1 am now going to ask you some questions about how you've been feeling over the past few weeks. For each question, please choose the answer that best applies to you. 
Not at all No more Rather more Much more than usual than usual than usual 41 aý Have you lost much sleep over 
worry? ........................................................... 
Q 
.... .... 
Q.. 
.... .. 
Q.. 
.... .. 
Q 
41b , ', Have you had difficulty in staying 
asleep once you are of? ............................... 
Q 
.... .. 
Q.. 
.... 
Q 
.... ... 
Q 
41c Have you felt constantly under QQ strain? ........................................................... .... 
Q...... Q 
41d Have you been getting edgy and QQ bad-tempered? .............................................. . .... .. 
Q.. 
.... .Q 
4l e Have you been getting scared or 
panicky for no good reason 2 ......................... 
Q 
.... .... 
Q 
.... .... 
Q 
.... .... 
Q 
41f Have you found everything getting aQQ 
on topofyou? ............................................... . .... .. 
41g 
anHave d strun 
b 
up b 1l the time? .......................... EJ ED El El 
42 These 
oach qustioon 
are tchoowoseothe 
answer that 
over a the last 
Yes No 4ý please PP J' 
42a Are you basically satisfied with your life? .................................................................. 
Q. * 
42b Have you dropped many of your activities and interests? .......................................... 
CQ 
42c Do you feel that your life is empty? .......................................................................... *n 
n 
Do you often get bored? .......................................................................... ................. *Q 
Q 
Are you in good spirits most of the time? ................................................................... 
Q Q* 
Are you afraid that something bad is going to happen to you? ................................. *E1 
Q 
Do you feel happy most of the time? .......................................................................... .Q 
Q* 
Do you often feel helpless? ....................................................................................... ''Q 
Q 
Do you prefer to stay at home rather than going out and doing new things? ............. 'ýQ 
Q 
Do you feel you have more problems with memory than most? ................................. *Q 
Q 
Do you think it is wonderful to be alive now? ............................................................ .Q 
Q* 
Do you feel pretty worthless the way you are now? .................................................. ýQ 
Q 
Do you feel full of energy? ........................................................................................ .. 
Q Q* 
Do you feel that your situation is hopeless? .............................................................. "Q 
Q 
Do you think that most people are better off than you are? ....................................... ''Q 
Q 
01234 
Count the number of asterisked replies: 
567 69 
10 
If score is 7 or less, go to 43. Total Score: 1 
If score is more than 7, ask: 
42q Are you receiving treatment for these feelings? 
42r How long have you 
been having this treatment For more than 6 months 
Yes Q No Q'-go to 42s 
Q6 months or less Q 
42s Action: 
Refer to team if score more than 7 and no treatment or more than 6 months on present treatment. 
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43a Do you smoke cigarettes (including hand rolled) at present? Yes 
No 
8 
4-go to (c) 
43b How many cigarettes do you smoke a day? 
0123456789 
10 Cigarettes 
1 go to (f) 
0123458789 
or how many ozs of tobacco do you smoke a day? 1 Ozs of 
10.1 tobacco 
go to (f) 
43c If current non-smoker ask, have you ever smoked cigarettes? Yes 
No +--goto44 
0123456789 
43d How many cigarettes did you smoke a day? 
HI 10 Cigarettes 
0123456789 
or how many ozs of tobacco did you smoke a day? ' On of 
o"1 tobacco 
0123456789 
43e How old were you when you stopped smoking? 10 Years 
Ask all current and ex-smokers: 0123456789 10 
Of How old were you when you started smoking? F= ' Years 
44a 
44b 
44c 
44d 
44e 
During the last year have you taken an alcoholic drink? Yes 
No +-go to (f) 
During the past week how many drinks have you had of each of the following? 0123456789 
Record number, including zero. 10 Spirits - number of singles 1 
0123458789 
Wine, Sherry or Port - number of glasses 
10 
0123456789 
Beer - number of half pints 
10 
Compared with 5 years ago, would you say that on the whole More nowadays 
you drink more, less, or about the same nowadays? Less nowadays 
About the same 
44f If a non-drinker ask, have you always been 
a non-drinker or did you stop drinking 
for some reason? 
44g If stopped drinking, why did you stop? 
(Tick all that apply) 
If "Other", please specify: 
Always a non-drinker 8 ý--go to 45 
Used to drink but stopped 
Yes No 
Illness, doctor's advice 
Concerned about health 
Too expensive 
Other 
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45a Do you have any problems with your eyesight? 
45b Do you wear glasses? 
(If patient is wearing glasses, don't ask, just tick) 
45c If yes, do you wear them 
all the time, for reading only 
or other reason? 
Visual Acuity 
45d Are you registered as blind or partially sighted? 
46 
46a 
46b 
ý_0 
Blind 
Partially sighted 
No 
Test with patient wearing usual glasses. Using Glasgow chart, measure the patient's vision at 3 metres. I 
the patient cannot see the biggest letters, then measure at 1 metre. Measure both eyes first, then each eye 
separately. Scores can be plus or minus. The greater the score, the worse the vision. 
Both eyes 
Plus E] Minus Q 
0 1 2 3 4 5 6 7 8 9 
1 
0.1 
001 
0.001 
Measured at 3 metres 
Measured at 1 metre 
Unable to read at 1 metre 
Yes 8 
No 
Yes 
No . -go to (c) 
Wears glasses all the time 
Wears glasses for reading only 
Other, please specify 
Left eye 
Plus Q Minus Q 
0123456789 
IIIIIIIIIIII 
0.1 
TTL= o. ol 
IT= o. ool 
Measured at 3 metres 
Measured at 1 metre 
Unable to read at 1 metre 
Right eye 
Plus Q Minus Q 
01234ee789 
o. i 
0.01 
a. oo1 
Measured at 3 metres 
Measured at 1 metre 
Unable to read at 1 metre 
If a minus score, or score less than 0.5, go to Q47, If score is 0.5 or greater, re-test using pinhole. 
Pinhole score: Left eye 
Plus Q Minus Q 
0123456789 
IIIIIIIIIIII 
0.1 
10 01 
o. ool 
Measured at 3 metres 
Measured at 1 metre 
Unable to read at 1 metre 
Right eye 
Plus Q Minus Q 
01 2 3 4 5 e 7 e 9 
F Tý 
o. 1 
11 7 1 -- F1 o. ol 
o. 001 
Measured at 3 metres 
Measured at 1 metre 
Unable to read at 1 metre 
Action: 
If pinhole score improves to less than 0.5, refer to the optician. 
If pinhole score is 0.5 or more, ask if investigated in the last year: -º Yes Q No Q 
If No, refer to ophthalmologist. 
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47a Do you have any leg or foot ulcers? 
47b Are they/Is it being treated? 
Yes 
No 
8 
4--goto48 
Yes 8 
No 
47c Are they/Is it healing alright? Yes 
No 
Action: 
If ulcer(s) not treated or not healing with present treatment, refer to Community Nursing services. 
48a Do you have any other problems with your feet? 
48b If yes, examine feet and specify: 
(Tick all that apply) 
If "Other problem", please specify 
Yes 
No 
R 
E--go to 49 
Yes No 
Bunions 
Corns 
Ingrowing toe nail 
Very long toenails 
Other problem 
48c If yes, are you receiving chiropody? 
Action: If no, refer for chiropody. 
49a Do you have any ulcers or sores anywhere on your body? 
49b If yes, examine for pressure 
sores and record if present: 
If "Other", please specify 
49c Are they/Is it being treated? Yes 
No 
No 
e 
49d Are they/Is it healing alright? Yes 
No 
Action: 
If ulcer(s) not treated or not healing with present treatment, refer to Community Nursing services. 
50 In the last year have you had knee pain for most days 
(more than 14) of any month? 
Yes 8 
No 
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Yes 
No 
Yes 
No +-go to 50 
Yes 
Sacrum 
Buttock 
Heel 
Other 
ýý ,., 
51a "Please can you show me the tablets or medicine that you are currently taking. " For each one ask, 
"How many of these or how much do you take each day? 
Any tablets or medicines shown? Yes 
Q No Q 
Print from container 
51b Name of tablet, medicine etc Total daily dosage Units Dosage as required Units 
ýoQoQ ýýQoQ D 
D 
D 
D 
D 
O 
D 
51c Number of different medications 
51d Check drug list for interactions. 
Are there any interactions? 
Action: 
If possible drug interaction, refer to team. 
Yes B 
No 
L 
0Q 
0Q 
F___________ _____ 
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1 
Thank youvery much for your time and help. All l need to do now is take a blood test and check 
your urine f. 
Take blood and test urine (MSU if incontinent and stool specimen if necessary) 
52 
Has the patient been fasting (not eaten in the last 12 hours) 
Immediate Action 
(inform GP) 
Blood Constituent Patient Result Refer to Team (within 8 hours) 
Haemoglobin g/dl <9 or >1 8 <8.0 
White cell count x 10^9/1 <3 or > 16 <2 or >17 
Platelets F TI x 10^9/1 <100 or >900 <80 
TSH MU/1 <0.1 or >4 >16 
Glucose [71 7 F -I >7.5 (fasting) or mmol/l > 12 (not fasting) >15 
Sodium mmol/1 <129 <125 or>152 
Potassium I_ I_i l 
_ 
I_ mmolIl <3.3 X3.0 or >6.0 
Urea FT ý mmol/1 >18 >24 
Creatinine mmol/1 >250 >350 
Total protein 9/1 
Albumin E. II g/1 <30 <25 
Calcium 
--- 
F7] -F-- F-l mmo111 
<2.0 or >2.7 >2.8 
Phosphate 
F] 
- 
F] 77] 
mmol/I 
Bilirubin 
M 
mmol/1 >35 >50 
Alkaline phosphatase iU/1 >350 
AST 1 1 
7 
iU/1 >80 >120 
Uric acid II I I I mmoUI >0.8 j 
53 Dip stick results Positive (record number of +s) Negative Action if result is positive 
+ ++ +++ ++++ 
Glucose QQQQ Q Refer to team 
Protein QQQQ Q MSU 
Blood QQQQ Q MSU 
54 Where applicable: MSU (tick appropriate box) Infected Q Not infected El 
Immediate Action: If grossly infected, plus acute symptoms, inform GP within 8 hours. 
Action: If infected 
, refer to team 
55 Where applicable: Stool specimen 
Report shows presence of occult blood Yes Q, No Q 
Action: If occult b lood present, refer to team. 
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56a Any other serious condition which, in the nurse's opinion 
Yes No 
needs further assessment? 
56b If yes, give details: 
57a Are there any assessor's comments relevant to the assessment? 
57b if yes, give details: 
Yes E 
Interview finish time (24 hour clock) 
012 
FT-F 3456789 
Hours 1 111111111 
012345 
8789 
Minutes 
Visit finish time (24 hour clock) 
012 
3456789 
Hours 
012345 
8789 
Minutes 
Referral Agencies 
(tick all that patient has been referred to) 
GEM/PCT 
Dentist 
Chiropodist 
Ophthalmologist 
Optician 
Audiometry 
Community Psychiatric Nurse 
Memory Clinic 
Continence Advisor 
Community Nursing Services 
Social Services 
Occupational therapist 
Dietician 
Other 
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